


**CUMULATIVE
SUPPLEMENT 4
APRIL 2023**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**Cumulative Supplement 4
April 2023**

CONTENTS

	<i>PAGE</i>
Contents	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT	vi
1.3 APPLICANT NAME CHANGES.....	vii
1.4 LEVOTHYROXINE SODIUM	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**CUMULATIVE SUPPLEMENT 4
APRIL 2023**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
ALEOR DERMACEUTICALS LTD (ALEOR DERMACEUTICALS)	ALEMBIC PHARMACEUTICALS LTD (ALEMBIC)
ALLERGAN (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN HOLDINGS UNLTD CO (ALLERGAN HOLDINGS)	ABBVIE INC (ABBVIE)
ALLERGAN INC (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBIE (ABBVIE)

ALLERGAN SALES LLC (ALLERGAN)	ABBVIE INC (ABBVIE)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS LTD)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EPIC PHARMA INC (EPIC PHARMA)	EPIC PHARMA LLC (EPIC PHARMA LLC)
EPIC PHARMA INC (EPIC PHARMA INC)	EPIC PHARMA LLC (EPIC PHARMA LLC)
HERITAGE PHARMA LABS INC (HERITAGE PHARMA)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC (HERITAGE PHARMA AVET)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MAYNE PHARMA INC (MAYNE PHARMA INC)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA INTL)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA LLC (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2022</u>	<u>MAR 2023</u>	<u>JUN 2023</u>	<u>SEP 2023</u>	<u>DEC 2024</u>
DRUG PRODUCTS	21983	22398			
LISTED SINGLE SOURCE	2718 (12.4%)	2759 (12.3%)			
MULTISOURCE	19265 (87.6%)	19639 (87.7%)			
THERAPEUTICALLY EQUIVALENT	19165 (87.2%)	19554 (87.3%)			
NOT THERAPEUTICALLY EQUIVALENT	100 (0.5%)	85 (0.4%)			
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)			
NEW MOLECULAR ENTITIES APPROVED	8	19			
NUMBER OF APPLICANTS	1211	1222			

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET; ORAL
ABIRATERONE ACETATE

AB	FLORIDA	500MG	A215086	001	Mar 23, 2023	Mar NEWA
AB	TEVA PHARMS USA	500MG	A210726	001	Jan 26, 2023	Jan NEWA

ACARBOSE

TABLET; ORAL
ACARBOSE

@ DASH PHARMS	25MG	A091053	001	Jan 06, 2011	Feb CAHN
@	50MG	A091053	002	Jan 06, 2011	Feb CAHN
@	100MG	A091053	003	Jan 06, 2011	Feb CAHN

ACETAMINOPHEN

SOLUTION; INTRAVENOUS
ACETAMINOPHEN

>A> AP	HQ SPCLT PHARMA	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Apr NEWA
>A> AP	WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Apr NEWA
	@ ZYDUS PHARMS	1GM/100ML (10MG/ML)	A216467	001	Oct 25, 2022	Mar DISC

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET; ORAL
APADAZ

+ @ KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Mar DISC
+ @	325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Mar DISC
+ @	325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Mar DISC

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTALBITAL AND ACETAMINOPHEN

AA	SENORES PHARMS	300MG;50MG	A214088	001	Apr 07, 2022	Jan CAHN
AA		325MG;25MG	A214088	002	Apr 07, 2022	Jan CAHN
AA		325MG;50MG	A214088	003	Apr 07, 2022	Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

>D> AA	NOSTRUM LABS INC	300MG;15MG	A088629	002	Mar 06, 1985	Apr DISC
>A>	@	300MG;15MG	A088629	002	Mar 06, 1985	Apr DISC
>D> AA		300MG;30MG	A088629	003	Mar 06, 1985	Apr DISC
>A>	@	300MG;30MG	A088629	003	Mar 06, 1985	Apr DISC
>D> AA	+!	300MG;60MG	A088629	001	Mar 06, 1985	Apr DISC
>A>	+ @	300MG;60MG	A088629	001	Mar 06, 1985	Apr DISC

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL
COMBOGESIC

+! AFT PHARMS LTD	325MG;97.5MG	N209471	001	Mar 01, 2023	Mar NEWA
-------------------	--------------	---------	-----	--------------	----------

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

>A>	@ DR REDDYS LABS SA	325MG;2.5MG	A090177	001	Oct 20, 2008	Apr CAHN
>A>	@	325MG;5MG	A090177	002	Oct 20, 2008	Apr CAHN
>A>	@	325MG;7.5MG	A090177	003	Oct 20, 2008	Apr CAHN
>A>	@	325MG;10MG	A090177	004	Oct 20, 2008	Apr CAHN
>A>	@	500MG;7.5MG	A090177	005	Oct 20, 2008	Apr CAHN
>A>	@	650MG;10MG	A090177	006	Oct 20, 2008	Apr CAHN
>D> AA	MAYNE PHARMA INC	325MG;2.5MG	A090177	001	Oct 20, 2008	Apr CAHN
>D> AA		325MG;5MG	A090177	002	Oct 20, 2008	Apr CAHN
>D> AA		325MG;7.5MG	A090177	003	Oct 20, 2008	Apr CAHN
>D> AA		325MG;10MG	A090177	004	Oct 20, 2008	Apr CAHN
>D>	@	500MG;7.5MG	A090177	005	Oct 20, 2008	Apr CAHN
>D>	@	650MG;10MG	A090177	006	Oct 20, 2008	Apr CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	! AMNEAL PHARMS	325MG;37.5MG	A090485	001	Dec 09, 2009	Mar CHRS
	+ @ JANSSEN PHARMS	325MG;37.5MG	N021123	001	Aug 15, 2001	Mar DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB	INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Feb CMFD
	TABLET;ORAL					
	ACETAZOLAMIDE					
>A> AB	AARKISH PHARMS NJ	125MG	A217197	001	May 09, 2023	Apr NEWA
>A> AB		250MG	A217197	002	May 09, 2023	Apr NEWA
	@ BRECKENRIDGE	125MG	A207503	001	Apr 30, 2020	Jan DISC
	@	250MG	A207503	002	Apr 30, 2020	Jan DISC
AB	ZYDUS	125MG	A211069	001	Apr 04, 2023	Mar NEWA
AB		250MG	A211069	002	Apr 04, 2023	Mar NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

@ CHARTWELL RX 2%

A040166 001 Jul 26, 1996 Jan CAHN

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

>A> AP	STERISCIENCE	6GM/30ML (200MG/ML)	A217182	001	Apr 19, 2023	Apr NEWA
--------	--------------	---------------------	---------	-----	--------------	----------

ACYCLOVIR

CREAM;TOPICAL

ACYCLOVIR

AB	ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Feb NEWA
	SUSPENSION;ORAL					
	ACYCLOVIR					
AB	MSN	200MG/5ML	A217393	001	Mar 09, 2023	Mar NEWA
	TABLET;ORAL					
	ACYCLOVIR					
>A>	@ AUROBINDO PHARMA USA	400MG	A075211	001	Sep 28, 1998	Apr CAHN
>A>	@	800MG	A075211	002	Sep 28, 1998	Apr CAHN
>D>	@ MYLAN	400MG	A075211	001	Sep 28, 1998	Apr CAHN
>D>	@	800MG	A075211	002	Sep 28, 1998	Apr CAHN

ADAPALENE

GEL;TOPICAL

ADAPALENE

>D>	@ ENCUBE ETHICALS	0.3%	A200298	001	Jun 14, 2012	Apr CMFD
>A> AB		0.3%	A200298	001	Jun 14, 2012	Apr CMFD

ALBUTEROL SULFATE

TABLET;ORAL

ALBUTEROL SULFATE

AB	DASH PHARMS NATCO	EQ 2MG BASE	A072894	002	Jan 17, 1991	Feb CAHN
AB	!	EQ 4MG BASE	A072894	001	Jan 17, 1991	Feb CAHN

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED;INHALATION

AIRSUPRA

+!	ASTRAZENECA	EQ 90MCG BASE/INH;80MCG/INH	N214070	001	Jan 10, 2023	Feb CAHN
+!	BOND	EQ 90MCG BASE/INH;80MCG/INH	N214070	001	Jan 10, 2023	Jan NEWA

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

AB	PAR PHARM	12MG	A216843	001	Jan 24, 2023	Jan NEWA
----	-----------	------	---------	-----	--------------	----------

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL	AMANTADINE HYDROCHLORIDE					
AB	STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	Feb CTEC
TABLET;ORAL	AMANTADINE HYDROCHLORIDE					
AB	STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	Feb CTEC

AMIKACIN SULFATE

INJECTABLE;INJECTION	AMIKACIN SULFATE				
@ FRESENIUS KABI USA	EQ 50MG BASE/ML	A205605	001	Dec 09, 2015	Feb DISC
! HIKMA	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Feb CTEC

AMINO ACIDS

INJECTABLE;INJECTION	FREAMINE HBC 6.9%				
@ B BRAUN	6.9% (6.9GM/100ML)	N016822	006	May 17, 1983	Jan DISC
FREAMINE III 10%					
@ B BRAUN	10% (10GM/100ML)	N016822	005		Jan DISC
FREAMINE III 8.5%					
@ B BRAUN	8.5% (8.5GM/100ML)	N016822	004		Jan DISC
HEPATAMINE 8%					
@ B BRAUN	8% (8GM/100ML)	N018676	001	Aug 03, 1982	Jan DISC

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION	PROCALAMINE				
@ B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML ;41MG/100ML;150MG/100ML;200MG/100L;120MG/100ML	N018582	001	May 08, 1982	Jan DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION	FREAMINE III 8.5% W/ ELECTROLYTES				
@ B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/ 100ML;440MG/100ML;690MG/100ML	N016822	007	Jul 01, 1988	Jan DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION	FREAMINE III 3% W/ ELECTROLYTES				
@ B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100 ML;200MG/100ML;120MG/100ML	N016822	003		Jan DISC

AMINOCAPROIC ACID

SOLUTION;ORAL	AMINOCAPROIC ACID				
@ VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Mar DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL	AMITRIPTYLINE HYDROCHLORIDE					
>A> AB	RUBICON	10MG	A215376	001	May 01, 2023	Apr NEWA
>A> AB		25MG	A215376	002	May 01, 2023	Apr NEWA
>A> AB		50MG	A215376	003	May 01, 2023	Apr NEWA
>A> AB		75MG	A215376	004	May 01, 2023	Apr NEWA
>A> AB		100MG	A215376	005	May 01, 2023	Apr NEWA
>A> AB		150MG	A215376	006	May 01, 2023	Apr NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL	LIMBITROL				
+ @ CHARTWELL RX	EQ 12.5MG BASE;5MG	N016949	001		Mar CAHN
+ @ CHARTWELL RX	EQ 25MG BASE;10MG	N016949	002		Mar CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	COREPHARMA	EQ 2.5MG BASE	A076719	001	May 23, 2007	Feb CAHN
AB		EQ 5MG BASE	A076719	002	May 23, 2007	Feb CAHN
AB		EQ 10MG BASE	A076719	003	May 23, 2007	Feb CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>D> AP	ESSENTIAL ISOTOPES	3.75mCi-260mCi/ML	A205687	001	Dec 17, 2015	Apr DISC
>A>	@	3.75mCi-260mCi/ML	A205687	001	Dec 17, 2015	Apr DISC
	@ WISCONSIN	3.75mCi-260mCi/ML	A204356	001	Dec 18, 2014	Feb DISC

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

@ CHARTWELL RX	125MG/5ML	A 062059	001	Jan CAHN
@	250MG/5ML	A 062059	002	Jan CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Feb CMFD
AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Feb CTNA
AB		5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Feb CTNA
AB	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Feb CTNA
AB		1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Jan NEWA
AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Feb CTNA
AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Jan NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A217027	006	Jan 23, 2023	Jan NEWA
AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CMFD
	@	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CMFD
	@	2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CMFD
	@	3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CTNA
AB		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Feb CMFD
	@	5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Feb CMFD
	@	6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Feb CMFD
	@	7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Feb CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Feb CMFD
AB		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Feb CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Feb CMFD
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Feb CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Feb CMFD
AB		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Feb CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Feb CMFD

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

@ STERISCIENCE	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Jan CAHN
@	EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Jan CAHN
AP	EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Jan CAHN
AP	EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Jan CAHN
AP	EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Jan CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	STERISCIENCE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Jan CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Jan CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Jan CAHN

APALUTAMIDE

TABLET; ORAL

ERLEADA

+ JANSSEN BIOTECH

60MG

N210951 001 Feb 14, 2018

Feb CHRS

+! 240MG

N210951 002 Feb 17, 2023

Feb NEWA

APIXABAN

TABLET; ORAL

APIXABAN

AB	ZYDUS PHARMS	2.5MG	A210185	001	Feb 27, 2023	Feb NEWA
AB		5MG	A210185	002	Feb 27, 2023	Feb NEWA

APREMILAST

TABLET; ORAL

APREMILAST

AB	SHILPA	10MG	A211774	001	Apr 07, 2023	Mar NEWA
AB		20MG	A211774	002	Apr 07, 2023	Mar NEWA
AB		30MG	A211774	003	Apr 07, 2023	Mar NEWA
@	TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Feb DISC
@		20MG	A211897	002	Aug 18, 2022	Feb DISC
@		30MG	A211897	003	Aug 18, 2022	Feb DISC

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

ARFORMOTEROL TARTRATE

AN	RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb CMFD
----	---------------	---------------------	---------	-----	--------------	----------

ARIPIPRAZOLE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY ASIMTUFI

>A>	+ OTSUKA	720MG/2.4ML (300MG/ML)	N217006	001	Apr 27, 2023	Apr NEWA
>A>	+!	960MG/3.2ML (300MG/ML)	N217006	002	Apr 27, 2023	Apr NEWA

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

@ COREPHARMA

50MG

A201514 001 Mar 25, 2019

Feb CAHN

@ 150MG

A201514 002 Mar 25, 2019

Feb CAHN

@ 250MG

A201514 003 Mar 25, 2019

Feb CAHN

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

ARSENIC TRIOXIDE

>A> AP	ORBICULAR	1MG/ML	A217413	001	Apr 20, 2023	Apr NEWA
>A> AP		2MG/ML	A217413	002	Apr 20, 2023	Apr NEWA

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

>A>	@ DR REDDYS LABS SA	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015	Apr CAHN
>D>	@ MAYNE PHARMA INC	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015	Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

@ CHARTWELL RX

325MG;200MG

A089594 001 Mar 31, 1989

Mar CAHN

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

ROBAXISAL

+ @ ROBINS AH

325MG;400MG

N012281 001

Mar CRLD

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

>A>	@ DR REDDYS LABS SA	325MG;4.8355MG	A091670	001	Mar 16, 2011	Apr CAHN
>D>	@ MAYNE PHARMA INC	325MG;4.8355MG	A091670	001	Mar 16, 2011	Apr CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

>A>	@ AUROBINDO PHARMA USA	50MG;25MG	A074203	001	Oct 31, 1993	Apr CAHN
>A>	@	100MG;25MG	A074203	002	Oct 31, 1993	Apr CAHN
>D>	@ MYLAN	50MG;25MG	A074203	001	Oct 31, 1993	Apr CAHN
>D>	@	100MG;25MG	A074203	002	Oct 31, 1993	Apr CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	10MG	A079017	007	Apr 05, 2023	Mar NEWA
----	----------------------	------	---------	-----	--------------	----------

ATORVASTATIN CALCIUM

SUSPENSION; ORAL

ATORVALIQ

+! CMP DEV LLC

20MG/5ML

N213260 001 Feb 01, 2023 Feb NEWA

TABLET; ORAL

ATORVASTATIN CALCIUM

>D> AB	LEPU PHARM	EQ 10MG BASE	A216848	001	Nov 03, 2022	Apr DISC
>A>	@	EQ 10MG BASE	A216848	001	Nov 03, 2022	Apr DISC
>D> AB		EQ 20MG BASE	A216848	002	Nov 03, 2022	Apr DISC
>A>	@	EQ 20MG BASE	A216848	002	Nov 03, 2022	Apr DISC
>D> AB		EQ 40MG BASE	A216848	003	Nov 03, 2022	Apr DISC
>A>	@	EQ 40MG BASE	A216848	003	Nov 03, 2022	Apr DISC
>D> AB		EQ 80MG BASE	A216848	004	Nov 03, 2022	Apr DISC
>A>	@	EQ 80MG BASE	A216848	004	Nov 03, 2022	Apr DISC

AZELAIC ACID

AEROSOL, FOAM; TOPICAL

FINACEA

+! LEO PHARMA AS

15%

N207071 001 Jul 29, 2015 Feb CTEC

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

@ ACI

EQ 250MG BASE

A215772 001 Jul 15, 2022 Jan DISC

@

EQ 500MG BASE

A215773 001 Jul 12, 2022 Jan DISC

AB ZYDUS PHARMS

EQ 250MG BASE

A213275 001 Apr 11, 2023 Mar NEWA

AB

EQ 500MG BASE

A213056 001 Apr 07, 2023 Mar NEWA

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

@ AKORN 400 UNITS/GM;1%;EQ 3.5MG

BASE/GM;10,000 UNITS/GM

A065213 001 Jul 25, 2012 Jan DISC

! BAUSCH AND LOMB

400 UNITS/GM;1%;EQ 3.5MG

A064068 001 Oct 30, 1995 Jan CTEC

BASE/GM;10,000 UNITS/GM

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

@ AKORN 400 UNITS/GM;EQ 3.5MG

BASE/GM;10,000 UNITS/GM

A065088 001 Feb 06, 2004 Jan DISC

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

AP	RUBICON	0.5MG/ML	A217324	001	Feb 22, 2023	Feb NEWA
AP		1MG/ML	A217324	002	Feb 22, 2023	Feb NEWA
AP		2MG/ML	A217324	003	Feb 22, 2023	Feb NEWA

TABLET; ORAL

BACLOFEN

AB UNICHEM 5MG

A212067 003 Mar 09, 2023 Mar NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL
 BALSALAZIDE DISODIUM
 @ DASH PHARMS NATCO 750MG A077807 001 Dec 28, 2007 Feb CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL
 BENAZEPRIL HYDROCHLORIDE
 AB COREPHARMA 5MG A077128 001 Mar 08, 2006 Mar CAHN
 AB 10MG A077128 002 Mar 08, 2006 Mar CAHN
 AB 20MG A077128 003 Mar 08, 2006 Mar CAHN
 AB 40MG A077128 004 Mar 08, 2006 Mar CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)
 BENDAMUSTINE HYDROCHLORIDE
 AP BRECKENRIDGE 25MG/VIAL A205447 001 Feb 14, 2023 Feb NEWA
 AP 100MG/VIAL A205447 002 Feb 14, 2023 Feb NEWA
 >A> AP MYLAN LABS LTD 25MG/VIAL A204104 001 Apr 28, 2023 Apr NEWA
 >A> AP 100MG/VIAL A204104 002 Apr 28, 2023 Apr NEWA
 SOLUTION;INTRAVENOUS
 BENDAMUSTINE HYDROCHLORIDE
 + @ HOSPIRA 25MG/ML (25MG/ML) N211530 001 Dec 15, 2022 Jan DISC
 + @ 100MG/4ML (25MG/ML) N211530 002 Dec 15, 2022 Jan DISC
 + @ 200MG/8ML (25MG/ML) N211530 003 Dec 15, 2022 Jan DISC

BENZONATATE

CAPSULE;ORAL
 BENZONATATE
 AA CHARTWELL RX 100MG A040682 001 Jul 30, 2007 Feb CAHN
 AA 200MG A040682 002 Jul 30, 2007 Feb CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL
 BENZACLIN
 + @ BAUSCH 5%;EQ 1% BASE N050756 001 Dec 21, 2000 Feb DISC
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
 AB ! GLENMARK PHARMS 5%;EQ 1% BASE A209252 001 Mar 14, 2019 Feb CHRS

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC
 BEPOTASTINE BESILATE
 AT ALEMBIC 1.5% A214588 001 Apr 05, 2023 Mar NEWA

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
 BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
 AB HIKMA 3MG/ML;EQ 3MG BASE/ML A077838 001 Jan 17, 2023 Jan NEWA

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
 AB GLENMARK PHARMS LTD 0.064%;0.005% A214688 001 Mar 21, 2023 Mar NFTG
 ENSTILAR
 AB +! LEO PHARMA AS 0.064%;0.005% N207589 001 Oct 16, 2015 Mar CFTG
 OINTMENT;TOPICAL
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
 @ TOLMAR 0.064%;0.005% A201615 001 Jan 14, 2013 Feb DISC
 SUSPENSION;TOPICAL
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
 AB COSETTE 0.064%;0.005% A210765 001 May 11, 2020 Feb CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL
 BETAMETHASONE VALERATE
 >A> AB XIROMED 0.12% A210639 001 Apr 18, 2023 Apr NEWA

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

@ AKORN

EQ 0.5% BASE

A075386 001 Jun 30, 2000 Feb DISC

BEXAGLIFLOZIN

TABLET;ORAL

BRENZAVVY

+! THERACOSBIO

20MG

N214373 001 Jan 20, 2023 Jan NEWA

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB PINNACLE LIFE SCI 50MG

A079089 001 Jul 06, 2009 Jan CAHN

BIMATOPROST

IMPLANT;OPHTHALMIC

DURYSTA

+! ABBVIE

10MCG

N211911 001 Mar 04, 2020 Jan CAHN

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB PAR PHARM 140MG;125MG;125MG A205770 001 Mar 06, 2023 Feb NFTG
PYLERA
AB +! ABBVIE 140MG;125MG;125MG N050786 001 Sep 28, 2006 Mar CAHN
AB +! ALLERGAN 140MG;125MG;125MG N050786 001 Sep 28, 2006 Feb CFTGBISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB ALEMBIC 5MG A204891 001 Jan 11, 2017 Feb CAHN
AB 10MG A204891 002 Jan 11, 2017 Feb CAHN
@ DASH PHARMS NATCO 5MG A075831 001 Dec 14, 2005 Feb CAHN
@ 10MG A075831 002 Dec 14, 2005 Feb CAHNBORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

@ ACCORD HLTHCARE

3.5MG/VIAL

A204405 001 Jul 26, 2022 Feb DISC

SOLUTION;INTRAVENOUS

BORTEZOMIB

+ @ ACCORD HLTHCARE

2.5MG/ML (2.5MG/ML)

N215441 001 Jul 26, 2022 Feb DISC

+ @

3.5MG/1.4ML (2.5MG/ML)

N215441 002 Jul 26, 2022 Feb DISC

BOSENTAN

TABLET;ORAL

BOSENTAN

>D> AB PAR PHARM INC 62.5MG A205699 001 Apr 26, 2019 Apr DISC
>A> @ 62.5MG A205699 001 Apr 26, 2019 Apr DISC
>D> AB 125MG A205699 002 Apr 26, 2019 Apr DISC
>A> @ 125MG A205699 002 Apr 26, 2019 Apr DISCBRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

@ BRECKENRIDGE

50MG/ML

A204386 001 Dec 21, 2018 Feb DISC

BREXIPIPRAZOLE

TABLET;ORAL

BREXIPIPRAZOLE

AB AJANTA PHARMA LTD 0.25MG A213718 001 Feb 03, 2023 Jan NEWA
AB 0.5MG A213718 002 Feb 03, 2023 Jan NEWA
AB 1MG A213718 003 Feb 03, 2023 Jan NEWA
AB 2MG A213718 004 Feb 03, 2023 Jan NEWA
AB 3MG A213718 005 Feb 03, 2023 Jan NEWA
AB 4MG A213718 006 Feb 03, 2023 Jan NEWA
@ AMNEAL 0.25MG A213562 001 Jan 31, 2023 Mar DISC
AB 0.25MG A213562 001 Jan 31, 2023 Jan NEWA
@ 0.5MG A213562 002 Jan 31, 2023 Mar DISC
AB 0.5MG A213562 002 Jan 31, 2023 Jan NEWA

TABLET;ORAL
BREXPIPRAZOLE

AB	@	1MG	A213562	003	Jan 31, 2023	Mar DISC
		1MG	A213562	003	Jan 31, 2023	Jan NEWA
AB	@	2MG	A213562	004	Jan 31, 2023	Mar DISC
		2MG	A213562	004	Jan 31, 2023	Jan NEWA
AB	@	3MG	A213562	005	Jan 31, 2023	Mar DISC
		3MG	A213562	005	Jan 31, 2023	Jan NEWA
AB	@	4MG	A213562	006	Jan 31, 2023	Mar DISC
		4MG	A213562	006	Jan 31, 2023	Jan NEWA
AB	LUPIN LTD	0.25MG	A213512	001	Mar 17, 2023	Mar NEWA
AB		0.5MG	A213512	002	Mar 17, 2023	Mar NEWA
AB		1MG	A213512	003	Mar 17, 2023	Mar NEWA
AB		2MG	A213512	004	Mar 17, 2023	Mar NEWA
AB		3MG	A213512	005	Mar 17, 2023	Mar NEWA
AB		4MG	A213512	006	Mar 17, 2023	Mar NEWA
	TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Feb DISC
	@	0.5MG	A213692	002	Aug 11, 2022	Feb DISC
	@	1MG	A213692	003	Aug 11, 2022	Feb DISC
	@	2MG	A213692	004	Aug 11, 2022	Feb DISC
	@	3MG	A213692	005	Aug 11, 2022	Feb DISC
	@	4MG	A213692	006	Aug 11, 2022	Feb DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC
BRIMONIDINE TARTRATE

AT	ALEMBIC	0.15%	A215225	001	Mar 29, 2023	Mar NEWA
----	---------	-------	---------	-----	--------------	----------

BRIVARACETAM

TABLET;ORAL
BRIVARACETAM

@ AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023	Mar DISC
@	100MG	A214848	002	Jan 06, 2023	Mar DISC
@ LUPIN LTD	10MG	A214918	001	Dec 20, 2022	Mar DISC
@	25MG	A214918	002	Dec 20, 2022	Mar DISC
@	50MG	A214918	003	Dec 20, 2022	Mar DISC
@	75MG	A214918	004	Dec 20, 2022	Mar DISC
@	100MG	A214918	005	Dec 20, 2022	Mar DISC
BRIVIACT					
+ UCB INC	10MG	N205836	001	May 12, 2016	Mar CTEC
+	25MG	N205836	002	May 12, 2016	Mar CTEC
+	50MG	N205836	003	May 12, 2016	Mar CTEC
+	75MG	N205836	004	May 12, 2016	Mar CTEC
+!	100MG	N205836	005	May 12, 2016	Mar CTEC

BROMOCRIPTINE MESYLATE

TABLET;ORAL

BROMOCRIPTINE MESYLATE

>A>	@ AUROBINDO PHARMA USA	EQ 2.5MG BASE	A076962	001	Sep 24, 2004	Apr CAHN
>D>	@ MYLAN	EQ 2.5MG BASE	A076962	001	Sep 24, 2004	Apr CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ BRECKENRIDGE	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jan DISC
----------------	---------------------------	---------	-----	--------------	----------

BUDESONIDE

AEROSOL, FOAM;RECTAL

BUDESONIDE

AB	PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Mar NFTG
AB	UCERIS					
AB	+! SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Mar CFTG

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED;INHALATION

SYMBICORT AEROSPHERE

>A>	+! ASTRAZENECA	0.16MG/INH;0.0048MG/INH	N216579	001	Apr 28, 2023	Apr NEWA
-----	----------------	-------------------------	---------	-----	--------------	----------

>A>	+! ASTRAZENECA	0.16MG/INH;0.0048MG/INH	N216579	001	Apr 28, 2023	Apr NEWA
-----	----------------	-------------------------	---------	-----	--------------	----------

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL
BUPRENORPHINE

AB	ALVOGEN	7.5MCG/HR	A207490	005	Mar 21, 2023	Mar NEWA
----	---------	-----------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>A>	@ DR REDDYS LABS SA	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Apr CAHN
>A>	@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Apr CAHN
>D>	@ MAYNE PHARMA INC	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Apr CAHN
>D>	@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Apr CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

@ GRAVITI PHARMS	5MG	A075413	001	Mar 19, 2002	Feb CAHN	
@	10MG	A075413	002	Mar 19, 2002	Feb CAHN	
@	15MG	A075413	003	Mar 19, 2002	Feb CAHN	
AB	ZYDUS PHARMS	7.5MG	A078888	005	Mar 21, 2023	Mar NEWA

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

@ AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Jan DISC
@ ARTHUR GRP	6MG/ML	A205106	001	Sep 21, 2018	Mar DISC

CABAZITAXEL

SOLUTION;INTRAVENOUS
CABAZITAXEL

+! APCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Feb CMFD
AP APOTEX	60MG/1.5ML (40MG/ML)	A207736	001	Feb 10, 2023	Feb NEWA
AP DR REDDYS	60MG/1.5ML (40MG/ML)	A207718	001	Feb 10, 2023	Feb NEWA
+! SANDOZ INC	45MG/4.5ML (10MG/ML)	N208715	001	Jan 05, 2023	Jan NEWA
+!	60MG/6ML (10MG/ML)	N208715	002	Jan 05, 2023	Jan NEWA

CALCIPOTRIENE

CREAM;TOPICAL
CALCIPOTRIENE

@ TOLMAR	0.005%	A200935	001	May 30, 2012	Feb DISC
SOLUTION;TOPICAL CALCIPOTRIENE					
AT ! COSETTE	0.005%	A078468	001	Mar 24, 2011	Feb CHRS
@ TOLMAR	0.005%	A077029	001	Nov 20, 2009	Feb DISC

CALCIUM ACETATE

CAPSULE;ORAL
CALCIUM ACETATE

AB SQUARE PHARMS	667MG	A217205	001	Mar 13, 2023	Mar NEWA
------------------	-------	---------	-----	--------------	----------

CAPECITABINE

TABLET;ORAL
XELODA

>A> AB + CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Apr CAHN
>A> AB +!	500MG	N020896	002	Apr 30, 1998	Apr CAHN
>D> AB + HOFFMANN LA ROCHE	150MG	N020896	001	Apr 30, 1998	Apr CAHN
>D> AB +!	500MG	N020896	002	Apr 30, 1998	Apr CAHN

CAPTOPRIL

TABLET;ORAL
CAPTOPRIL

AB CHANGZHOU PHARM	12.5MG	A214442	001	Jan 27, 2023	Jan NEWA
AB	25MG	A214442	002	Jan 27, 2023	Jan NEWA
AB	50MG	A214442	003	Jan 27, 2023	Jan NEWA
AB	100MG	A214442	004	Jan 27, 2023	Jan NEWA
AB COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Mar CAHN
AB	25MG	A074737	002	Oct 28, 1998	Mar CAHN
AB	50MG	A074737	003	Oct 28, 1998	Mar CAHN
AB	100MG	A074737	004	Oct 28, 1998	Mar CAHN

CARBAMAZEPINE

SUSPENSION;ORAL

CARBAMAZEPINE

AB	CHARTWELL RX	100MG/5ML	A075714	001	Jun 05, 2002	Jan CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	CARBAMAZEPINE					
AB	AJANTA PHARMA LTD	100MG	A216193	001	Mar 24, 2023	Mar NEWA
AB		200MG	A216193	002	Mar 24, 2023	Mar NEWA
AB		400MG	A216193	003	Mar 24, 2023	Mar NEWA
AB	SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Feb NEWA
AB		200MG	A216235	002	Mar 02, 2023	Feb NEWA
AB		400MG	A216235	003	Mar 02, 2023	Feb NEWA

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

AB	ZYDUS PHARMS	10MG;100MG	A215999	001	Apr 04, 2023	Mar NEWA
AB		25MG;100MG	A215999	002	Apr 04, 2023	Mar NEWA
AB		25MG;250MG	A215999	003	Apr 04, 2023	Mar NEWA
	TABLET, ORALLY DISINTEGRATING;ORAL					
	CARBIDOPA AND LEVODOPA					
>D> AB	SUN PHARM	10MG;100MG	A078690	001	Jul 31, 2009	Apr CTEC
>A>		10MG;100MG	A078690	001	Jul 31, 2009	Apr CTEC
>D> AB		25MG;100MG	A078690	002	Jul 31, 2009	Apr CTEC
>A>		25MG;100MG	A078690	002	Jul 31, 2009	Apr CTEC

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

AP	CAPLIN	EQ 0.25MG BASE/ML	A216882	001	Feb 13, 2023	Feb NEWA
----	--------	-------------------	---------	-----	--------------	----------

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

VRAYLAR

+!	ABBVIE	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan CAHN
+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan CAHN
+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan CAHN
+		EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan CAHN

CARMUSTINE

INJECTABLE; INJECTION

CARMUSTINE

AP	ACCORD HLTHCARE	100MG/VIAL	A214117	001	Dec 27, 2022	Mar CTNA
	@ MYLAN LABS LTD	100MG/VIAL	A215368	001	Mar 03, 2023	Mar DISC
AP		100MG/VIAL	A215368	001	Mar 03, 2023	Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

@	HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Mar DISC
@		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Mar DISC
@		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Mar DISC
@		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Mar DISC

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	MYLAN	100MG	A078857	002	Feb 11, 2015	Mar DISC
AB	YABAO PHARM	100MG	A212564	001	Apr 10, 2023	Mar NEWA
AB		200MG	A212564	002	Apr 10, 2023	Mar NEWA
AB		400MG	A212564	003	Apr 10, 2023	Mar NEWA
	SOLUTION;ORAL					
	ELYXYB					
+ @ SCILEX HLDG		25MG/ML	N212157	001	May 05, 2020	Feb CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA	30MG	A215056	001	Apr 18, 2023	Apr NEWA
AB	RUBICON	30MG	A216682	001	Apr 06, 2023	Mar NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT CHARTWELL RX 0.12% A075006 001 Mar 03, 2004 Jan CAHN

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

>D> BX	AMNEAL PHARMS CO	10MG	A209755	001	Sep 10, 2018	Apr CTEC
>A> AB		10MG	A209755	001	Sep 10, 2018	Apr CTEC
>D> BX		25MG	A209755	002	Sep 10, 2018	Apr CTEC
>A> AB		25MG	A209755	002	Sep 10, 2018	Apr CTEC
>D> BX		50MG	A209755	003	Sep 10, 2018	Apr CTEC
>A> AB		50MG	A209755	003	Sep 10, 2018	Apr CTEC
>D> BX		100MG	A209755	004	Sep 10, 2018	Apr CTEC
>A> AB		100MG	A209755	004	Sep 10, 2018	Apr CTEC
>D> BX		200MG	A209755	005	Sep 10, 2018	Apr CTEC
>A> AB		200MG	A209755	005	Sep 10, 2018	Apr CTEC

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

>A> AA	ACME LABS	500MG	A214365	001	Apr 27, 2023	Apr NEWA
AB	APPCO	375MG	A212047	001	Jan 27, 2023	Jan NEWA
AB		750MG	A212047	002	Jan 27, 2023	Jan NEWA
AA	BELCHER	250MG	A215540	001	Jan 24, 2023	Jan NEWA
AA	COREPHARMA	250MG	A214702	001	Apr 10, 2023	Mar NEWA

CICLOPIROX

SOLUTION;TOPICAL

CICLOPIROX

AT !	PADAGIS US	8%	A077623	001	Sep 18, 2007	Jan CHRS
	PENLAC					
+ @	VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999	Jan DISC

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

>A>	@ AUROBINDO PHARMA USA	50MG	A077019	001	Nov 23, 2004	Apr CAHN
>A>	@	100MG	A077019	002	Nov 23, 2004	Apr CAHN
>D>	@ MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004	Apr CAHN
>D>	@	100MG	A077019	002	Nov 23, 2004	Apr CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA XTRIUM LABS INC EQ 300MG BASE/5ML A074757 001 Oct 17, 1997 Mar CAHN

CIPROFLOXACIN

INJECTABLE, SUSPENSION;OTIC

OTIPRIO

+ @ ALK ABELLO 6% (60MG/ML) N207986 001 Dec 10, 2015 Jan DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

@ AKORN EQ 0.3% BASE A076555 001 Dec 11, 2008 Feb DISC

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

>A> AP HIKMA EQ 2MG BASE/ML A203079 001 Apr 19, 2023 Apr NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB +	ABBVIE	EQ 10MG BASE	N020822	001	Apr 27, 2000	Feb CAHN
AB +		EQ 20MG BASE	N020822	002	Jul 17, 1998	Feb CAHN
AB +!		EQ 40MG BASE	N020822	003	Jul 17, 1998	Feb CAHN
	@	EQ 60MG BASE	N020822	004	Jul 17, 1998	Feb CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	EQ 75MG BASE	A216957	001	Mar 10, 2023	Mar NEWA
AB		EQ 150MG BASE	A216957	002	Mar 10, 2023	Mar NEWA
AB		EQ 300MG BASE	A216957	003	Mar 10, 2023	Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	CHARTWELL RX	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Feb CAHN
----	--------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

AP	HIKMA	EQ 6MG BASE/ML	A214401	001	Apr 05, 2023	Mar NEWA
AP		EQ 12MG BASE/ML	A214401	002	Apr 05, 2023	Mar NEWA
AP		EQ 18MG BASE/ML	A214401	003	Apr 05, 2023	Mar NEWA
	SOLUTION;TOPICAL					
	CLINDAMYCIN PHOSPHATE					
	@ XTTRIUM LABS INC	EQ 1% BASE	A063304	001	Jul 15, 1997	Jan CAHN

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

@ ACCORD HLTHCARE	2.5MG/ML	A216008	001	Sep 06, 2022	Mar DISC
@ UPSHER SMITH LABS	2.5MG/ML	A210569	001	Oct 22, 2018	Mar DISC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

@ TORRENT	0.05%	A211836	001	Dec 30, 2019	Feb DISC	
	CLOBETASOL PROPIONATE (EMOLlient)					
>D> AB2	ANI PHARMS	0.05%	A075733	001	Aug 22, 2001	Apr DISC

>A> @ 0.05%

A075733 001 Aug 22, 2001

A075733 001 Aug 22, 2001

Apr DISC

Apr DISC

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

@ EUGIA PHARMA	20MG/20ML (1MG/ML)	A212457	001	Oct 03, 2022	Mar DISC
----------------	--------------------	---------	-----	--------------	----------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	AUROBINDO PHARMA	25MG	A216440	001	Mar 20, 2023	Mar NEWA
AB		50MG	A216440	002	Mar 20, 2023	Mar NEWA
AB		75MG	A216440	003	Mar 20, 2023	Mar NEWA

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB	AUROBINDO PHARMA USA	0.5MG	A075150	001	Oct 05, 1998	Jan CMFD
AB		1MG	A075150	002	Oct 05, 1998	Jan CMFD
AB		2MG	A075150	003	Oct 05, 1998	Jan CMFD

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@ DASH PHARMS	3.75MG	A071509	001	Oct 19, 1987	Feb CAHN
@	7.5MG	A071510	001	Oct 19, 1987	Feb CAHN
@	15MG	A071511	001	Oct 19, 1987	Feb CAHN

CLOZAPINE

TABLET;ORAL

CLOZAPINE

>A>	@ DR REDDYS LABS SA	25MG	A203807	001	Sep 17, 2015	Apr CAHN
>A>	@	50MG	A203807	003	Aug 22, 2017	Apr CAHN
>A>	@	100MG	A203807	002	Sep 17, 2015	Apr CAHN
>A>	@	200MG	A203807	004	Aug 22, 2017	Apr CAHN
>D> AB	MAYNE PHARMA	25MG	A203807	001	Sep 17, 2015	Apr CAHN
>D> AB		50MG	A203807	003	Aug 22, 2017	Apr CAHN

TABLET;ORAL
CLOZAPINE

>D> AB	100MG	A203807	002	Sep 17, 2015	Apr CAHN
>D> AB	200MG	A203807	004	Aug 22, 2017	Apr CAHN

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL
TRIACIN-C
! ANIMA

10MG/5ML;30MG/5ML;1.25MG/5ML	A088704	001	Mar 22, 1985	Mar CAHN
------------------------------	---------	-----	--------------	----------

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL
COLESEVELAM HYDROCHLORIDE

AB IMPAX	3.75GM/PACKET	A212886	001	Jan 18, 2023	Jan NEWA
----------	---------------	---------	-----	--------------	----------

COlestipol HYDROCHLORIDE

TABLET;ORAL
COlestipol HYDROCHLORIDE

>A> AB ANI PHARMS	1GM	A216517	001	Mar 10, 2023	Apr CAHN
>D> AB PRAXGEN	1GM	A216517	001	Mar 10, 2023	Apr CAHN
AB	1GM	A216517	001	Mar 10, 2023	Mar NEWA

CROMOLYN SODIUM

SOLUTION;INHALATION
CROMOLYN SODIUM

>D> AN FERA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Apr CAHN
>A> AN VIRTUS	10MG/ML	A075437	001	Apr 21, 2000	Apr CAHN
SOLUTION/DROPS;OPHTHALMIC					
CROMOLYN SODIUM					
@ AKORN	4%	A074706	001	Apr 29, 1998	Feb DISC
! SANDOZ INC	4%	A075282	001	Jun 16, 1999	Feb CTEC
AT !	4%	A075282	001	Jun 16, 1999	Feb CHRS

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

@ APOTEX	15MG	A206703	001	Jul 24, 2018	Mar DISC
@	30MG	A206703	002	Jul 24, 2018	Mar DISC

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB CHARTWELL RX	5MG	A078218	002	Jun 19, 2015	Feb CAHN
AB	7.5MG	A078218	003	Nov 03, 2020	Feb CAHN
AB	10MG	A078218	001	Apr 18, 2008	Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CYCLOGYL

+! ALCON LABS INC 0.5%
CYCLOPENTOLATE HYDROCHLORIDE

@ AKORN 0.5%

A084109	001		Feb CTEC
A205937	001	Dec 09, 2015	Feb DISC

CYCLOSPORINE

EMULSION;OPHTHALMIC
CYCLOSPORINE

AB APOTEX	0.05%	A207606	001	Jan 12, 2023	Jan NEWA
SOLUTION;ORAL					
CYCLOSPORINE					
AB2 XTRRIUM LABS INC	100MG/ML	A065133	001	Sep 17, 2004	Jan CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA CHARTWELL RX	4MG	A088212	001	May 26, 1983	Mar CMFD
-----------------	-----	---------	-----	--------------	----------

CYSTEINE HYDROCHLORIDE

INJECTABLE;INJECTION
CYSTEINE HYDROCHLORIDE

>A> @ HIKMA	7.25%	A213073	001	Jan 26, 2023	Apr CAHN
>D> NIVAGEN PHARMS INC	7.25%	A213073	001	Jan 26, 2023	Apr CAHN
	7.25%	A213073	001	Jan 26, 2023	Jan NFTG

DABRAFENIB MESYLATE

TABLET, FOR SUSPENSION;ORAL

TAFINLAR

+! NOVARTIS

EQ 10MG BASE

N217514 001 Mar 16, 2023 Mar NEWA

DAPRODUSTAT

TABLET;ORAL

JESDUVROQ

+ GLAXOSMITHKLINE

1MG

N216951 001 Feb 01, 2023 Feb NEWA

+ GLAXOSMITHKLINE

2MG

N216951 002 Feb 01, 2023 Feb NEWA

+ GLAXOSMITHKLINE

4MG

N216951 003 Feb 01, 2023 Feb NEWA

+ GLAXOSMITHKLINE

6MG

N216951 004 Feb 01, 2023 Feb NEWA

+! GLAXOSMITHKLINE

8MG

N216951 005 Feb 01, 2023 Feb NEWA

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

@ HAINAN POLY PHARM

500MG/VIAL

A215890 001 Aug 18, 2022 Feb DISC

+! XELLIA PHARMS APS

350MG/VIAL

N217415 001 Jan 30, 2023 Jan NEWA

+! XELLIA PHARMS APS

500MG/VIAL

N217415 002 Jan 30, 2023 Jan NEWA

SOLUTION; INTRAVENOUS

DAPTOMYCIN IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP

350MG/50ML (7MG/ML)

N213645 002 Feb 27, 2023 Mar NEWA

+! BAXTER HLTHCARE CORP

500MG/50ML (10MG/ML)

N213645 003 Feb 27, 2023 Mar NEWA

+! BAXTER HLTHCARE CORP

700MG/100ML (7MG/ML)

N213645 004 Feb 27, 2023 Mar NEWA

+! BAXTER HLTHCARE CORP

1GM/100ML (10MG/ML)

N213645 005 Feb 27, 2023 Mar NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

ENABLEX

>A> + @ ABBVIE

EQ 7.5MG BASE

N021513 001 Dec 22, 2004 Apr CAHN

>A> + @

EQ 15MG BASE

N021513 002 Dec 22, 2004 Apr CAHN

>D> + @ APIL

EQ 7.5MG BASE

N021513 001 Dec 22, 2004 Apr CAHN

>D> + @

EQ 15MG BASE

N021513 002 Dec 22, 2004 Apr CAHN

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

AB ANNORA PHARMA

90MG

A216229 003 Mar 16, 2023 Mar NEWA

TABLET;ORAL

DEFERASIROX

AB CHARTWELL RX

90MG

A212669 001 May 27, 2021 Mar CAHN

AB

180MG

A212669 002 May 27, 2021 Mar CAHN

AB

360MG

A212669 003 May 27, 2021 Mar CAHN

@ CIPLA

90MG

A211852 001 Feb 11, 2020 Mar DISC

@ CIPLA

180MG

A211852 003 Jun 15, 2020 Mar DISC

@ CIPLA

360MG

A211852 002 Feb 11, 2020 Mar DISC

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

@ TEVA PHARMS USA

125MG

A207124 001 Sep 23, 2022 Mar DISC

@ TEVA PHARMS USA

250MG

A207124 002 Sep 23, 2022 Mar DISC

@ TEVA PHARMS USA

500MG

A207124 003 Sep 23, 2022 Mar DISC

DESLORATADINE

TABLET;ORAL

DESLORATADINE

@ DASH PHARMS

5MG

A078351 001 Feb 10, 2012 Feb CAHN

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

AP GLAND

0.004MG/ML

A216904 001 Mar 20, 2023 Mar NEWA

DEUTETETRABENAZINE

TABLET, EXTENDED RELEASE;ORAL

AUSTEDO XR

+ TEVA

6MG

N216354 001 Feb 17, 2023 Feb NEWA

+ TEVA

12MG

N216354 002 Feb 17, 2023 Feb NEWA

+!

24MG

N216354 003 Feb 17, 2023 Feb NEWA

DEXAMETHASONE

ELIXIR; ORAL	DEXAMETHASONE					
+ @ XTTRIUM LABS INC	0.5MG/5ML		A088254	001	Jul 27, 1983	Jan CAHN
TABLET; ORAL	DEXAMETHASONE					
>D> BP	ALVOGEN	4MG	A088481	004	Apr 28, 1983	Apr CTEC
>A> AB		4MG	A088481	004	Apr 28, 1983	Apr CTEC
>D> BP		6MG	A088481	001	Nov 28, 1983	Apr CTEC
>A> AB		6MG	A088481	001	Nov 28, 1983	Apr CTEC
>A> AB	BIONPHARMA INC	2MG	A217538	001	Apr 26, 2023	Apr NEWA
>A> AB		4MG	A217001	001	Apr 19, 2023	Apr NEWA
>A> AB		6MG	A217001	002	Apr 19, 2023	Apr NEWA
>A> AB	NOVITIUM PHARMA	2MG	A217696	001	May 09, 2023	Apr NEWA
>D>	@ PRASCO	4MG	A080399	002	Apr 20, 2022	Apr CMFD
>A> AB		4MG	A080399	002	Apr 20, 2022	Apr CMFD
	@	4MG	A080399	002	Apr 20, 2022	Feb DISC

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL	DEXTROAMPHETAMINE SULFATE					
AA ! PRASCO	5MG/5ML		A040776	001	Jan 29, 2008	Mar CAHN
TABLET; ORAL	DEXTROAMPHETAMINE SULFATE					
AA ARBOR PHARMS LLC	2.5MG		A090533	001	Oct 25, 2011	Jan CTEC
AA	7.5MG		A090533	003	Oct 25, 2011	Jan CTEC
AA	15MG		A090533	005	Oct 25, 2011	Jan CTEC
AA	20MG		A090533	006	Oct 25, 2011	Jan CTEC
AA	30MG		A090533	007	Oct 25, 2011	Jan CTEC
AA WINDER LABS LLC	2.5MG		A212160	001	Jun 07, 2021	Jan CMFD
AA	5MG		A212160	002	Jun 07, 2021	Jan CMFD
AA	7.5MG		A212160	003	Jun 07, 2021	Jan CMFD
AA	10MG		A212160	004	Jun 07, 2021	Jan CMFD
AA	15MG		A212160	005	Jun 07, 2021	Jan CMFD
AA	20MG		A212160	006	Jun 07, 2021	Jan CMFD
AA	30MG		A212160	007	Jun 07, 2021	Jan CMFD

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION						
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
AP FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Mar CMFD	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Mar CMFD	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
AP FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Mar CMFD	
AP +! ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CHRS	
AP +	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CTEC	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Mar CMFD	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Mar CMFD	
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP FRESENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Mar CMFD	
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP FRESENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Mar CMFD	
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP FRESENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Mar CMFD	

DICLOFENAC POTASSIUM

TABLET; ORAL	DICLOFENAC POTASSIUM					
AB SENORES PHARMS	50MG		A215787	001	Mar 15, 2023	Mar NEWA

DICLOFENAC SODIUM

GEL; TOPICAL	DICLOFENAC SODIUM					
AB AMNEAL	3%		A200936	001	Oct 28, 2013	Feb CAHN
SOLUTION; TOPICAL	DICLOFENAC SODIUM					
AB AUROLIFE PHARMA LLC	2%		A213040	001	Feb 03, 2023	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

>A>	@ AUROBINDO PHARMA USA	100MG	A076152	001	Dec 13, 2001	Apr CAHN
>D>	@ MYLAN	100MG	A076152	001	Dec 13, 2001	Apr CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

AB	COREPHARMA	10MG	A216639	001	Mar 24, 2023	Mar NEWA
	INJECTABLE; INJECTION					
	BENTYL					
AP	+! ABBVIE	10MG/ML	N008370	001	Oct 15, 1984	Feb CAHN
	BENTYL PRESERVATIVE FREE					
AP	+! ABBVIE	10MG/ML	N008370	002	Oct 15, 1984	Feb CAHN
	TABLET;ORAL					
	DICYCLOMINE HYDROCHLORIDE					
AB	AUROBINDO PHARMA USA	20MG	A040317	001	Sep 07, 1999	Feb CMFD

DIETHYLPROMION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROMION HYDROCHLORIDE

!	LANNETT CO INC	75MG	A091680	001	Oct 24, 2011	Feb CTEC
---	----------------	------	---------	-----	--------------	----------

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL

DIHYDROERGOTAMINE MESYLATE

>D>	@ AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Apr CMFD
>A> AB		0.5MG/SPRAY	A214105	001	Jan 04, 2022	Apr CMFD

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB1	TWI PHARMS	60MG	A217377	001	Mar 01, 2023	Feb NEWA
AB1		90MG	A217377	002	Mar 01, 2023	Feb NEWA
AB1		120MG	A217377	003	Mar 01, 2023	Feb NEWA
	INJECTABLE; INJECTION					
	DILTIAZEM HYDROCHLORIDE					
AP	EUGIA PHARMA	5MG/ML	A216552	001	Mar 29, 2023	Mar NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	DILTIAZEM HYDROCHLORIDE					
AB	AMTA	120MG	A216439	001	Mar 07, 2023	Feb NEWA
AB		180MG	A216439	002	Mar 07, 2023	Feb NEWA
AB		240MG	A216439	003	Mar 07, 2023	Feb NEWA
AB		300MG	A216439	004	Mar 07, 2023	Feb NEWA
AB		360MG	A216439	005	Mar 07, 2023	Feb NEWA
AB		420MG	A216439	006	Mar 07, 2023	Feb NEWA
AB	SCIEGEN PHARMS INC	120MG	A216327	001	Apr 06, 2023	Mar NEWA
AB		180MG	A216327	002	Apr 06, 2023	Mar NEWA
AB		240MG	A216327	003	Apr 06, 2023	Mar NEWA
AB		300MG	A216327	004	Apr 06, 2023	Mar NEWA
AB		360MG	A216327	005	Apr 06, 2023	Mar NEWA
AB		420MG	A216327	006	Apr 06, 2023	Mar NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

AB	SOLA PHARMS	120MG	A210436	001	Mar 26, 2021	Feb CMFD
		240MG	A210436	002	Mar 26, 2021	Feb CMFD

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

>D>	! PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982	Apr CRLD
>A>	+!	12.5MG/5ML	A087513	001	Feb 10, 1982	Apr CRLD

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

>D> AB	ANI PHARMS	25MG	A086944	002	Apr 16, 1991	Apr DISC
>A>	@	25MG	A086944	002	Apr 16, 1991	Apr DISC
>D> AB		50MG	A086944	001	Feb 25, 1992	Apr DISC
>A>	@	50MG	A086944	001	Feb 25, 1992	Apr DISC

TABLET;ORAL
DIPYRIDAMOLE

>D> AB		75MG	A 086944 003 Feb 25, 1992	Apr DISC
>A>	@	75MG	A 086944 003 Feb 25, 1992	Apr DISC

DISULFIRAM

TABLET;ORAL
DISULFIRAM
@ DASH PHARMS

250MG	A 203916 001 Mar 04, 2015	Feb CAHN
500MG	A 203916 002 Mar 04, 2015	Feb CAHN

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

AP	ALEMBIC	20MG/2ML (10MG/ML)	A 215744 001 Feb 28, 2023	Feb NEWA
AP		80MG/8ML (10MG/ML)	A 215744 002 Feb 28, 2023	Feb NEWA
AP		160MG/16ML (10MG/ML)	A 215744 003 Feb 28, 2023	Feb NEWA
>A> AP	MYLAN LABS LTD	20MG/ML (20MG/ML)	A 203892 001 May 11, 2023	Apr NEWA
>A> AP		80MG/4ML (20MG/ML)	A 203892 002 May 11, 2023	Apr NEWA

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

>D> AP	+! B BRAUN	80MG/100ML	N 019099 002 Oct 15, 1986	Apr DISC
>A>	+ @	80MG/100ML	N 019099 002 Oct 15, 1986	Apr DISC
>D> AP	+!	320MG/100ML	N 019099 004 Oct 15, 1986	Apr DISC
>A>	+ @	320MG/100ML	N 019099 004 Oct 15, 1986	Apr DISC
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER				
>D>	+! B BRAUN	40MG/100ML	N 019099 001 Oct 15, 1986	Apr DISC
>A>	+ @	40MG/100ML	N 019099 001 Oct 15, 1986	Apr DISC
>D> AP	+!	160MG/100ML	N 019099 003 Oct 15, 1986	Apr DISC
>A>	+ @	160MG/100ML	N 019099 003 Oct 15, 1986	Apr DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>A> AT	INGENUS PHARMS LLC	EQ 2% BASE;EQ 0.5% BASE	A 217260 001 May 01, 2023	Apr NEWA
--------	--------------------	-------------------------	---------------------------	----------

DOXEPEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPEPIN HYDROCHLORIDE

AB	ZYDUS LIFESCIENCES	EQ 10MG BASE	A 210700 001 Mar 23, 2023	Mar CAHN
AB		EQ 25MG BASE	A 210700 002 Mar 23, 2023	Mar CAHN
AB		EQ 50MG BASE	A 210700 003 Mar 23, 2023	Mar CAHN
AB		EQ 75MG BASE	A 210700 004 Mar 23, 2023	Mar CAHN
AB		EQ 100MG BASE	A 210700 005 Mar 23, 2023	Mar CAHN
AB		EQ 150MG BASE	A 210140 001 Mar 21, 2023	Mar CAHN
AB	ZYDUS PHARMS	EQ 10MG BASE	A 210700 001 Mar 23, 2023	Mar NEWA
AB		EQ 25MG BASE	A 210700 002 Mar 23, 2023	Mar NEWA
AB		EQ 50MG BASE	A 210700 003 Mar 23, 2023	Mar NEWA
AB		EQ 75MG BASE	A 210700 004 Mar 23, 2023	Mar NEWA
AB		EQ 100MG BASE	A 210700 005 Mar 23, 2023	Mar NEWA
AB		EQ 150MG BASE	A 210140 001 Mar 21, 2023	Mar NEWA

CREAM;TOPICAL

DOXEPEPIN HYDROCHLORIDE

AB	TEVA PHARMS	5%	A 215408 001 Feb 17, 2023	Feb NFTG
----	-------------	----	---------------------------	----------

ZONALON

AB	+! MYLAN	5%	N 020126 001 Apr 01, 1994	Feb CFTG
----	----------	----	---------------------------	----------

TABLET;ORAL

DOXEPEPIN HYDROCHLORIDE

AB	MSN	EQ 3MG BASE	A 214823 001 Apr 03, 2023	Mar NEWA
----	-----	-------------	---------------------------	----------

AB		EQ 6MG BASE	A 214823 002 Apr 03, 2023	Mar NEWA
----	--	-------------	---------------------------	----------

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

AP	GLAND PHARMA LTD	EQ 100MG BASE/VIAL	A 215583 001 Apr 12, 2023	Mar NEWA
----	------------------	--------------------	---------------------------	----------

TABLET;ORAL

DOXYCYCLINE HYCLATE

@ ORYZA PHARMS SHENZHEN	EQ 100MG BASE	A 213475 001 Mar 10, 2021	Feb CAHN
-------------------------	---------------	---------------------------	----------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DRIZALMA SPRINKLE

+ @ SUN PHARM	EQ 30MG BASE	N212516	002	Jul 19, 2019	Mar DISC
+ @	EQ 40MG BASE	N212516	003	Jul 19, 2019	Jan DISC
+ @	EQ 60MG BASE	N212516	004	Jul 19, 2019	Mar DISC

DULOXETINE HYDROCHLORIDE

>A> AB ZYDUS HLTHCARE EQ 40MG BASE A090739 004 Apr 18, 2023 Apr NEWA

ECONAZOLE NITRATE

CREAM;TOPICAL
ECONAZOLE NITRATE

>A>	@ AUROBINDO PHARMA USA	1%	A210364	001	Apr 18, 2018	Apr CAHN
>D>	@ MYLAN PHARMS	1%	A210364	001	Apr 18, 2018	Apr CAHN

EDETA TE CALCIUM DISODIUM

INJECTABLE;INJECTION
CALCIUM DISODIUM VERSENATE

+ @ BAUSCH	200MG/ML	N008922	001		Mar DISC
------------	----------	---------	-----	--	----------

>A> EDETA TE CALCIUM DISODIUM

>A> ! CASPER PHARMA LLC 200MG/ML A216435 001 May 03, 2023 Apr NFTG

EFAVIRENZ

CAPSULE;ORAL
EFAVIRENZ

AUROBINDO PHARMA	50MG	A078064	001	Dec 15, 2017	Mar CTEC
!	200MG	A078064	003	Dec 15, 2017	Mar CHRS
	200MG	A078064	003	Dec 15, 2017	Mar CTEC

SUSTIVA

+ @ BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998	Mar DISC
+ @	200MG	N020972	003	Sep 17, 1998	Mar DISC

ELACESTRANT DIHYDROCHLORIDE

TABLET;ORAL
ORSERDU

+ STEMLINE THERAP	EQ 86MG BASE	N217639	001	Jan 27, 2023	Jan NEWA
+!	EQ 345MG BASE	N217639	002	Jan 27, 2023	Jan NEWA

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

>A>	GRANULES;ORAL					
>A>	TRIKAFTA (COPACKAGED)					
>A>	+ VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG	N217660	001	Apr 26, 2023	Apr NEWA
>A>	+!	100MG, 75MG, 50MG;75MG	N217660	002	Apr 26, 2023	Apr NEWA

ELIGLUSTAT TARTRATE

CAPSULE;ORAL
ELIGLUSTAT TARTRATE

>A> AB ZENARA	EQ 84MG BASE	A212420	001	May 02, 2023	Apr NEWA
---------------	--------------	---------	-----	--------------	----------

EMPAGLIFLOZIN

TABLET;ORAL
EMPAGLIFLOZIN

@ ZYDUS PHARMS	10MG	A212138	001	Aug 03, 2022	Jan DISC
@	25MG	A212138	002	Aug 03, 2022	Jan DISC

JARDIANCE

+ BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014	Jan CTEC
+!	25MG	N204629	002	Aug 01, 2014	Jan CTEC

EMTRICITABINE

CAPSULE;ORAL
EMTRICITABINE

AB AUROBINDO PHARMA LTD	200MG	A079188	001	Mar 15, 2023	Mar NEWA
-------------------------	-------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>D> AB APOTEX	200MG;300MG	A208740	001	Jun 16, 2021	Apr DISC
>A> @	200MG;300MG	A208740	001	Jun 16, 2021	Apr DISC
AB AUROBINDO PHARMA LTD	100MG;150MG	A211640	001	Mar 09, 2023	Mar NEWA
AB	133MG;200MG	A211640	002	Mar 09, 2023	Mar NEWA
AB	167MG;250MG	A211640	003	Mar 09, 2023	Mar NEWA

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

>D>	@ DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000	Apr CMFD
>A> AP		1.25MG/ML	A075578	001	Aug 22, 2000	Apr CMFD

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	SHENZHEN TECHDOW	30MG/0.3ML (100MG/ML)	A205660	001	Mar 15, 2023	Mar NEWA
AP		40MG/0.4ML (100MG/ML)	A205660	002	Mar 15, 2023	Mar NEWA
AP		60MG/0.6ML (100MG/ML)	A205660	003	Mar 15, 2023	Mar NEWA
AP		80MG/0.8ML (100MG/ML)	A205660	004	Mar 15, 2023	Mar NEWA
AP		100MG/ML (100MG/ML)	A205660	005	Mar 15, 2023	Mar NEWA
AP		120MG/0.8ML (150MG/ML)	A205660	006	Mar 15, 2023	Mar NEWA
AP		150MG/ML (150MG/ML)	A205660	007	Mar 15, 2023	Mar NEWA

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

EMERPHED

+! NEXUS PHARMS	25MG/5ML (5MG/ML)	N213407	002	Feb 28, 2023	Mar NEWA
AP SAGENT PHARMS INC	50MG/ML (50MG/ML)	A214528	001	Mar 09, 2023	Feb NEWA

EPINEPHRINE

SOLUTION; INTRAVENOUS

EPINEPHRINE IN 0.9% SODIUM CHLORIDE

>A> +! PAR STERILE PRODUCTS	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	Apr NEWA
>A> +!	4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	Apr NEWA
>A> +!	5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	Apr NEWA
>A> +!	8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Apr NEWA
>A> +!	10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Apr NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>D> AP ! HOSPIRA	0.01MG/ML; 2%	A089646	001	Jun 21, 1988	Apr CTEC
>A> !	0.01MG/ML; 2%	A089646	001	Jun 21, 1988	Apr CTEC

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

AP2 ! SUN PHARM VELETRI	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb CHRS
AP2 + ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CHRS

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

AA + VALIDUS PHARMS ERGOCALCIFEROL	50,000 IU	N003444	001		Feb CHRS
AA CHARTWELL RX	50,000 IU	A040833	001	May 20, 2009	Feb CAHN
AA ! STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010	Feb CHRS

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

>D> AB ZYDUS PHARMS	EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr CHRS
>A> AB ! TARCEVA	EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr CHRS
>D> AB + OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Apr DISC
>A> + @	EQ 25MG BASE	N021743	001	Nov 18, 2004	Apr DISC
>D> AB +	EQ 100MG BASE	N021743	002	Nov 18, 2004	Apr DISC
>A> + @	EQ 100MG BASE	N021743	002	Nov 18, 2004	Apr DISC
>D> AB + !	EQ 150MG BASE	N021743	003	Nov 18, 2004	Apr DISC
>A> + @	EQ 150MG BASE	N021743	003	Nov 18, 2004	Apr DISC

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
ERTAPENEM SODIUM

>A> AP SUN PHARM EQ 1GM BASE/VIAL A209145 001 May 02, 2023 Apr NEWA

ERYTHROMYCIN

TABLET; ORAL
ERYTHROMYCIN

AB ARBOR PHARMS LLC	500MG	A061621 002	Jan CHRS
AB ! CADILA PHARMS LTD	500MG	A213628 002	Jun 28, 2021
AB ZYDUS	250MG	A212693 001	Mar 07, 2023
	500MG	A212693 002	Feb NEWA

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

>A> @ AUROBINDO PHARMA USA EQ 400MG BASE A062847 001 Sep 14, 1988 Apr CAHN
>D> @ MYLAN EQ 400MG BASE A062847 001 Sep 14, 1988 Apr CAHN

ESCITALOPRAM OXALATE

SOLUTION; ORAL
LEXAPRO

+ @ ABBVIE EQ 5MG BASE/5ML

N021365 001 Nov 27, 2002 Jan CAHN

TABLET; ORAL

ESCITALOPRAM OXALATE

@ DASH PHARMS EQ 5MG BASE

A077550 001 May 14, 2015 Feb CAHN

@ EQ 10MG BASE

A077550 002 May 14, 2015 Feb CAHN

@ EQ 20MG BASE

A077550 003 May 14, 2015 Feb CAHN

LEXAPRO

AB + ABBVIE	EQ 5MG BASE	N021323 001 Aug 14, 2002	Jan CAHN
AB +	EQ 10MG BASE	N021323 002 Aug 14, 2002	Jan CAHN
AB +!	EQ 20MG BASE	N021323 003 Aug 14, 2002	Jan CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

AP +! BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003	Jan CTEC
AP +! BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001	Jan CTEC

ESMOLOL HYDROCHLORIDE

AP AMNEAL	1GM/100ML	A216603 001	Dec 13, 2022	Jan CPOT
AP	2GM/100ML	A216603 002	Dec 13, 2022	Jan CPOT
AP EUGIA PHARMA	1GM/100ML	A216244 001	Mar 21, 2022	Jan CPOT
AP	2GM/100ML	A216244 002	Mar 21, 2022	Jan CPOT
AP HQ SPCLT PHARMA	1GM/100ML	A214172 001	Dec 02, 2022	Jan CPOT
AP	2GM/100ML	A214172 002	Dec 02, 2022	Jan CPOT
AP MYLAN LABS LTD	1GM/100ML	A206608 001	Jun 08, 2018	Jan CPOT
AP	2GM/100ML	A206608 002	Jun 08, 2018	Jan CPOT
AP SAGENT PHARMS INC	1GM/100ML	A207107 001	Jun 08, 2018	Jan CPOT
AP	2GM/100ML	A207107 002	Jun 08, 2018	Jan CPOT

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL
ESOMEPRAZOLE MAGNESIUM

AB PRINSTON INC	EQ 20MG BASE	A214920 001	Mar 28, 2023	Mar NEWA
AB	EQ 40MG BASE	A214920 002	Mar 28, 2023	Mar NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

@ ACTAVIS LABS FL INC	EQ 20MG BASE; 375MG	A204470 001	Aug 24, 2022	Feb DISC
@	EQ 20MG BASE; 500MG	A204470 002	Aug 24, 2022	Feb DISC

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657 002	Aug 10, 2016	Jan CHRS
>D> AP GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349 001	Apr 01, 2020	Apr CTEC
>A>	EQ 20MG BASE/VIAL	A203349 001	Apr 01, 2020	Apr CTEC

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ESTRADIOL

>D>	AB2	ZYDUS NOVELTECH INC	0.025MG/24HR	A202985	001	Mar 29, 2023	Apr CAHN
	AB2		0.025MG/24HR	A202985	001	Mar 29, 2023	Mar NEWA
>D>	AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Apr CAHN
	AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Mar NEWA
>D>	AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Apr CAHN
	AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Mar NEWA
>D>	AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Apr CAHN
	AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Mar NEWA
>D>	AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Apr CAHN
	AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Mar NEWA
>D>	AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Apr CAHN
	AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Mar NEWA
>A>	AB2	ZYDUS PHARMS	0.025MG/24HR	A202985	001	Mar 29, 2023	Apr CAHN
	AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Apr CAHN
>A>	AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Apr CAHN
>A>	AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Apr CAHN
>A>	AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Apr CAHN
>A>	AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Apr CAHN

INSERT;VAGINAL

IMVEXXY

+ MAYNE PHARMA

0.004MG

+!

0.01MG

N208564 001 May 29, 2018 Jan CAHN

N208564 002 May 29, 2018 Jan CAHN

SYSTEM;TRANSDERMAL

ESTRADIOL

>A>		ZYDUS NOVELTECH INC	0.014MG/24HR	A204379	001	Apr 17, 2023	Apr NFTG
>A>	AB	MENOSTAR					
>D>	+!	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004	Apr CFTG

>A>	AB	+!	0.014MG/24HR	N021674	001	Jun 08, 2004	Apr CFTG
-----	----	----	--------------	---------	-----	--------------	----------

ESTRADIOL VALERATE

INJECTABLE;INJECTION

ESTRADIOL VALERATE

>A>	AO	XIROMED	10MG/ML	A216656	001	Apr 28, 2023	Apr NEWA
>A>	AO		20MG/ML	A216656	002	Apr 28, 2023	Apr NEWA
>A>	AO		40MG/ML	A216656	003	Apr 28, 2023	Apr NEWA

ETHINYLM ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYLM ESTRADIOL

@	AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014	Jan DISC
@		0.03MG;0.15MG	A201095	001	Dec 08, 2014	Jan DISC
AB1	HETERO LABS	0.02MG;0.1MG	A212298	001	Feb 13, 2023	Feb NEWA
AB	LUPIN LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015	Jan CTEC

ETHINYLM ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

RHUZDAH

>D>		AUROBINDO PHARMA	0.035MG;0.4MG	A207585	001	Oct 11, 2022	Apr DISC
>A>		@	0.035MG;0.4MG	A207585	001	Oct 11, 2022	Apr DISC

ETHINYLM ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

HAILEY 24 FE

AB	!	GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Feb CTNA
>D>		MINASTRIN 24 FE					
>D>	AB	+!	APIL	N203667	001	May 08, 2013	Apr DISC
>A>		+	@	N203667	001	May 08, 2013	Apr DISC
			NORETHINDRONE ACETATE AND ETHINYLM ESTRADIOL AND FERROUS FUMARATE				
>D>	AB	GLENMARK PHARMS LTD	0.02MG;1MG	A210369	001	Dec 26, 2017	Apr CHRS
>A>	AB	!	0.02MG;1MG	A210369	001	Dec 26, 2017	Apr CHRS

ETHINYLM ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYLM ESTRADIOL

@	AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A203870	001	Nov 12, 2015	Jan DISC
---	---------------	---	---------	-----	--------------	----------

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING;VAGINAL

ANNOVERA

+! MAYNE PHARMA

0.013MG/24HR;0.15MG/24HR

N209627 001 Aug 10, 2018 Jan CAHN

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

@ DASH PHARMS

20MG/ML

A204927 001 Oct 31, 2017 Mar CAHN

@ DASH PHARMS NATCO

20MG/ML

A203507 001 Nov 20, 2017 Feb CAHN

EVEROLIMUS

TABLET; ORAL

EVEROLIMUS

>D> @ TEVA PHARMS USA

10MG

A210050 004 Dec 09, 2019 Apr CMFD

>A> AB

10MG

A210050 004 Dec 09, 2019 Apr CMFD

EXEMESTANE

TABLET; ORAL

EXEMESTANE

@ ALVOGEN

25MG

A200898 001 Jul 28, 2014 Feb DISC

EZETIMIBE

TABLET; ORAL

EZETIMIBE

@ ORIENT PHARMA

10MG

A215693 001 Sep 13, 2022 Mar DISC

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

>D> AP ZYDUS PHARMS

10MG/ML

A215828 001 Nov 22, 2022 Apr DISC

>A> @

10MG/ML

A215828 001 Nov 22, 2022 Apr DISC

TABLET; ORAL

FAMOTIDINE

>A> AB ALKEM LABS LTD

20MG

A217375 001 Apr 24, 2023 Apr NEWA

>A> AB

40MG

A217375 002 Apr 24, 2023 Apr NEWA

AB VKT PHARMA

20MG

A215630 001 Jan 07, 2022 Jan CAHN

AB

40MG

A215630 002 Jan 07, 2022 Jan CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

IBUPROFEN AND FAMOTIDINE

AB ASCENT PHARMS INC

26.6MG;800MG

A216814 001 Mar 15, 2023 Mar NEWA

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

AB ZYDUS LIFESCIENCES

40MG

A205443 001 Jan 09, 2023 Jan CAHN

AB

80MG

A205443 002 Jan 09, 2023 Jan CAHN

FENOFLIBRATE

TABLET; ORAL

FENOFLIBRATE

AB CHARTWELL RX

54MG

A209660 001 Feb 11, 2019 Feb CAHN

AB

160MG

A209660 002 Feb 11, 2019 Feb CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-87

AB MYLAN TECHNOLOGIES

87.5MCG/HR

A076258 008 Dec 29, 2014 Jan CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP +! HIKMA

EQ 0.025MG BASE/0.5ML

N019101 002 Jan 20, 2023 Jan NEWA

AP +!

EQ 0.05MG BASE/ML

N019101 001 Jul 11, 1984 Jan CTNA

TABLET; BUCCAL, SUBLINGUAL

FENTANYL CITRATE

>A> @ DR REDDYS LABS SA

EQ 0.1MG BASE

A206329 001 Aug 22, 2022 Apr CAHN

>A> @

EQ 0.2MG BASE

A206329 002 Aug 22, 2022 Apr CAHN

TABLET;BUCCAL, SUBLINGUAL
FENTANYL CITRATE

>A>	@	EQ 0.3MG BASE	A206329	003	Aug 22, 2022	Apr CAHN
>A>	@	EQ 0.4MG BASE	A206329	004	Aug 22, 2022	Apr CAHN
>A>	@	EQ 0.6MG BASE	A206329	005	Aug 22, 2022	Apr CAHN
>A>	@	EQ 0.8MG BASE	A206329	006	Aug 22, 2022	Apr CAHN
>D>	@ MAYNE PHARMA	EQ 0.1MG BASE	A206329	001	Aug 22, 2022	Apr CAHN
>D>	@	EQ 0.2MG BASE	A206329	002	Aug 22, 2022	Apr CAHN
>D>	@	EQ 0.3MG BASE	A206329	003	Aug 22, 2022	Apr CAHN
>D>	@	EQ 0.4MG BASE	A206329	004	Aug 22, 2022	Apr CAHN
>D>	@	EQ 0.6MG BASE	A206329	005	Aug 22, 2022	Apr CAHN
>D>	@	EQ 0.8MG BASE	A206329	006	Aug 22, 2022	Apr CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
 FESOTERODINE FUMARATE

@ LUPIN LTD	4MG	A204983	001	Jan 05, 2023	Feb DISC
@	8MG	A204983	002	Jan 05, 2023	Feb DISC

FINAFLOXACIN

SUSPENSION/DROPS;OTIC
 XTORO

+ @ FONSECA BIOSCIENCES	0.3%	N206307	001	Dec 17, 2014	Jan CAHN
-------------------------	------	---------	-----	--------------	----------

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL
 FINGOLIMOD HYDROCHLORIDE

AB	BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Jan CMFD
----	------------	---------------	---------	-----	--------------	----------

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION
 FLUDARABINE PHOSPHATE

AP2	ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Jan CTEC
AP1	AREVA PHARMS	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	Jan CTEC
AP1	FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CTEC
AP		50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CHRS
AP1	SAGENT PHARMS INC	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan CTEC
AP2	+! SANDOZ	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jan CTEC

FLUDROCORTISONE ACETATE

TABLET;ORAL
 FLUDROCORTISONE ACETATE

>D> AB	HIKMA	0.1MG	A216013	001	Oct 27, 2022	Apr DISC
>A>	@	0.1MG	A216013	001	Oct 27, 2022	Apr DISC

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL
 FLUOCINOLONE ACETONIDE

@ INVATECH	0.025%	A088045	001	Dec 16, 1982	Mar CAHN
------------	--------	---------	-----	--------------	----------

FLUOCINONIDE

CREAM;TOPICAL
 FLUOCINONIDE

AB1	! AMNEAL	0.05%	A210554	001	Aug 21, 2018	Feb CHRS
	+ @ TARO	0.05%	N019117	001	Jun 26, 1984	Feb DISC

OINTMENT;TOPICAL
 FLUOCINONIDE

>A> AB	CHARTWELL RX	0.05%	A207538	001	Jul 31, 2017	Apr CAHN
>D> AB	NOVEL LABS INC	0.05%	A207538	001	Jul 31, 2017	Apr CAHN

FLUOROMETHOLONE

SUSPENSION/DROPS;OPHTHALMIC
 FML

+! ABBVIE	0.1%	N016851	002	Jul 28, 1982	Jan CAHN
-----------	------	---------	-----	--------------	----------

SUSPENSION/DROPS;OPHTHALMIC

FML FORTE

+! ABBVIE 0.25%

N019216 001 Apr 23, 1986 Jan CAHN

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP ALEMBIC 2.5GM/50ML (50MG/ML)

A217295 001 Mar 03, 2023 Feb NEWA

FLUOXETINE HYDROCHLORIDE

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA NOSTRUM LABS INC EQ 20MG BASE/5ML

A075292 001 Feb 07, 2002 Mar CMFD

AA XTTRIUM LABS INC EQ 20MG BASE/5ML

A075514 001 Aug 29, 2002 Jan CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

@ PIRAMAL HLTHCARE UK EQ 10MG BASE

A211444 001 Sep 13, 2022 Mar DISC

@ EQ 20MG BASE

A211444 002 Sep 13, 2022 Mar DISC

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO GLAND PHARMA LTD 25MG/ML

A215509 001 Mar 30, 2023 Mar NEWA

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

>D> AB PRASCO 1MG	A089804 002 Aug 12, 1988	Apr DISC
>A> @ 1MG	A089804 002 Aug 12, 1988	Apr DISC
>D> AB 2.5MG	A089804 003 Aug 12, 1988	Apr DISC
>A> @ 2.5MG	A089804 003 Aug 12, 1988	Apr DISC
>D> AB 5MG	A089804 004 Aug 12, 1988	Apr DISC
>A> @ 5MG	A089804 004 Aug 12, 1988	Apr DISC
>D> AB 10MG	A089804 001 Aug 12, 1988	Apr DISC
>A> @ 10MG	A089804 001 Aug 12, 1988	Apr DISC

FLUVOXAMINE MALEATE

TABLET;ORAL

LUVOX

AB + ANI PHARMS 25MG
AB + 50MG
AB + 100MGN021519 001 Dec 20, 2007 Jan CRLD
N021519 002 Dec 20, 2007 Jan CRLD
N021519 003 Dec 20, 2007 Jan CRLDFORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

AN MANKIND PHARMA 0.02MG/2ML

A215883 001 Mar 22, 2023 Mar NEWA

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

FOSPHENYTOIN SODIUM

>D> AP MYLAN LABS LTD EQ 50MG PHENYTOIN NA/ML	A078736 001 Jun 08, 2010	Apr DISC
>A> @ EQ 50MG PHENYTOIN NA/ML	A078736 001 Jun 08, 2010	Apr DISC

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

>D> AB MYLAN EQ 2.5MG BASE	A202931 001 Aug 28, 2014	Apr DISC
>A> @ EQ 2.5MG BASE	A202931 001 Aug 28, 2014	Apr DISC

FUROSEMIDE

SOLUTION;ORAL

FUROSEMIDE

@ XTTRIUM LABS INC 10MG/ML

A070655 001 Oct 02, 1987 Jan CAHN

TABLET;ORAL

FUROSEMIDE

@ CHARTWELL RX 20MG

N018413 001 Nov 30, 1983 Mar CAHN

@ 40MG

N018413 002 Nov 30, 1983 Mar CAHN

GABAPENTIN

SOLUTION;ORAL						
GABAPENTIN						
AA	RUBICON	250MG/5ML	A216492	001	Jan 18, 2023	Jan NEWA
TABLET;ORAL						
GABAPENTIN						
AB	GRANULES	600MG	A217116	001	Mar 28, 2023	Mar NEWA
AB		800MG	A217116	002	Mar 28, 2023	Mar NEWA

GADOBUTROL

SOLUTION;INTRAVENOUS						
GADOBUTROL						
AP	HAINAN POLY PHARM	4.5354GM/7.5ML (604.72MG/ML)	A217480	001	Mar 15, 2023	Mar NEWA
AP		9.0708GM/15ML (604.72MG/ML)	A217480	002	Mar 15, 2023	Mar NEWA

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS						
GADOTERATE MEGLUMINE						
AP	HENGRIU PHARMA	37.69GM/100ML (376.9MG/ML)	A215304	005	Apr 15, 2022	Feb CMS1

GANIRELIX ACETATE

INJECTABLE; INJECTION						
GANIRELIX ACETATE						
AP	GLAND PHARMA LTD	250MCG/0.5ML	A215658	001	Feb 28, 2023	Feb NEWA

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC						
ZYMAR						
+ @ ALLERGAN	0.3%	N021493	001	Mar 28, 2003	Mar DISC	
ZYMAXID						
AT +!	ABBVIE	0.5%	N022548	001	May 18, 2010	Jan CAHN

GEFITINIB

TABLET;ORAL						
GEFITINIB						
>A> AB	ACTAVIS LABS FL INC	250MG	A208913	001	Apr 26, 2023	Apr NEWA
AB	QILU PHARM HAINAN	250MG	A211591	001	Feb 13, 2023	Feb NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION						
GEMCITABINE HYDROCHLORIDE						
AP	HIKMA	200MG/5.26ML (38MG/ML)	A213175	001	Mar 07, 2023	Feb NEWA
AP		1GM/26.3ML (38MG/ML)	A213175	002	Mar 07, 2023	Feb NEWA
AP		2GM/52.6ML (38MG/ML)	A213175	003	Mar 07, 2023	Feb NEWA

GENTAMICIN SULFATE

OINTMENT;OPHTHALMIC					
GENTAMICIN SULFATE					
@ AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995	Feb DISC
! FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb CTEC
AT !	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb CHRS
SOLUTION/DROPS;OPHTHALMIC					
GENOPTIC					
@ ALLERGAN	EQ 0.3% BASE	A062452	001	Oct 10, 1984	Feb DISC
GENTAK					
@ AKORN	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb DISC
GENTAMICIN SULFATE					
AT ! SANDOZ INC	EQ 0.3% BASE	A062196	001		Feb CHRS

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC					
PRED-G					
+ @ ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989	Jan DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL					
GLIPIZIDE AND METFORMIN HYDROCHLORIDE					
@ DASH PHARMS	2.5MG;250MG	A078083	001	Apr 12, 2007	Feb CAHN
@	2.5MG;500MG	A078083	002	Apr 12, 2007	Feb CAHN
@	5MG;500MG	A078083	003	Apr 12, 2007	Feb CAHN

GLUCAGON

SOLUTION;SUBCUTANEOUS
GVOKE PFS
+ @ XERIS 0.5MG/0.1ML (0.5MG/0.1ML) N212097 001 Sep 10, 2019 Jan DISC

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL
RAVICTI
+! HORIZON THERAP US 1.1GM/ML N203284 001 Feb 01, 2013 Jan CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION
GLYCOPYRROLATE
>D> AP LUPIN LTD 0.2MG/ML A213655 001 Feb 07, 2023 Apr DISC
>A> @ 0.2MG/ML A213655 001 Feb 07, 2023 Apr DISC
AP 0.2MG/ML A213655 001 Feb 07, 2023 Jan NEWA
AP MANKIND PHARMA 0.2MG/ML A217354 001 Feb 27, 2023 Feb NEWA
TABLET;ORAL
GLYCOPYRROLATE
AA ALEMBIC 1MG A203657 001 Nov 30, 2018 Feb CAHN
AA 2MG A203657 002 Nov 30, 2018 Feb CAHN
AA AUROBINDO PHARMA 1MG A202675 001 Apr 15, 2013 Jan CAHN
AA 2MG A202675 002 Oct 30, 2018 Jan CAHN

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
PREVDUO
+! SLAYBACK PHARMA LLC 0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML) N216903 001 Feb 23, 2023 Feb NEWA

GUANFACINE HYDROCHLORIDE

TABLET;ORAL
GUANFACINE HYDROCHLORIDE
>A> AB AJANTA PHARMA LTD EQ 1MG BASE A217293 001 Apr 27, 2023 Apr NEWA
>A> AB EQ 2MG BASE A217293 002 Apr 27, 2023 Apr NEWA

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL
@ ACTAVIS GROUP 0.5MG A200854 001 Jul 01, 2022 Jan DISC
@ 1MG A200854 002 Jul 01, 2022 Jan DISC
@ 2MG A200854 003 Jul 01, 2022 Jan DISC
@ 5MG A200854 004 Jul 01, 2022 Jan DISC
@ 10MG A200854 005 Jul 01, 2022 Jan DISC
@ 20MG A200854 006 Jul 01, 2022 Jan DISC
AB ZYDUS PHARMS USA 0.5MG A077580 001 Jan 17, 2023 Jan NEWA
AB 1MG A077580 002 Jan 17, 2023 Jan NEWA
AB 2MG A077580 006 Jan 17, 2023 Jan NEWA

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM
AP NANJING KING-FRIEND 5,000 UNITS/ML A212061 001 Jul 15, 2020 Feb CMFD
HEPARIN SODIUM PRESERVATIVE FREE
AP NANJING KING-FRIEND 10,000 UNITS/ML A212060 001 Apr 02, 2020 Feb CMFD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE
AP EUGIA PHARMA 20MG/ML A215147 001 Feb 13, 2023 Feb NEWA

HYDROCHLOROTHIAZIDE

TABLET;ORAL
HYDROCHLOROTHIAZIDE
>A> AB HERITAGE PHARMS 12.5MG A085182 003 May 02, 2023 Apr NEWA

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	ZYDUS PHARMS	12.5MG; 20MG	A206377	001	Feb 24, 2023	Feb NEWA
AB		12.5MG; 40MG	A206377	002	Feb 24, 2023	Feb NEWA
AB		25MG; 40MG	A206377	003	Feb 24, 2023	Feb NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX	12.5MG; EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan CAHN
AB		12.5MG; EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan CAHN
AB		25MG; EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan CAHN
>A>	@ CHARTWELL RX	12.5MG; EQ 10MG BASE	A076374	001	Mar 31, 2004	Apr CAHN
>A>	@	12.5MG; EQ 20MG BASE	A076374	002	Mar 31, 2004	Apr CAHN
>A>	@	25MG; EQ 20MG BASE	A076374	003	Mar 31, 2004	Apr CAHN
>D>	@ LUPIN	12.5MG; EQ 10MG BASE	A076374	001	Mar 31, 2004	Apr CAHN
>D>	@	12.5MG; EQ 20MG BASE	A076374	002	Mar 31, 2004	Apr CAHN
>D>	@	25MG; EQ 20MG BASE	A076374	003	Mar 31, 2004	Apr CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

	HOSPIRA INC	0.25MG/0.5ML	N200403	005	Mar 03, 2023	Mar NEWA
>D> AP		4MG/ML	N200403	003	Dec 01, 2011	Apr CTEC
>A>		4MG/ML	N200403	003	Dec 01, 2011	Apr CTEC

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+ @ AKORN 1%; 0.25%

N019261 001 Jan 30, 1992 Feb DISC

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+! BAUSCH 5MG
+! BAUSCH AND LOMB INC 5MGN018771 001 Jan CAHN
N018771 001 Jan CAHNHYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

+!	AM REGENT	25MG/ML	A087408	001		Feb CRLD
+!		50MG/ML	A087408	002		Feb CRLD

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB	CHARTWELL RX	10MG	A040804	001	Jun 30, 2008	Jan CAHN
AB		25MG	A040804	002	Jun 30, 2008	Jan CAHN
AB		50MG	A040804	003	Jun 30, 2008	Jan CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar CTEC
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar CTEC

ICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYL

AB	DR REDDYS	500MG	A209499	002	Mar 08, 2023	Feb NEWA
AB	HIKMA	500MG	A209457	002	Mar 08, 2023	Feb NEWA
>A> AB	ZYDUS	500MG	A217656	001	Apr 20, 2023	Apr NEWA
>A> AB		1GM	A217656	002	Apr 20, 2023	Apr NEWA

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

AB	@ BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019	Mar DISC
AB	CHARTWELL RX	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan CAHN
AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan CAHN

IMIQUIMOD

CREAM;TOPICAL					
ALDARA					
+ @ BAUSCH	5%		N020723	001	Feb 27, 1997
IMIQUIMOD					Feb DISC
AB ! GLENMARK GENERICS	5%		A201994	001	Mar 06, 2012
					Feb CHRS

INDAPAMIDE

TABLET;ORAL					
INDAPAMIDE					
>A@ @ AUROBINDO PHARMA USA	1.25MG		A075105	001	Jul 23, 1998
>A@ @	2.5MG		A075105	002	Jul 23, 1998
>D@ @ MYLAN PHARMS INC	1.25MG		A075105	001	Jul 23, 1998
>D@ @	2.5MG		A075105	002	Jul 23, 1998
					Apr CAHN

INDOMETHACIN

CAPSULE;ORAL					
INDOMETHACIN					
AB CHARTWELL MOLECULES	25MG		N018829	002	Aug 06, 1984
AB	50MG		N018829	001	Aug 06, 1984
					Feb CMFD

INFIGRATINIB PHOSPHATE

>D@ CAPSULE;ORAL					
>D@ TRUSELTIQ					
>D@ + HELSINN HLTHCARE	25MG		N214622	001	May 28, 2021
>A@ + @	25MG		N214622	001	May 28, 2021
>D@ + !	100MG		N214622	002	May 28, 2021
>A@ + @	100MG		N214622	002	May 28, 2021
					Apr DISC

IOPAMIDOL

INJECTABLE;INJECTION					
IOPAMIDOL					
AP HAINAN POLY	41%		A215382	001	Feb 27, 2023
AP	61%		A215382	002	Feb 27, 2023
ISOVUE-M 200					Feb NEWA
AP +! BRACCO	41%		N018735	001	Dec 31, 1985
ISOVUE-M 300			N018735	004	Dec 31, 1985
AP +! BRACCO	61%				Feb CTEC

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL					
IPRATROPIUM BROMIDE					
>A@ @ AUROBINDO PHARMA USA	0.021MG/SPRAY		A075552	001	Mar 31, 2003
>A@ @	0.042MG/SPRAY		A075553	001	Mar 31, 2003
>D@ @ MYLAN SPECIALITY LP	0.021MG/SPRAY		A075552	001	Mar 31, 2003
>D@ @	0.042MG/SPRAY		A075553	001	Mar 31, 2003
					Apr CAHN

ISONIAZID

TABLET;ORAL					
LANIAZID					
@ CHARTWELL MOLECULAR	50MG		A080140	001	
@	100MG		A080140	002	
					Feb CAHN
					Feb CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION					
ISOPROTERENOL HYDROCHLORIDE					
>D@ AP AM REGENT	0.2MG/ML		A214775	001	Oct 19, 2022
>A@ @	0.2MG/ML		A214775	001	Oct 19, 2022
>A@ AP HIKMA	0.2MG/ML		A211703	001	Apr 26, 2023
>A@ AP ZYDUS PHARMS	0.2MG/ML		A215557	001	Apr 14, 2023
					Apr NEWA
					Apr NEWA

IVERMECTIN

CREAM;TOPICAL					
IVERMECTIN					
@ ZYDUS	1%		A215210	001	Aug 02, 2022
					Jan DISC

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jan NEWA
AP		EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jan NEWA
AP	GLAND PHARMA LTD	EQ 50MG BASE/ML	A216809	002	Jan 24, 2023	Jan NEWA
AP		EQ 100MG BASE/ML	A216809	003	Jan 24, 2023	Jan NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>A> AP	CAPLIN	15MG/ML	A217789	001	May 10, 2023	Apr NEWA
>A> AP		30MG/ML	A217789	002	May 10, 2023	Apr NEWA
	SOLUTION/DROPS; OPHTHALMIC					
	ACULAR					
AT	+! ABBVIE	0.5%	N019700	001	Nov 09, 1992	Jan CAHN
	KETOROLAC TROMETHAMINE					
	@ AKORN	0.5%	A078434	001	Nov 05, 2009	Jan DISC
	TABLET; ORAL					
	KETOROLAC TROMETHAMINE					
AB	BIONPHARMA INC	10MG	A216759	001	Feb 23, 2023	Feb NEWA
AB	LEADING	10MG	A215745	001	Feb 23, 2023	Feb NEWA

LACOSAMIDE

SOLUTION; INTRAVENOUS

LACOSAMIDE

AP	MSN	200MG/20ML (10MG/ML)	A215979	001	Feb 09, 2023	Feb NEWA
	SOLUTION; ORAL					
	LACOSAMIDE					
AA	MEDLEY PHARMS	10MG/ML	A216461	001	Feb 06, 2023	Jan NEWA
	TABLET; ORAL					
	LACOSAMIDE					
	@ ACCORD HLTHCARE	50MG	A205011	001	Jul 12, 2022	Jan DISC
	@	100MG	A205011	002	Jul 12, 2022	Jan DISC
	@	150MG	A205011	003	Jul 12, 2022	Jan DISC
	@	200MG	A205011	004	Jul 12, 2022	Jan DISC
	@ APOTEX	50MG	A214567	001	Sep 23, 2022	Mar DISC
	@	100MG	A214567	002	Sep 23, 2022	Mar DISC
	@	150MG	A214567	003	Sep 23, 2022	Mar DISC
	@	200MG	A214567	004	Sep 23, 2022	Mar DISC

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA	XTRRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Mar CMFD
	SOLUTION; ORAL, RECTAL					
	LACTULOSE					
AA	BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Feb CMFD

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TEMIXYS

+ @ CHARTWELL RX

300MG; 300MG

N211284 001 Nov 16, 2018 Mar CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ CHARTWELL MOLECULAR

25MG

A077783 001 Nov 01, 2010 Jan CAHN

@

100MG

A077783 002 Nov 01, 2010 Jan CAHN

@

150MG

A077783 003 Nov 01, 2010 Jan CAHN

@

200MG

A077783 004 Nov 01, 2010 Jan CAHN

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

LANSOPRAZOLE

AB	AUROBINDO PHARMA LTD	15MG	A207167	001	Mar 28, 2023	Mar NEWA
AB		30MG	A207167	002	Mar 28, 2023	Mar NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

@ AKORN

0.005%

A090887 001 Jul 19, 2011 Jan DISC

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB	APOTEX	2.5MG	A211022	005	Mar 07, 2023	Feb NEWA
AB		20MG	A211022	006	Mar 07, 2023	Feb NEWA
AB	ARROW INTL	2.5MG	A201452	005	Mar 06, 2023	Feb NEWA
AB		20MG	A201452	006	Mar 06, 2023	Feb NEWA
AB	CIPLA	2.5MG	A214618	001	Mar 06, 2023	Feb NEWA
AB		20MG	A210435	005	Mar 06, 2023	Feb NEWA
AB	EUGIA PHARMA	2.5MG	A213885	001	Mar 06, 2023	Feb NEWA
AB		5MG	A213885	002	Mar 06, 2023	Feb NEWA
AB		10MG	A213885	003	Mar 06, 2023	Feb NEWA
AB		15MG	A213885	004	Mar 06, 2023	Feb NEWA
AB		20MG	A213885	005	Mar 06, 2023	Feb NEWA
AB		25MG	A213885	006	Mar 06, 2023	Feb NEWA
AB	LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023	Feb NEWA
AB		20MG	A210480	006	Mar 06, 2023	Feb NEWA
AB	MYLAN	2.5MG	A213912	005	Mar 06, 2023	Feb NEWA
AB		20MG	A213912	006	Mar 06, 2023	Feb NEWA
AB	SUN PHARM	2.5MG	A211846	005	Mar 06, 2023	Feb NEWA
AB		5MG	A211846	001	Feb 08, 2023	Jan NEWA
AB		10MG	A211846	002	Feb 08, 2023	Jan NEWA
AB		15MG	A211846	003	Feb 08, 2023	Jan NEWA
AB		20MG	A211846	006	Mar 06, 2023	Feb NEWA
AB		25MG	A211846	004	Feb 08, 2023	Jan NEWA
AB	TORRENT	10MG	A213405	001	Feb 17, 2023	Feb NEWA
AB		25MG	A213405	002	Feb 17, 2023	Feb NEWA
AB	ZYDUS PHARMS	2.5MG	A210154	005	Mar 06, 2023	Feb NEWA
AB		20MG	A210154	006	Mar 06, 2023	Feb NEWA

LENIOLISIB PHOSPHATE

TABLET;ORAL

JOENJA

+! PHARMING

EQ 70MG BASE

N217759 001 Mar 24, 2023 Mar NEWA

LETROZOLE

TABLET;ORAL

LETROZOLE

@ CHARTWELL RX

2.5MG

A202716 001 May 16, 2013 Feb CAHN

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

>D> AP	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr CHRS
>A>	!	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr CHRS
>D>		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Apr CHRS
>A>	!	EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Apr CHRS
	LEUCOVORIN CALCIUM PRESERVATIVE FREE					
>D> AP	! HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Apr DISC
>A>	@	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Apr DISC

LEUPROLIDE ACETATE

POWDER;INTRAMUSCULAR

LUPRON DEPOT-PED KIT

>A>	+! ABBVIE ENDOCRINE INC	45MG	N020263	009	Apr 14, 2023	Apr NEWA
	POWDER;SUBCUTANEOUS					
	ELIGARD KIT					
+!	TOLMAR	7.5MG	N021343	001	Jan 23, 2002	Feb CAHN
+!		22.5MG	N021379	001	Jul 24, 2002	Feb CAHN
+!		30MG	N021488	001	Feb 13, 2003	Feb CAHN
+!		45MG	N021731	001	Dec 14, 2004	Feb CAHN

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM IN SODIUM CHLORIDE

AP	FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Jan NEWA
AP		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Jan NEWA
	SOLUTION; ORAL					
	LEVETIRACETAM					
AA	ALEMVIC	100MG/ML	A203067	001	May 09, 2013	Feb CAHN
AA	QUAGEN	100MG/ML	A090079	001	Apr 11, 2012	Feb CAHN
	@ XTRRIUM LABS INC	100MG/ML	A090028	001	Mar 03, 2010	Mar CAHN
	TABLET; ORAL					
	LEVETIRACETAM					
>D> AB	MYLAN	250MG	A076919	001	Nov 04, 2008	Apr DISC
>A>	@	250MG	A076919	001	Nov 04, 2008	Apr DISC
	TABLET, EXTENDED RELEASE; ORAL					
	LEVETIRACETAM					
>A>	@ AUROBINDO PHARMA USA	500MG	A200475	001	Dec 19, 2011	Apr CAHN
>A>	@	750MG	A200475	002	Dec 19, 2011	Apr CAHN
>A>	@	1GM	A200475	003	Dec 07, 2015	Apr CAHN
>D>	@ MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011	Apr CAHN
>D>	@	750MG	A200475	002	Dec 19, 2011	Apr CAHN
>D>	@	1GM	A200475	003	Dec 07, 2015	Apr CAHN
>A> AB	OVERSEAS	500MG	A212688	002	May 05, 2023	Apr NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

@ AKORN	0.5%	A090268	001	Dec 20, 2010	Jan DISC
! RISING	0.5%	A077700	001	Dec 20, 2010	Jan CTEC

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMA

AB	+ ABBVIE	EQ 20MG BASE	N204168	001	Jul 25, 2013	Mar CTEC
	+	EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CAHN
AB	+	EQ 40MG BASE	N204168	002	Jul 25, 2013	Mar CTEC
	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CAHN
AB	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Mar CTEC
	+!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Mar CTEC
AB	+!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CAHN
	LEVOMILNACIPRAN HYDROCHLORIDE					
	@ AUROBINDO PHARMA LTD	EQ 20MG BASE	A210826	001	Jan 06, 2023	Mar DISC
	@	EQ 40MG BASE	A210826	002	Jan 06, 2023	Mar DISC
	@	EQ 80MG BASE	A210826	003	Jan 06, 2023	Mar DISC
	@	EQ 120MG BASE	A210826	004	Jan 06, 2023	Mar DISC
AB	PRINSTON INC	EQ 20MG BASE	A210771	001	Mar 20, 2023	Mar NEWA
AB		EQ 40MG BASE	A210771	002	Mar 20, 2023	Mar NEWA
AB		EQ 80MG BASE	A210771	003	Mar 20, 2023	Mar NEWA
AB		EQ 120MG BASE	A210771	004	Mar 20, 2023	Mar NEWA

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

AB	HIKMA	2MG	A074278	001	Mar 31, 2000	Jan CMFD
>D>	! NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Apr CTEC
>A> AB	!	3MG	A213479	002	Jan 12, 2021	Apr CTEC
>A> AB	SUN PHARM INDs INC	3MG	A213906	002	Apr 25, 2023	Apr NEWA

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

LEVOTHYROXINE SODIUM

>A> AB	TEVA PHARMS USA INC	0.137MG	A211369	005	May 02, 2023	Apr NFTG
>A> AB		0.175MG	A211369	006	May 02, 2023	Apr NFTG
	TIROSINT					
>D>	+ INSTITUT BIOCHIMIQUE	0.137MG	N021924	009	Oct 02, 2009	Apr CFTG
>A> AB	+	0.137MG	N021924	009	Oct 02, 2009	Apr CFTG
>D>	+	0.175MG	N021924	011	Apr 25, 2017	Apr CFTG
>A> AB	+	0.175MG	N021924	011	Apr 25, 2017	Apr CFTG

POWDER; INTRAVENOUS
LEVOTHYROXINE SODIUM

AP	ZYDUS PHARMS	100MCG/VIAL	A217066	001	Mar 24, 2023	Mar NEWA
AP		200MCG/VIAL	A217066	002	Mar 24, 2023	Mar NEWA
AP		500MCG/VIAL	A217066	003	Mar 24, 2023	Mar NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL
LEVOTHYROXINE SODIUM

AB4	ASCENT PHARMS INC	0.025MG	A215259	001	Jan 18, 2023	Jan NEWA
AB4		0.05MG	A215259	002	Jan 18, 2023	Jan NEWA
AB4		0.075MG	A215259	003	Jan 18, 2023	Jan NEWA
AB4		0.088MG	A215259	004	Jan 18, 2023	Jan NEWA
AB4		0.1MG	A215259	005	Jan 18, 2023	Jan NEWA
AB4		0.112MG	A215259	006	Jan 18, 2023	Jan NEWA
AB4		0.125MG	A215259	007	Jan 18, 2023	Jan NEWA
AB4		0.137MG	A215259	008	Jan 18, 2023	Jan NEWA
AB4		0.15MG	A215259	009	Jan 18, 2023	Jan NEWA
AB4		0.175MG	A215259	010	Jan 18, 2023	Jan NEWA
AB4		0.2MG	A215259	011	Jan 18, 2023	Jan NEWA
AB4		0.3MG	A215259	012	Jan 18, 2023	Jan NEWA
AB2	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Jan CTEC
AB2		0.05MG	A211417	002	Dec 21, 2022	Jan CTEC
AB2		0.075MG	A211417	003	Dec 21, 2022	Jan CTEC
AB2		0.088MG	A211417	004	Dec 21, 2022	Jan CTEC
AB2		0.1MG	A211417	005	Dec 21, 2022	Jan CTEC
AB2		0.112MG	A211417	006	Dec 21, 2022	Jan CTEC
AB2		0.125MG	A211417	007	Dec 21, 2022	Jan CTEC
AB2		0.137MG	A211417	008	Dec 21, 2022	Jan CTEC
AB2		0.15MG	A211417	009	Dec 21, 2022	Jan CTEC
AB2		0.175MG	A211417	010	Dec 21, 2022	Jan CTEC
AB2		0.2MG	A211417	011	Dec 21, 2022	Jan CTEC
AB2		0.3MG	A211417	012	Dec 21, 2022	Jan CTEC

LIDOCAINE

PATCH; TOPICAL
LIDOCAINE

>A> AB	INST BIOCHIMIQUE SA	5%	A209190	001	Apr 30, 2020	Apr CAHN
>D> AB	RHODES PHARMS	5%	A209190	001	Apr 30, 2020	Apr CAHN

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL
GLYDO

>D> AT	SAGENT PHARMS INC	2%	A201094	001	Apr 28, 2014	Apr CHRS
>A> AT	!	2%	A201094	001	Apr 28, 2014	Apr CHRS
LIDOCAINE HYDROCHLORIDE						
>D> AT	! AKORN	2%	A040433	001	Feb 12, 2003	Apr CHRS
>A> AT		2%	A040433	001	Feb 12, 2003	Apr CHRS

SOLUTION; ORAL
LIDOCAINE HYDROCHLORIDE

AT	RUBICON	2%	A216780	001	Mar 28, 2023	Mar NEWA
----	---------	----	---------	-----	--------------	----------

LINACLOTIDE

CAPSULE; ORAL
LINACLOTIDE

AB	@ AUROBINDO PHARMA	145MCG	A209611	001	Feb 07, 2023	Mar DISC
		145MCG	A209611	001	Feb 07, 2023	Jan NEWA
AB	@	290MCG	A209611	002	Feb 07, 2023	Mar DISC
		290MCG	A209611	002	Feb 07, 2023	Jan NEWA
LINZESS						
	+! ABBVIE	145MCG	N202811	001	Aug 30, 2012	Mar CTEC
	+	290MCG	N202811	002	Aug 30, 2012	Mar CTEC
AB	+! ALLERGAN	145MCG	N202811	001	Aug 30, 2012	Jan CTEC
AB	+	290MCG	N202811	002	Aug 30, 2012	Jan CTEC

LINAGLIPTIN

TABLET; ORAL
LINAGLIPTIN

AB	ZYDUS PHARMS	5MG	A208448	001	Mar 30, 2023	Mar NEWA
----	--------------	-----	---------	-----	--------------	----------

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB	ZYDUS PHARMS	2.5MG;500MG	A208449	001	Mar 30, 2023	Mar NEWA
AB		2.5MG;850MG	A208449	002	Mar 30, 2023	Mar NEWA
AB		2.5MG;1GM	A208449	003	Mar 30, 2023	Mar NEWA

LINEZOLID

TABLET;ORAL

LINEZOLID

AB	CHARTWELL RX	600MG	A210702	001	Apr 25, 2019	Mar CAHN
----	--------------	-------	---------	-----	--------------	----------

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Mar CMFD
AB		5MG	A075752	002	Jul 01, 2002	Mar CMFD
AB		10MG	A075752	003	Jul 01, 2002	Mar CMFD
AB		20MG	A075752	004	Jul 01, 2002	Mar CMFD
AB		30MG	A075752	005	Jul 01, 2002	Mar CMFD
AB		40MG	A075752	006	Jul 01, 2002	Mar CMFD

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

AB	RUBICON	2MG	A216876	001	Jan 26, 2023	Jan NEWA
>A> AB	ZYDUS LIFESCIENCES	2MG	A217471	001	Mar 23, 2023	Apr CAHN
>D> AB	ZYDUS PHARMS	2MG	A217471	001	Mar 23, 2023	Apr CAHN
AB		2MG	A217471	001	Mar 23, 2023	Mar NEWA

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB	GRANULES	25MG	A215959	001	Feb 23, 2023	Feb NEWA
AB		50MG	A215959	002	Feb 23, 2023	Feb NEWA
AB		100MG	A215959	003	Feb 23, 2023	Feb NEWA

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS;OPHTHALMIC

ALREX

AB	+! BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998	Mar CFTG
AB	AKORN	0.2%	A215933	001	Apr 12, 2023	Mar NFTG

LOVASTATIN

TABLET;ORAL

LOVASTATIN

>A>	@ AUROBINDO PHARMA USA	10MG	A075935	001	Dec 17, 2001	Apr CAHN
>A>	@	20MG	A075935	002	Dec 17, 2001	Apr CAHN
>A>	@	40MG	A075935	003	Dec 17, 2001	Apr CAHN
>D>	@ MYLAN	10MG	A075935	001	Dec 17, 2001	Apr CAHN
>D>	@	20MG	A075935	002	Dec 17, 2001	Apr CAHN
>D>	@	40MG	A075935	003	Dec 17, 2001	Apr CAHN

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

AB	AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan CMFD
AB		24MCG	A209450	002	Nov 30, 2021	Jan CMFD
AB	ZYDUS PHARMS	8MCG	A214131	001	Mar 23, 2023	Mar NEWA
AB		24MCG	A214131	002	Mar 23, 2023	Mar NEWA

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208002	002	Jan 03, 2019	Feb CMFD
AB		60MG	A208002	003	Jan 03, 2019	Feb CMFD
AB		80MG	A208002	004	Jan 03, 2019	Feb CMFD
AB		120MG	A208002	005	Jan 03, 2019	Feb CMFD
AB	AUROBINDO PHARMA LTD	20MG	A208045	001	Mar 10, 2023	Mar NEWA

TABLET;ORAL
LURASIDONE HYDROCHLORIDE

AB		40MG	A208045	002	Mar 10, 2023	Mar NEWA
AB		60MG	A208045	003	Mar 10, 2023	Mar NEWA
AB		80MG	A208045	004	Mar 10, 2023	Mar NEWA
AB		120MG	A208045	005	Mar 10, 2023	Mar NEWA
	@ AVET LIFESCIENCES	120MG	A208058	005	Feb 28, 2023	Mar DISC
AB		120MG	A208058	005	Feb 28, 2023	Feb NEWA
AB	LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208031	002	Jan 03, 2019	Feb CMFD
AB		60MG	A208031	003	Jan 03, 2019	Feb CMFD
AB		80MG	A208031	004	Jan 03, 2019	Feb CMFD
AB		120MG	A208031	005	Jan 03, 2019	Feb CMFD
AB	PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Feb CMFD
AB		40MG	A212091	002	Dec 28, 2020	Feb CMFD
AB		60MG	A212091	003	Dec 28, 2020	Feb CMFD
AB		80MG	A212091	004	Dec 28, 2020	Feb CMFD
AB		120MG	A212091	005	Dec 28, 2020	Feb CMFD
AB	TORRENT	20MG	A208055	001	Jan 03, 2019	Feb CMFD
AB		40MG	A208055	002	Jan 03, 2019	Feb CMFD
AB		80MG	A208055	003	Jan 03, 2019	Feb CMFD
AB		120MG	A208055	004	Jan 03, 2019	Feb CMFD

MACITENTAN**TABLET;ORAL****MACITENTAN**

>A>	@ AUROBINDO PHARMA LTD	10MG	A211198	001	Apr 18, 2023	Apr DISC
>D>	+! ACTELION	10MG	N204410	001	Oct 18, 2013	Apr CTEC
>A>	+!	10MG	N204410	001	Oct 18, 2013	Apr CTEC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE**INJECTABLE;INJECTION****MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5**

AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Mar CMFD
AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Mar CMFD

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Mar CTEC
AP	+! BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	Mar CTEC

MAGNESIUM SULFATE**INJECTABLE;INJECTION****MAGNESIUM SULFATE IN PLASTIC CONTAINER**

AP	AMNEAL	2GM/50ML (40MG/ML)	A216597	001	Feb 15, 2023	Feb NEWA
AP		4GM/100ML (40MG/ML)	A216597	002	Feb 15, 2023	Feb NEWA

MECLOFENAMATE SODIUM**CAPSULE;ORAL****MECLOFENAMATE SODIUM**

@	CHARTWELL RX	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan CAHN
@		EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan CAHN

MEGESTROL ACETATE**SUSPENSION;ORAL****MEGESTROL ACETATE**

AB	@ BRECKENRIDGE	125MG/ML	A204688	001	Dec 01, 2017	Jan DISC
AB	XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Jan CAHN

MELOXICAM**TABLET;ORAL****MELOXICAM**

AB	COREPHARMA	7.5MG	A077882	001	Jul 20, 2006	Feb CAHN
AB		15MG	A077882	002	Jul 20, 2006	Feb CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

>D>	AB	@ ANI PHARMS	28MG	A205365	004	Feb 28, 2020	Feb DISC
>A>		XIAMEN LP PHARM CO	7MG	A213985	001	Oct 11, 2022	Apr DISC
>D>	AB	@	7MG	A213985	001	Oct 11, 2022	Apr DISC
>A>			14MG	A213985	002	Oct 11, 2022	Apr DISC
>D>	AB	@	14MG	A213985	002	Oct 11, 2022	Apr DISC
>D>	AB		28MG	A213985	003	Oct 11, 2022	Apr DISC
>A>		@	28MG	A213985	003	Oct 11, 2022	Apr DISC
		NAMENDA XR					
AB	+	ABBVIE	7MG	N022525	001	Jun 21, 2010	Feb CAHN
AB	+		14MG	N022525	002	Jun 21, 2010	Feb CAHN
AB	+		21MG	N022525	003	Jun 21, 2010	Feb CAHN
AB	+	!	28MG	N022525	004	Jun 21, 2010	Feb CAHN
		TABLET;ORAL					
		MEMANTINE HYDROCHLORIDE					
		@ YILING	5MG	A212947	001	Apr 03, 2020	Mar CAHN
		@	10MG	A212947	002	Apr 03, 2020	Mar CAHN
		NAMENDA					
AB	+	ABBVIE	5MG	N021487	001	Oct 16, 2003	Feb CAHN
AB	+	!	10MG	N021487	002	Oct 16, 2003	Feb CAHN

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

@ BROOKS STERISCIENCE	500MG/VIAL	A216154	001	Aug 18, 2022	Mar DISC
@	1GM/VIAL	A216154	002	Aug 18, 2022	Mar DISC

MESALAMINECAPSULE, DELAYED RELEASE;ORAL
DELZICOL

AB	+	ABBVIE	400MG	N204412	001	Feb 01, 2013	Feb CAHN
		CAPSULE, EXTENDED RELEASE;ORAL					
		MESALAMINE					
AB		AUROBINDO PHARMA LTD	375MG	A214477	001	Mar 31, 2023	Mar NEWA
		SUPPOSITORY;RECTAL					
		CANASA					
		@ ABBVIE	500MG	N021252	001	Jan 05, 2001	Feb CAHN
AB	+		1GM	N021252	002	Nov 05, 2004	Feb CAHN

METAXALONETABLET;ORAL
METAXALONE
+! PRIMUS PHARMS 640MG

N022503 001 Jun 01, 2015 Feb CMFD

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATETABLET;ORAL
JANUMET

+! MSD SUB MERCK	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	Mar CAHN
+!	1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	Mar CAHN

METHOCARBAMOLSOLUTION;IM-IV
METHOCARBAMOL
@ BAXTER HLTHCARE CORP 1GM/10ML (100MG/ML)

A215065 001 Jul 14, 2022 Feb DISC

AA		TABLET;ORAL					
		METHOCARBAMOL					
AA		AUROBINDO PHARMA LTD	500MG	A213967	002	Feb 09, 2023	Feb NEWA
AA			750MG	A213967	001	Aug 12, 2020	Feb CMFD
AA		DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb CAHN
AA			750MG	A203550	002	Feb 08, 2017	Feb CAHN

METHSUXIMIDECAPSULE;ORAL
CELONTIN
>D> +! PARKE DAVIS 300MG
>A> AB +! 300MG
>A> METHSUXIMIDE
>A> AB NOVITIUM PHARMA 300MG

N010596 008 Apr CFTG

N010596 008 Apr CFTG

A217213 001 May 01, 2023 Apr NFTG

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

>D> AB	+	PFIZER	2MG	N 011153	002	Apr	CTEC
>A>	+		2MG	N 011153	002	Apr	CTEC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

>A> AB		EUGIA PHARMA	40MG/ML	A 211930	001	Apr 13,	2023	Apr	NEWA
>A> AB			80MG/ML	A 211930	002	Apr 13,	2023	Apr	NEWA
>A> AB		SLAYBACK PHARMA LLC	40MG/ML	A 214870	002	May 10,	2023	Apr	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	!	XTTRIUM LABS INC	EQ 5MG BASE/5ML	A 074703	001	Oct 31,	1997	Jan	CAHN
----	---	------------------	-----------------	----------	-----	---------	------	-----	------

METOLAZONE

TABLET;ORAL

METOLAZONE

>D> AB		AACE PHARMS	2.5MG	A 216216	001	Oct 25,	2022	Apr	DISC
>A>	@		2.5MG	A 216216	001	Oct 25,	2022	Apr	DISC
>D> AB			5MG	A 216216	002	Oct 25,	2022	Apr	DISC
>A>	@		5MG	A 216216	002	Oct 25,	2022	Apr	DISC
>D> AB			10MG	A 216216	003	Oct 25,	2022	Apr	DISC
>A>	@		10MG	A 216216	003	Oct 25,	2022	Apr	DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

>D> AB		ACCORD HLTHCARE	EQ 25MG TARTRATE	A 215637	001	Oct 18,	2022	Apr	DISC
>A>	@		EQ 25MG TARTRATE	A 215637	001	Oct 18,	2022	Apr	DISC
>D> AB			EQ 50MG TARTRATE	A 215637	002	Oct 18,	2022	Apr	DISC
>A>	@		EQ 50MG TARTRATE	A 215637	002	Oct 18,	2022	Apr	DISC
>D> AB			EQ 100MG TARTRATE	A 215637	003	Oct 18,	2022	Apr	DISC
>A>	@		EQ 100MG TARTRATE	A 215637	003	Oct 18,	2022	Apr	DISC
>D> AB			EQ 200MG TARTRATE	A 215637	004	Oct 18,	2022	Apr	DISC
>A>	@		EQ 200MG TARTRATE	A 215637	004	Oct 18,	2022	Apr	DISC

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

>A> AB		ZYDUS PHARMS	25MG	A 212402	001	Apr 19,	2023	Apr	NEWA
>A> AB			50MG	A 212402	002	Apr 19,	2023	Apr	NEWA
>A> AB			100MG	A 212402	003	Apr 19,	2023	Apr	NEWA

METRONIDAZOLE

CREAM;TOPICAL

METRONIDAZOLE

>A> AB		ZYDUS LIFESCIENCES	0.75%	A 217128	001	Apr 21,	2023	Apr	NEWA
		GEL;TOPICAL							
		METRONIDAZOLE							
AB		COSETTE	1%	A 216692	001	Jan 23,	2023	Jan	NEWA
	@	TOLMAR	1%	A 090903	001	Jul 22,	2011	Feb	DISC
		GEL;VAGINAL							
		METRONIDAZOLE							
	@	ENCUBE	0.75%	A 077264	001	Oct 31,	2006	Mar	CAHN
		TABLET;ORAL							
		METRONIDAZOLE							
AB		ALEMBIC	250MG	A 208681	001	Jun 20,	2017	Feb	CAHN
AB			500MG	A 208681	002	Jun 20,	2017	Feb	CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

AB		LEADING	150MG	A 215876	001	Feb 27,	2023	Feb	NEWA
AB			200MG	A 215876	002	Feb 27,	2023	Feb	NEWA
AB			250MG	A 215876	003	Feb 27,	2023	Feb	NEWA
AB		ZENARA	150MG	A 215315	001	Aug 26,	2022	Feb	CAHN
AB			200MG	A 215315	002	Aug 26,	2022	Feb	CAHN

AB	CAPSULE;ORAL MEXILETINE HYDROCHLORIDE	250MG	A215315 003 Aug 26, 2022	Feb CAHN
<u>MICAFUNGIN SODIUM</u>				
	INJECTABLE;INTRAVENOUS MICAFUNGIN SODIUM			
@ ZYDUS PHARMS	EQ 50MG BASE/VIAL	A215241 001 Oct 24, 2022	Mar DISC	
@	EQ 100MG BASE/VIAL	A215241 002 Oct 24, 2022	Mar DISC	
<u>MIDAZOLAM</u>				
	SOLUTION;INTRAVENOUS MIDAZOLAM IN 0.9% SODIUM CHLORIDE			
>A> AP	HIKMA 50MG/50ML (1MG/ML)	A216159 001 Apr 17, 2023	Apr NFTG	
>A> AP	100MG/100ML (1MG/ML)	A216159 002 Apr 17, 2023	Apr NFTG	
>D>	+! INFORLIFE 50MG/50ML (1MG/ML)	N211844 001 Mar 22, 2021	Apr CFTG	
>A> AP	+! 50MG/50ML (1MG/ML)	N211844 001 Mar 22, 2021	Apr CFTG	
>D>	+! 100MG/100ML (1MG/ML)	N211844 002 Mar 22, 2021	Apr CFTG	
>A> AP	+! 100MG/100ML (1MG/ML)	N211844 002 Mar 22, 2021	Apr CFTG	
<u>MILNACIPRAN HYDROCHLORIDE</u>				
	TABLET;ORAL SAVELLA			
+	ABBVIE 12.5MG	N022256 001 Jan 14, 2009	Jan CAHN	
+	25MG	N022256 002 Jan 14, 2009	Jan CAHN	
+!	50MG	N022256 003 Jan 14, 2009	Jan CAHN	
+	100MG	N022256 004 Jan 14, 2009	Jan CAHN	
<u>MILRINONE LACTATE</u>				
	INJECTABLE;INJECTION MILRINONE LACTATE			
AP	SHANDONG EQ 1MG BASE/ML	A216373 001 Jan 23, 2023	Jan NEWA	
<u>MIRABEGRON</u>				
	TABLET, EXTENDED RELEASE;ORAL MIRABEGRON			
@ ZYDUS PHARMS	25MG	A209488 001 Sep 29, 2022	Mar DISC	
@	50MG	A209488 002 Sep 29, 2022	Mar DISC	
<u>MIRTAZAPINE</u>				
	TABLET;ORAL MIRTAZAPINE			
AB	PRASCO 7.5MG	A216751 001 Jan 18, 2023	Jan NEWA	
AB	15MG	A216751 002 Jan 18, 2023	Jan NEWA	
AB	30MG	A216751 003 Jan 18, 2023	Jan NEWA	
AB	45MG	A216751 004 Jan 18, 2023	Jan NEWA	
	REMERON			
>A> AB	+! ORGANON 15MG	N020415 001 Jun 14, 1996	Apr CAHN	
>A> AB	+ 30MG	N020415 002 Jun 14, 1996	Apr CAHN	
>A>	+ @ 45MG	N020415 003 Mar 17, 1997	Apr CAHN	
>D> AB	+! ORGANON USA INC 15MG	N020415 001 Jun 14, 1996	Apr CAHN	
>D> AB	+ 30MG	N020415 002 Jun 14, 1996	Apr CAHN	
>D>	+ @ 45MG	N020415 003 Mar 17, 1997	Apr CAHN	
<u>MISOPROSTOL</u>				
	TABLET;ORAL MISOPROSTOL			
@ NOVEL LABS INC	0.1MG	A091667 001 Jul 25, 2012	Feb DISC	
@	0.2MG	A091667 002 Jul 25, 2012	Feb DISC	
<u>MOMETASONE FUROATE</u>				
	LOTION;TOPICAL ELOCON			
+ @ ORGANON	0.1%	N019796 001 Mar 30, 1989	Mar DISC	
	MOMETASONE FUROATE			
AB	! PADAGIS ISRAEL 0.1%	A077180 001 Apr 06, 2005	Mar CHRS	

MONTELUKAST SODIUM

	TABLET, CHEWABLE;ORAL MONTELUKAST SODIUM					
AB	CHARTWELL MOLECULAR	EQ 4MG BASE	A207464	001	Dec 06, 2018	Jan CAHN
AB		EQ 5MG BASE	A207464	002	Dec 06, 2018	Jan CAHN

MORPHINE SULFATE

	INJECTABLE;INJECTION MORPHINE SULFATE					
AP	HIKMA	2MG/ML	A211452	001	Jan 12, 2023	Jan NFTG
AP		4MG/ML	A211452	002	Jan 12, 2023	Jan NEWA
AP		8MG/ML	A211452	003	Jan 12, 2023	Jan NEWA
AP		10MG/ML	A211452	004	Jan 12, 2023	Jan NEWA
		15MG/ML	A211452	005	Jan 12, 2023	Jan NFTG
AP	+! HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011	Jan CFTG
	TABLET;ORAL MORPHINE SULFATE					
>A>	@ DR REDDYS LABS SA	15MG	A207270	001	Jan 12, 2022	Apr CAHN
>A>	@	30MG	A207270	002	Jan 12, 2022	Apr CAHN
>D> AB	MAYNE PHARMA INC	15MG	A207270	001	Jan 12, 2022	Apr CAHN
>D> AB		30MG	A207270	002	Jan 12, 2022	Apr CAHN
	TABLET, EXTENDED RELEASE;ORAL MORPHINE SULFATE					
>A>	@ DR REDDYS LABS SA	15MG	A205386	001	Oct 28, 2016	Apr CAHN
>A>	@	30MG	A205386	002	Oct 28, 2016	Apr CAHN
>A>	@	60MG	A205386	003	Oct 28, 2016	Apr CAHN
>A>	@	100MG	A205386	004	Oct 28, 2016	Apr CAHN
>D> AB	MAYNE PHARMA INC	15MG	A205386	001	Oct 28, 2016	Apr CAHN
>D> AB		30MG	A205386	002	Oct 28, 2016	Apr CAHN
>D> AB		60MG	A205386	003	Oct 28, 2016	Apr CAHN
>D> AB		100MG	A205386	004	Oct 28, 2016	Apr CAHN

MOXIFLOXACIN HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC MOXIFLOXACIN HYDROCHLORIDE					
	@ AKORN	EQ 0.5% BASE	A202916	001	Nov 09, 2017	Jan DISC
	TABLET;ORAL MOXIFLOXACIN HYDROCHLORIDE					
>A> AB	CHARTWELL RX	EQ 400MG BASE	A207285	001	Feb 13, 2017	Apr CAHN
AB	HETERO LABS LTD V	EQ 400MG BASE	A204836	001	Mar 02, 2023	Feb NEWA
>D> AB	NOVEL LABS INC	EQ 400MG BASE	A207285	001	Feb 13, 2017	Apr CAHN
	@ TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Feb DISC

NABUMETONE

	TABLET;ORAL NABUMETONE					
>A>	@ AUROBINDO PHARMA USA	500MG	A090516	001	Jul 12, 2010	Apr CAHN
>A>	@	750MG	A090516	002	Jul 12, 2010	Apr CAHN
>D>	@ MYLAN PHARMS INC	500MG	A090516	001	Jul 12, 2010	Apr CAHN
>D>	@	750MG	A090516	002	Jul 12, 2010	Apr CAHN

NAFCILLIN SODIUM

	INJECTABLE;INJECTION NAFCILLIN SODIUM					
AP	! EUGIA PHARMA SPECLTS	EQ 1GM BASE/VIAL	A091613	001	Dec 26, 2012	Jan CHRS
AP	!	EQ 2GM BASE/VIAL	A091613	002	Dec 26, 2012	Jan CHRS
AP	!	EQ 10GM BASE/VIAL	A091614	001	Dec 26, 2012	Jan CHRS
	@ SANDOZ	EQ 1GM BASE/VIAL	A062527	002	Aug 02, 1984	Jan DISC
	@	EQ 1GM BASE/VIAL	A062732	001	Dec 23, 1986	Jan DISC
	@	EQ 2GM BASE/VIAL	A062527	003	Aug 02, 1984	Jan DISC
	@	EQ 2GM BASE/VIAL	A062732	002	Dec 23, 1986	Jan DISC
	@	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Jan DISC

NAFTIFINE HYDROCHLORIDE

	CREAM;TOPICAL NAFTIFINE HYDROCHLORIDE					
AB	AMNEAL	2%	A206960	001	Apr 10, 2017	Feb CAHN
	GEL;TOPICAL NAFTIFINE HYDROCHLORIDE					
AB	AMNEAL	1%	A206165	001	Mar 20, 2019	Feb CAHN
AB	TARO	2%	A208201	001	Apr 10, 2019	Mar CMFD

NALOXEGOL OXALATE

TABLET;ORAL					
MOVANTIK					
+ VALINOR	EQ 12.5MG BASE		N 204760	001	Sep 16, 2014
+!	EQ 25MG BASE		N 204760	002	Sep 16, 2014
					Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION					
NALOXONE HYDROCHLORIDE					
@ PAR STERILE PRODUCTS	1MG/ML		A 215964	001	Jul 29, 2022
SPRAY, METERED;NASAL					Jan DISC
NALOXONE HYDROCHLORIDE					
+! AMPHASTAR PHARMS INC	4MG/SPRAY		N 208969	001	Mar 07, 2023
					Mar NEWA

NAPROXEN

TABLET, DELAYED RELEASE;ORAL					
NAPROXEN					
>A>	@ AUROBINDO PHARMA USA	375MG	A 075390	001	Apr 19, 2001
>A>	@	500MG	A 075390	002	Apr 19, 2001
>D>	@ MYLAN PHARMS INC	375MG	A 075390	001	Apr 19, 2001
>D>	@	500MG	A 075390	002	Apr 19, 2001
					Apr CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL					
NARATRIPTAN					
>A>	@ AUROBINDO PHARMA USA	EQ 1MG BASE	A 202431	001	May 31, 2012
>A>	@	EQ 2.5MG BASE	A 202431	002	May 31, 2012
>D>	@ MYLAN PHARMS INC	EQ 1MG BASE	A 202431	001	May 31, 2012
>D>	@	EQ 2.5MG BASE	A 202431	002	May 31, 2012
					Apr CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL					
NEBIVOLOL HYDROCHLORIDE					
AB	BEXIMCO PHARMS USA	EQ 2.5MG BASE	A 216568	001	Mar 30, 2023
AB		EQ 5MG BASE	A 216568	002	Mar 30, 2023
AB		EQ 10MG BASE	A 216568	003	Mar 30, 2023
AB		EQ 20MG BASE	A 216568	004	Mar 30, 2023
					Mar NEWA

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL					
NEFAZODONE HYDROCHLORIDE					
>A>	@ AUROBINDO PHARMA USA	100MG	A 076129	002	Sep 16, 2003
>A>	@	150MG	A 076129	003	Sep 16, 2003
>A>	@	200MG	A 076129	004	Sep 16, 2003
>A>	@	250MG	A 076129	005	Sep 16, 2003
>D>	@ MYLAN	100MG	A 076129	002	Sep 16, 2003
>D>	@	150MG	A 076129	003	Sep 16, 2003
>D>	@	200MG	A 076129	004	Sep 16, 2003
>D>	@	250MG	A 076129	005	Sep 16, 2003
					Apr CAHN

NELARABINE

INJECTABLE;INTRAVENOUS					
NELARABINE					
AP	AMNEAL	250MG/50ML (5MG/ML)	A 216346	001	Apr 04, 2023
AP	SHORLA	250MG/50ML (5MG/ML)	A 214809	001	Mar 03, 2023
					Mar NEWA
					Feb NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS					
NEOSTIGMINE METHYLSULFATE					
AP	SAGENT PHARMS INC	5MG/10ML (0.5MG/ML)	A 216542	001	Feb 17, 2023
AP		10MG/10ML (1MG/ML)	A 216542	002	Feb 17, 2023
					Feb NEWA

NICARDIPIINE HYDROCHLORIDE

CAPSULE;ORAL					
NICARDIPIINE HYDROCHLORIDE					
>A> AB	SQUARE PHARMS	20MG	A 217555	001	May 03, 2023
>A> AB		30MG	A 217555	002	May 03, 2023
					Apr NEWA
					Apr NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

>D>	AB2	PHARMADAX INC	30MG	A216019	001	Nov 18, 2022	Apr DISC
>A>	@		30MG	A216019	001	Nov 18, 2022	Apr DISC
>D>	AB2		60MG	A216019	002	Nov 18, 2022	Apr DISC
>A>	@		60MG	A216019	002	Nov 18, 2022	Apr DISC

NIRAPARIB TOSYLATE

>A>	TABLET;ORAL						
>A>	ZEJULA						
>A>	+	GLAXOSMITHKLINE	EQ 100MG BASE	N214876	001	Apr 26, 2023	Apr NEWA
>A>	+		EQ 200MG BASE	N214876	002	Apr 26, 2023	Apr NEWA
>A>	+!		EQ 300MG BASE	N214876	003	Apr 26, 2023	Apr NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

AB	AMTA	8.5MG	A216606	001	Apr 10, 2023	Mar NEWA
----	------	-------	---------	-----	--------------	----------

NITISINONE

CAPSULE;ORAL

NITISINONE

>A>	AB	MEDUNIK	20MG	A212390	004	Apr 27, 2023	Apr NEWA
-----	----	---------	------	---------	-----	--------------	----------

NITRIC OXIDE

GAS;INHALATION

GENOSYL

+!	VERO BIOTECH INC	800PPM
----	------------------	--------

N202860 001 Dec 20, 2019 Jan CAHN

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

>A>	AB	NOVITIUM PHARMA	25MG/5ML	A216385	001	Apr 14, 2023	Apr NEWA
-----	----	-----------------	----------	---------	-----	--------------	----------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

>D>	@	AUROBINDO PHARMA USA	50MG	A074967	001	Jul 09, 1997	Apr CMFD
>A>	AB		50MG	A074967	001	Jul 09, 1997	Apr CMFD
>D>	@		100MG	A074967	002	Jul 09, 1997	Apr CMFD
>A>	AB		100MG	A074967	002	Jul 09, 1997	Apr CMFD
AB	MANKIND PHARMA	25MG		A217272	001	Mar 21, 2023	Mar NEWA
AB		50MG		A217272	002	Mar 21, 2023	Mar NEWA
AB		100MG		A217272	003	Mar 21, 2023	Mar NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	@ ALVOGEN	75MG;25MG	A215002	001	Jul 20, 2022	Jan DISC
AB	AUROBINDO PHARMA	75MG;25MG	A209225	001	Mar 30, 2023	Mar NEWA

NOREpinephrine Bitartrate

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

>D>	+!	NEVAKAR INJECTABLES	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Apr DISC
>A>	+ @		EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Apr DISC
>D>	+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Apr DISC
>A>	+ @		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Apr DISC
>D>	+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Apr DISC
>A>	+ @		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Apr DISC

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

@ TORRENT

100,000 UNITS/GM

A211838 001 Jan 28, 2019 Mar DISC

SUSPENSION;ORAL

NILSTAT

>A> + @ CHARTWELL MOLECULES 100,000 UNITS/ML

N050299 001 Apr CAHN

>D> + @ GLENMARK PHARMS LTD 100,000 UNITS/ML

N050299 001 Apr CAHN

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP ASPIRO 10MG/VIAL

A217466 001 Mar 22, 2023 Mar NEWA

TABLET;ORAL

OLANZAPINE

AB CADILA PHARMS LTD 2.5MG

A210022 001 Feb 24, 2023 Feb NEWA

AB 5MG

A210022 002 Feb 24, 2023 Feb NEWA

AB 7.5MG

A210022 003 Feb 24, 2023 Feb NEWA

AB 10MG

A210022 004 Feb 24, 2023 Feb NEWA

AB 15MG

A210022 005 Feb 24, 2023 Feb NEWA

AB 20MG

A210022 006 Feb 24, 2023 Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

>D> @ HISUN PHARM HANGZHOU 5MG

A206892 001 Dec 31, 2020 Apr CMFD

>A> AB 5MG

A206892 001 Dec 31, 2020 Apr CMFD

>D> @ 10MG

A206892 002 Dec 31, 2020 Apr CMFD

>A> AB 10MG

A206892 002 Dec 31, 2020 Apr CMFD

>D> @ 15MG

A206892 003 Dec 31, 2020 Apr CMFD

>A> AB 15MG

A206892 003 Dec 31, 2020 Apr CMFD

>D> @ 20MG

A206892 004 Dec 31, 2020 Apr CMFD

>A> AB 20MG

A206892 004 Dec 31, 2020 Apr CMFD

AB ZYDUS PHARMS 5MG

A202889 001 Mar 09, 2023 Mar NEWA

AB 10MG

A202889 002 Mar 09, 2023 Mar NEWA

AB 15MG

A202889 003 Mar 09, 2023 Mar NEWA

AB 20MG

A202889 004 Mar 09, 2023 Mar NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB MSN 5MG

A217399 001 Jan 18, 2023 Jan NEWA

AB 20MG

A217399 002 Jan 18, 2023 Jan NEWA

AB 40MG

A217399 003 Jan 18, 2023 Jan NEWA

OMAVELOXOCLONE

CAPSULE;ORAL

SKYCLARYS

+! REATA PHARMS 50MG

N216718 001 Feb 28, 2023 Feb NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

! CHARTWELL MOLECULES 16MG

A077406 001 Dec 26, 2006 Mar CHRS

! 24MG

A077406 002 Dec 26, 2006 Mar CHRS

ONDANSETRON HYDROCHLORIDE

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

! CHARTWELL MOLECULES EQ 24MG BASE

A077303 004 Jun 25, 2007 Feb CTEC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

AB RISING 100MG

A040249 001 Jan 29, 1999 Jan CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

@ ACCORD HLTHCARE EQ 30MG BASE

A214726 001 Jul 25, 2022 Feb DISC

@ EQ 45MG BASE

A214726 002 Jul 25, 2022 Feb DISC

@ EQ 75MG BASE

A214726 003 Jul 25, 2022 Feb DISC

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

AB	EPIC PHARMA LLC	EQ 6MG BASE/ML	A215538	001	Feb 14, 2023	Feb NEWA
----	-----------------	----------------	---------	-----	--------------	----------

OXANDROLONE

TABLET;ORAL
OXANDROLONE

@ PAR PHARM	2.5MG	A077827	001	Jun 22, 2007	Feb DISC
@	10MG	A077827	002	Jun 22, 2007	Feb DISC
@ UPSHER SMITH LABS	2.5MG	A076761	001	Dec 01, 2006	Feb DISC
@	10MG	A078033	001	Mar 22, 2007	Feb DISC

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL
GELNIQUE

>A>	+! ABBVIE	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Apr CAHN
>D>	+! ALLERGAN	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Apr CAHN

SYRUP;ORAL
OXYBUTYNIN CHLORIDE

AA	CHARTWELL RX	5MG/5ML	A075039	001	Jan 29, 1999	Mar CMFD
	@ XTRIUM LABS INC	5MG/5ML	A074868	001	Feb 12, 1997	Mar CAHN
	TABLET;ORAL OXYBUTYNIN CHLORIDE					
	! APPCO	2.5MG	A209025	002	Feb 07, 2023	Jan NFTG

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL
OXYCODONE HYDROCHLORIDE

>A>	@ DR REDDYS LABS SA	5MG	A203107	001	Jul 26, 2012	Apr CAHN
>D> AB	MAYNE PHARMA INC	5MG	A203107	001	Jul 26, 2012	Apr CAHN

SOLUTION;ORAL
OXYCODONE HYDROCHLORIDE

>A>	@ DR REDDYS LABS SA	100MG/5ML	A204092	001	Jun 05, 2014	Apr CAHN
>D> AA	MAYNE PHARMA INC	100MG/5ML	A204092	001	Jun 05, 2014	Apr CAHN

TABLET;ORAL
OXYCODONE HYDROCHLORIDE

>A>	@ DR REDDYS LABS SA	5MG	A091313	001	Feb 18, 2011	Apr CAHN
>A>	@	10MG	A091313	004	Apr 29, 2016	Apr CAHN
>A>	@	15MG	A091313	002	Feb 18, 2011	Apr CAHN
>A>	@	20MG	A091313	005	Apr 29, 2016	Apr CAHN
>A>	@	30MG	A091313	003	Feb 18, 2011	Apr CAHN
>D>	@ MAYNE PHARMA INC	5MG	A091313	001	Feb 18, 2011	Apr CAHN
>D>	@	10MG	A091313	004	Apr 29, 2016	Apr CAHN
>D>	@	15MG	A091313	002	Feb 18, 2011	Apr CAHN
>D>	@	20MG	A091313	005	Apr 29, 2016	Apr CAHN
>D>	@	30MG	A091313	003	Feb 18, 2011	Apr CAHN

PACLITAXEL

INJECTABLE;INJECTION
PACLITAXEL

@ DASH PHARMS	6MG/ML	A091540	001	Sep 29, 2011	Feb CAHN
---------------	--------	---------	-----	--------------	----------

POWDER;INTRAVENOUS
PACLITAXEL

>A>	+! AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022	Apr CAHN
>D>	+! HBT LABS INC	100MG/VIAL	N211875	001	Jul 27, 2022	Apr CAHN

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

@ CIPLA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018	Feb DISC
@ INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Feb DISC

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

>D> AP	+ HOSPIRA	30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	Apr CHRS
>A> AP		30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	Apr CHRS
>D> AP	+	90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	Apr CHRS
>A> AP		90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	Apr CHRS

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB AJANTA PHARMA LTD EQ 40MG BASE A217416 001 Feb 09, 2023 Feb NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

@ EPIC PHARMA LLC EQ 12.5MG BASE A213612 001 Aug 11, 2021 Jan CAHN
@ EQ 25MG BASE A213612 002 Aug 11, 2021 Jan CAHN
@ EQ 37.5MG BASE A213612 003 May 26, 2022 Jan CAHNPEGCETACOPLAN

SOLUTION;INTRAVITREAL

SYFOVRE

+! APELLIS PHARMS 15MG/0.1ML (15MG/0.1ML)

N217171 001 Feb 17, 2023 Feb NEWA

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

PEMETREXED DISODIUM

>A> AP AMNEAL EQ 100MG BASE/VIAL A210047 002 May 08, 2023 Apr NEWA
AP MEITHEAL EQ 100MG BASE/VIAL A215479 001 Dec 13, 2022 Jan CAHN
AP EQ 500MG BASE/VIAL A215479 002 Dec 13, 2022 Jan CAHN
AP EQ 750MG BASE/VIAL A215479 003 Dec 13, 2022 Jan CAHN
AP EQ 1GM BASE/VIAL A215479 004 Dec 13, 2022 Jan CAHN
AP @ MYLAN LABS LTD EQ 500MG BASE/VIAL A203628 001 Mar 10, 2023 Mar DISC
AP EQ 500MG BASE/VIAL A203628 001 Mar 10, 2023 Mar NEWA

SOLUTION; INTRAVENOUS
PEMETREXED DISODIUM
+! SANDOZ INC EQ 100MG BASE/4ML (EQ 25MG
BASE/ML) N214657 001 May 26, 2022 Jan CMS1PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

PENTAMIDINE ISETHIONATE

AN X-GEN PHARMS INC 300MG/VIAL A206983 001 Jan 20, 2023 Jan NEWA

PERAMPANEL

SUSPENSION;ORAL

FYCOMPRA

+! CATALYST PHARMS 0.5MG/ML N208277 001 Apr 29, 2016 Feb CAHN
TABLET;ORAL
FYCOMPRA
+ CATALYST PHARMS 2MG N202834 001 Oct 22, 2012 Feb CAHN
+ 4MG N202834 002 Oct 22, 2012 Feb CAHN
+ 6MG N202834 003 Oct 22, 2012 Feb CAHN
+ 8MG N202834 004 Oct 22, 2012 Feb CAHN
+ 10MG N202834 005 Oct 22, 2012 Feb CAHN
+! 12MG N202834 006 Oct 22, 2012 Feb CAHNPHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

>A> AB AUROBINDO PHARMA 10MG A215600 001 May 08, 2023 Apr NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

@ LANNETT 15MG A087022 002 Jan 20, 2012 Feb DISC
@ 30MG A087022 001 Feb 03, 1983 Feb DISCPHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP2 AVET LIFESCIENCES 10MG/ML (10MG/ML) A209968 001 Feb 28, 2023 Feb NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC PLAIN

@ XTTRIUM LABS INC 5MG/5ML; 6.25MG/5ML

A088897 001 Jan 04, 1985 Jan CAHN

PHENYTOIN SODIUM

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

@ MYLAN 100MG EXTENDED

A040298 001 Dec 28, 1998 Mar DISC

UNICHEM 100MG EXTENDED

A213834 001 Oct 13, 2022 Apr DISC

>A> @ 100MG EXTENDED

A213834 001 Oct 13, 2022 Apr DISC

PHYTONADIONE

TABLET; ORAL

MEPHYTON

+ @ BAUSCH PHYTONADIONE

N010104 003 Feb DISC

AB ! ZYDUS 5MG

A210189 001 Feb 20, 2019 Feb CHRS

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

>D> AP QILU EQ 2GM BASE/VIAL; EQ 250MG

A204959 001 Aug 10, 2018 Apr CAHN

BASE/VIAL

A204959 002 Aug 10, 2018 Apr CAHN

EQ 3GM BASE/VIAL; EQ 375MG

A204959 003 Aug 10, 2018 Apr CAHN

BASE/VIAL

A204959 001 Aug 10, 2018 Apr CAHN

EQ 4GM BASE/VIAL; EQ 500MG

A204959 002 Aug 10, 2018 Apr CAHN

BASE/VIAL

A204959 003 Aug 10, 2018 Apr CAHN

ZOSYN IN PLASTIC CONTAINER

A204959 001 Aug 10, 2018 Apr CAHN

+! BAXTER HLTHCARE CORP EQ 40MG BASE/ML; EQ 5MG BASE/ML

A204959 002 Aug 10, 2018 Apr CAHN

+! EQ 60MG BASE/ML; EQ 7.5MG BASE/ML

A204959 003 Aug 10, 2018 Apr CAHN

+! EQ 4GM BASE/100ML; EQ 500MG

A204959 001 Aug 10, 2018 Apr CAHN

BASE/100ML

A204959 002 Aug 10, 2018 Apr CAHN

N050750 003 Aug 10, 2018 Apr CAHN

PIRTOBRUTINIB

TABLET; ORAL

JAYPIRCA

+ LOXO ONCOL 50MG

N050750 001 Feb 24, 1998 Mar CAHN

+! 100MG

N050750 002 Feb 24, 1998 Mar CAHN

+!

N050750 003 Feb 24, 1998 Mar CAHN

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

AB ZYDUS PHARMS EQ 1MG BASE

A206047 001 Feb 22, 2023 Feb NEWA

AB EQ 2MG BASE

A206047 002 Feb 22, 2023 Feb NEWA

AB EQ 4MG BASE

A206047 003 Feb 22, 2023 Feb NEWA

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

+ @ ALLERGAN 10,000 UNITS/ML; EQ 1MG BASE/ML

N050567 001 Oct 20, 1988 Feb DISC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT ! SANDOZ INC 10,000 UNITS/ML; EQ 1MG BASE/ML

A064211 001 Apr 13, 1998 Feb CHRS

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

+ BRISTOL 1MG

N204026 001 Feb 08, 2013 Jan CAHN

+ 2MG

N204026 002 Feb 08, 2013 Jan CAHN

+ 3MG

N204026 003 Feb 08, 2013 Jan CAHN

+! 4MG

N204026 004 Feb 08, 2013 Jan CAHN

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

AP EXELA PHARMA 2MEQ/ML A212692 001 Oct 20, 2021 Feb CMFD

POTASSIUM CHLORIDE

SOLUTION; ORAL

POTASSIUM CHLORIDE

AA BELCHER 20MEQ/15ML A216156 001 Mar 07, 2023 Feb NEWA

AA BELCHER 40MEQ/15ML A216156 002 Mar 07, 2023 Feb NEWA

TABLET, EXTENDED RELEASE; ORAL

K-TAB

+ @ ABBVIE 10MEQ N018279 001 Feb DISC

+ @ ABBVIE 20MEQ N018279 003 Nov 25, 2013 Feb DISC

POTASSIUM CHLORIDE

>A> AB3 TWI PHARMS 10MEQ A209688 001 Jan 12, 2018 Apr CAHN

>A> AB3 ! 20MEQ A209688 002 Jan 12, 2018 Apr CAHN

>D> AB3 VITRUVIAS THERAP 10MEQ A209688 001 Jan 12, 2018 Apr CAHN

>D> AB3 ! 20MEQ A209688 002 Jan 12, 2018 Apr CAHN

AB3 ! 20MEQ A209688 002 Jan 12, 2018 Feb CHRS

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL

AB AMNEAL PHARMS EQ 5MG BASE A205913 001 Jun 19, 2018 Mar CTEC

AB @ LUPIN LTD EQ 10MG BASE A205913 002 Jun 19, 2018 Mar CTEC

@ LUPIN LTD EQ 5MG BASE A205930 001 Jan 09, 2023 Feb DISC

@ LUPIN LTD EQ 10MG BASE A205930 002 Jan 09, 2023 Feb DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AB ALEMBIC EQ 1MG BASE A217268 001 Mar 06, 2023 Feb NEWA

AB EQ 2MG BASE A217268 002 Mar 06, 2023 Feb NEWA

AB EQ 5MG BASE A217268 003 Mar 06, 2023 Feb NEWA

AB AUROBINDO PHARMA LTD EQ 1MG BASE A213052 001 Mar 31, 2023 Mar NEWA

AB EQ 2MG BASE A213052 002 Mar 31, 2023 Mar NEWA

AB EQ 5MG BASE A213052 003 Mar 31, 2023 Mar NEWA

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA XTRIUM LABS INC 15MG/5ML A040313 001 Sep 10, 2003 Jan CAHN

TABLET; ORAL

PREDNISOLONE

AB AUROBINDO PHARMA LTD 5MG A215673 001 Mar 17, 2023 Mar NEWA

AB +! WATSON LABS 5MG A080354 001 Mar CTEC

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

PRED FORTE

AB +! ABBVIE 1% N017011 001 Jan CAHN

PRED MILD

AB +! ABBVIE 0.12% N017100 001 Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA EDENBRIDGE PHARMS EQ 15MG BASE/5ML A203559 003 Feb 06, 2023 Jan NEWA

AA EQ 15MG BASE/5ML A203559 003 Feb 06, 2023 Jan NEWA

AA EQ 25MG BASE/5ML A203559 004 Feb 06, 2023 Jan NEWA

AA EQ 25MG BASE/5ML A203559 004 Feb 06, 2023 Jan NEWA

AA ! MISSION PHARMA EQ 25MG BASE/5ML A091396 001 Sep 13, 2010 Jan CTEC

AA XTTRIUM LABS INC EQ 5MG BASE/5ML A075099 001 Jun 28, 2002 Jan CAHN

AA ! EQ 15MG BASE/5ML A076895 001 Oct 04, 2004 Jan CAHN

PREDNISONE

SOLUTION;ORAL

PREDNISONE

@ XTTRIUM LABS INC

5MG/5ML

A089726 001 Aug 02, 1988 Jan CAHN

TABLET;ORAL

PREDNISONE

AB +! HIKMA

2.5MG

A087801 001 Apr 22, 1982 Jan CRLD

AB +!

5MG

A080352 001 Jan CRLD

AB +!

50MG

A084283 001 Jan CRLD

>A> AB JUBILANT CADISTA

2.5MG

A040362 004 Apr 17, 2023 Apr NEWA

>A> AB

50MG

A040362 005 Apr 17, 2023 Apr NEWA

PREGABALIN

CAPSULE;ORAL

PREGABALIN

>A> AB ACI

25MG

A215755 001 Apr 26, 2023 Apr NEWA

>A> AB

50MG

A215755 002 Apr 26, 2023 Apr NEWA

>A> AB

75MG

A215755 003 Apr 26, 2023 Apr NEWA

>A> AB

100MG

A215755 004 Apr 26, 2023 Apr NEWA

>A> AB

150MG

A215755 005 Apr 26, 2023 Apr NEWA

>A> AB

200MG

A215755 006 Apr 26, 2023 Apr NEWA

>A> AB

225MG

A215755 007 Apr 26, 2023 Apr NEWA

>A> AB

300MG

A215755 008 Apr 26, 2023 Apr NEWA

AB AUROBINDO PHARMA

25MG

A205321 001 Mar 29, 2023 Mar NEWA

AB

50MG

A205321 002 Mar 29, 2023 Mar NEWA

AB

75MG

A205321 003 Mar 29, 2023 Mar NEWA

AB

100MG

A205321 004 Mar 29, 2023 Mar NEWA

AB

150MG

A205321 005 Mar 29, 2023 Mar NEWA

AB

200MG

A205321 006 Mar 29, 2023 Mar NEWA

AB

225MG

A205321 007 Mar 29, 2023 Mar NEWA

AB

300MG

A205321 008 Mar 29, 2023 Mar NEWA

SOLUTION;ORAL

PREGABALIN

AA PATRIN

20MG/ML

A212604 001 Feb 18, 2022 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

PREGABALIN

@ ZYDUS PHARMS

82.5MG

A215577 001 Aug 26, 2022 Jan DISC

@

165MG

A215577 002 Aug 26, 2022 Jan DISC

@

330MG

A215577 003 Aug 26, 2022 Jan DISC

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP ! HOSPIRA

500MG/ML

A089070 001 Feb 12, 1986 Feb CTEC

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

>A> AB AMNEAL

EQ 5MG BASE

A216598 001 Apr 17, 2023 Apr NEWA

>A> AB

EQ 10MG BASE

A216598 002 Apr 17, 2023 Apr NEWA

AB BIONPHARMA INC

EQ 5MG BASE

A217478 001 Apr 04, 2023 Mar NEWA

AB

EQ 10MG BASE

A217478 002 Apr 04, 2023 Mar NEWA

AB GLENMARK PHARMS LTD

EQ 5MG BASE

A216595 001 Mar 17, 2023 Mar NEWA

AB

EQ 10MG BASE

A216595 002 Mar 17, 2023 Mar NEWA

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

>A> @ AUROBINDO PHARMA USA

12.5MG

A091054 001 Aug 30, 2011 Apr CAHN

>A> @

25MG

A091054 002 Aug 30, 2011 Apr CAHN

>A> @

50MG

A091054 003 Aug 30, 2011 Apr CAHN

>D> @ MYLAN

12.5MG

A091054 001 Aug 30, 2011 Apr CAHN

>D> @

25MG

A091054 002 Aug 30, 2011 Apr CAHN

>D> @

50MG

A091054 003 Aug 30, 2011 Apr CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	225MG	A213096	001	Feb 21, 2023	Feb NEWA
AB		325MG	A213096	002	Feb 21, 2023	Feb NEWA
AB		425MG	A213096	003	Feb 21, 2023	Feb NEWA

PROPOFOL

INJECTABLE;INJECTION
PROPOFOL

AB	AVET LIFESCIENCES	10MG/ML	A206408	001	Oct 12, 2021	Jan CAHN
----	-------------------	---------	---------	-----	--------------	----------

PROPYLTHIOURACIL

TABLET;ORAL
PROPYLTHIOURACIL

>D> BD	+!	DAVA PHARMS INC	50MG	N 006188	001	Apr CTEC
>A> AB	+!		50MG	N 006188	001	Apr CTEC
>A> AB		MACLEODS PHARMS LTD	50MG	A208867	001	May 10, 2023

RAMELTEON

TABLET;ORAL
RAMELTEON

AB	@ INNOGENIX	8MG	A215435	001	Aug 24, 2022	Mar DISC
AB		8MG	A215435	001	Aug 24, 2022	Jan CAHN
AB	MICRO LABS	8MG	A215243	001	Feb 09, 2023	Feb NEWA

RAMIPRIL

CAPSULE;ORAL
RAMIPRIL

AB	COREPHARMA	1.25MG	A079116	001	Jun 20, 2008	Feb CAHN
AB		2.5MG	A079116	002	Jun 20, 2008	Feb CAHN
AB		5MG	A079116	003	Jun 20, 2008	Feb CAHN
AB		10MG	A079116	004	Jun 20, 2008	Feb CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL
RANEXA

+ @ GILEAD		500MG	N 021526	002	Jan 27, 2006	Jan DISC
+ @		1GM	N 021526	001	Feb 12, 2007	Jan DISC
	RANOLAZINE					
AB	! SUN PHARM	1GM	A211707	002	May 28, 2019	Jan CHRS
AB	UNICHEM	500MG	A213083	001	Mar 16, 2023	Mar NEWA
AB		1GM	A213083	002	Mar 16, 2023	Mar NEWA

REGADENOSON

SOLUTION;INTRAVENOUS
REGADENOSON

AP	HIKMA	0.4MG/5ML (0.08MG/ML)	A215827	001	Feb 02, 2023	Jan NEWA
>D>	@ IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	Apr CMFD
>A> AP		0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	Apr CMFD

REPAGLINIDE

TABLET;ORAL
REPAGLINIDE

AB	MACLEODS PHARMS LTD	0.5MG	A207209	001	Mar 22, 2023	Mar NEWA
AB		1MG	A207209	002	Mar 22, 2023	Mar NEWA
AB		2MG	A207209	003	Mar 22, 2023	Mar NEWA

REZAFUNGIN ACETATE

POWDER;INTRAVENOUS
REZZAYO

+! CIDARA THERAPS EQ 200MG BASE/VIAL

N 217417 001 Mar 22, 2023 Mar NEWA

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL
NURTEC ODT

+! PFIZER EQ 75MG BASE

N 212728 001 Feb 27, 2020 Feb CAHN

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

RYKINDO

+!	SHANDONG LUYE	12.5MG
+!		25MG
+!		37.5MG
+!		50MG

N 212849	001	Jan 13, 2023	Jan NEWA
N 212849	002	Jan 13, 2023	Jan NEWA
N 212849	003	Jan 13, 2023	Jan NEWA
N 212849	004	Jan 13, 2023	Jan NEWA

SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

UZEDY

>A>	+ TEVA	50MG/0.14ML (50MG/0.14ML)
>A>	+	75MG/0.21ML (75MG/0.21ML)
>A>	+	100MG/0.28ML (100MG/0.28ML)
>A>	+	125MG/0.35ML (125MG/0.35ML)
>A>	+	150MG/0.42ML (150MG/0.42ML)
>A>	+	200MG/0.56ML (200MG/0.56ML)
>A>	+	250MG/0.7ML (250MG/0.7ML)

N 213586	001	Apr 28, 2023	Apr NEWA
N 213586	002	Apr 28, 2023	Apr NEWA
N 213586	003	Apr 28, 2023	Apr NEWA
N 213586	004	Apr 28, 2023	Apr NEWA
N 213586	005	Apr 28, 2023	Apr NEWA
N 213586	006	Apr 28, 2023	Apr NEWA
N 213586	007	Apr 28, 2023	Apr NEWA

TABLET; ORAL

RISPERIDONE

@ DASH PHARMS	0.25MG
@	0.5MG
@	1MG
@	2MG
@	3MG
@	4MG

A 076288	001	Sep 15, 2008	Feb CAHN
A 076288	002	Sep 15, 2008	Feb CAHN
A 076288	003	Sep 15, 2008	Feb CAHN
A 076288	004	Sep 15, 2008	Feb CAHN
A 076288	005	Sep 15, 2008	Feb CAHN
A 076288	006	Sep 15, 2008	Feb CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

@ DASH PHARMS	0.25MG
@	0.5MG
@	1MG
@	2MG
@	3MG
@	4MG

A 091537	006	Feb 12, 2013	Feb CAHN
A 091537	001	Mar 30, 2011	Feb CAHN
A 091537	002	Mar 30, 2011	Feb CAHN
A 091537	003	Mar 30, 2011	Feb CAHN
A 091537	004	Mar 30, 2011	Feb CAHN
A 091537	005	Mar 30, 2011	Feb CAHN

RITONAVIR

SOLUTION; ORAL

NORVIR

+ @ ABBVIE	80MG/ML
------------	---------

N 020659	001	Mar 01, 1996	Feb DISC
----------	-----	--------------	----------

RIZATRIPTAN BENZOATE

>A> FILM; ORAL

RIZAFILM

>A> +! INTELGENX CORP	EQ 10MG BASE
-----------------------	--------------

N 205394	001	Apr 14, 2023	Apr NEWA
----------	-----	--------------	----------

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP CAPLTN	50MG/5ML (10MG/ML)
AP	100MG/10ML (10MG/ML)
>A> AP HONG KONG	50MG/5ML (10MG/ML)
>A> AP	100MG/10ML (10MG/ML)

A 216234	001	Mar 02, 2023	Feb NEWA
A 216234	002	Mar 02, 2023	Feb NEWA
A 213453	001	May 08, 2023	Apr NEWA
A 213453	002	May 08, 2023	Apr NEWA

ROFLUMILAST

TABLET; ORAL

ROFLUMILAST

>A> AB ALKEM LABS LTD	250MCG
>A> AB	500MCG
>A> AB AUROBINDO PHARMA LTD	500MCG
>A> AB HETERO LABS LTD III	250MCG
>A> AB MICRO LABS	250MCG
>A> AB ZYDUS PHARMS	250MCG

A 212490	001	Apr 18, 2023	Apr NEWA
A 212490	002	Apr 18, 2023	Apr NEWA
A 213298	001	Apr 17, 2023	Apr NEWA
A 208213	002	Apr 18, 2023	Apr NEWA
A 208180	002	Apr 18, 2023	Apr NEWA
A 208303	002	Apr 18, 2023	Apr NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

@ MYLAN	EQ 5MG BASE
---------	-------------

A 078881	007	May 19, 2008	Mar DISC
----------	-----	--------------	----------

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AMNEAL	200MG/100ML (2MG/ML)	A216605	001	Mar 08, 2023	Feb NEWA
AP		400MG/200ML (2MG/ML)	A216605	002	Mar 08, 2023	Feb NEWA
AP		500MG/100ML (5MG/ML)	A216605	003	Mar 07, 2023	Feb NEWA
AP		1GM/200ML (5MG/ML)	A216605	004	Mar 07, 2023	Feb NEWA

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@ DASH PHARMS NATCO 5MG

A074866 001 Nov 26, 1997 Mar CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

@ XTTRIUM LABS INC 2.5%

A088228 001 Sep 01, 1983 Mar CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	HERITAGE PHARMA AVET	EQ 25MG BASE	A076465	001	Aug 11, 2006	Mar CMFD
AB		EQ 50MG BASE	A076465	002	Aug 11, 2006	Mar CMFD
AB		EQ 100MG BASE	A076465	003	Aug 11, 2006	Mar CMFD

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

SEVELAMER CARBONATE

AB	HANGZHOU ANPRIME	800MG/PACKET	A217319	001	Mar 02, 2023	Feb NEWA
AB		2.4GM/PACKET	A217319	002	Mar 02, 2023	Feb NEWA

TABLET; ORAL

SEVELAMER CARBONATE

>A> AB	MACLEODS PHARMS LTD	800MG	A206100	001	Apr 19, 2023	Apr NEWA
--------	---------------------	-------	---------	-----	--------------	----------

SILDENAFIL CITRATE

SUSPENSION; ORAL

LIQREV

>A> +! CMP DEV LLC EQ 10MG BASE/ML

N214952 001 Apr 28, 2023 Apr NEWA

TABLET; ORAL

SILDENAFIL CITRATE

>A> AB	MACLEODS PHARMS LTD	EQ 25MG BASE	A202255	001	Apr 19, 2023	Apr NEWA
>A> AB		EQ 50MG BASE	A202255	002	Apr 19, 2023	Apr NEWA
>A> AB		EQ 100MG BASE	A202255	003	Apr 19, 2023	Apr NEWA

SIROLIMUS

SOLUTION; ORAL

SIROLIMUS

AA	MSN	1MG/ML	A216728	001	Jan 19, 2023	Jan NEWA
	TABLET; ORAL					

SIROLIMUS

AB	ZYDUS PHARMS	1MG	A201676	001	Feb 15, 2023	Feb NEWA
		2MG	A201676	002	Feb 15, 2023	Feb NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

+ B BRAUN 9MG/ML

N019635 005 Aug 08, 2016 Mar CPOT

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ @ LIEBEL-FLARSHEIM 450MG/50ML (9MG/ML)

N021569 001 Jul 27, 2006 Mar CPOT

+ 1.125GM/125ML (9MG/ML)

N021569 002 Jul 27, 2006 Mar CPOT

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

AB	+! HORIZON THERAP US	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Jan CAHN
	TABLET; ORAL					

BUPHENYL

AB	+! HORIZON THERAP US	500MG	N020572	001	May 13, 1996	Jan CAHN
----	----------------------	-------	---------	-----	--------------	----------

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES

AP ! FRESENIUS KABI USA 142MG/ML;276MG/ML A209997 001 Mar 30, 2022 Mar CHRS

SORAFENIB TOSYLATE

TABLET; ORAL

SORAFENIB TOSYLATE

AB TORRENT EQ 200MG BASE A217095 001 Apr 12, 2023 Mar NEWA

SOTORASIB

TABLET; ORAL

LUMAKRAS

+ AMGEN INC	120MG	N214665 001 May 28, 2021	Mar CHRS
+!	320MG	N214665 002 Jan 20, 2023	Mar CHRS
+	320MG	N214665 002 Jan 20, 2023	Feb NEWA

SPARSENTAN

TABLET; ORAL

FILSPARI

+ TRAVERE	200MG	N216403 001 Feb 17, 2023	Feb NEWA
+!	400MG	N216403 002 Feb 17, 2023	Feb NEWA

STERILE WATER FOR INJECTION

LIQUID; N/A

STERILE WATER FOR INJECTION

AP HIKMA 100% A212735 001 Jan 31, 2023 Jan NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

>D> AP BRECKENRIDGE	20MG/ML	A212638 001 Oct 09, 2019	Apr DISC
>A> @	20MG/ML	A212638 001 Oct 09, 2019	Apr DISC
AP MANKIND PHARMA	20MG/ML	A216127 001 Feb 02, 2023	Jan NEWA

SUCRALFATE

TABLET; ORAL

SUCRALFATE

>A> AB ZYDUS LIFESCIENCES 1GM A215705 001 May 03, 2023 Apr NEWA

SUFENTANIL CITRATE

TABLET; SUBLINGUAL

DSUVIA

>D> +! ACELRX PHARMS	EQ 0.03MG BASE	N209128 001 Nov 02, 2018	Apr CAHN
>A> +! VERTICAL PHARMS	EQ 0.03MG BASE	N209128 001 Nov 02, 2018	Apr CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

@ AKORN 10% A040215 001 May 25, 1999 Jan DISC

SULINDAC

TABLET; ORAL

SULINDAC

@ CHARTWELL RX	150MG	A072712 001 Aug 30, 1991	Jan CAHN
@	200MG	A072713 001 Aug 30, 1991	Jan CAHN

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

>A> AB HANGZHOU ZHONGMEI	EQ 0.5MG BASE	A210929 001 Apr 17, 2023	Apr NEWA
>A> AB	EQ 1MG BASE	A210929 002 Apr 17, 2023	Apr NEWA
>A> AB	EQ 5MG BASE	A210929 003 Apr 17, 2023	Apr NEWA

TADALAFIL

TABLET; ORAL

ALYQ

>D> AB2 TEVA PHARMS INC	20MG	A216932 001 Oct 12, 2022	Apr DISC
>A> @	20MG	A216932 001 Oct 12, 2022	Apr DISC

TABLET;ORALTADALAFIL

AB1	NOVITIUM PHARMA	5MG	A215949	001	Mar 03, 2023	Feb NEWA
AB1		10MG	A215949	002	Mar 03, 2023	Feb NEWA
AB1		20MG	A215949	003	Mar 03, 2023	Feb NEWA
AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Jan CTEC
AB1		5MG	A209250	002	Mar 26, 2019	Jan CTEC
AB1		10MG	A209250	003	Mar 26, 2019	Jan CTEC
AB1		20MG	A209250	004	Mar 26, 2019	Jan CTEC

TAMOXIFEN CITRATESOLUTION;ORALSOLTAMOX

+! MAYNE PHARMA COMMRCIAL EQ 20MG BASE/10ML

N021807 001 Oct 29, 2005 Feb CAHN

TASIMELTEONCAPSULE;ORALTASIMELTEON

AB	APOTEX	20MG	A211607	001	Dec 20, 2022	Jan CAHN
AB	MSN	20MG	A211654	001	Jan 12, 2023	Jan NEWA

TAVABOROLESOLUTION;TOPICALTAVABOROLE

AB	ZYDUS LIFESCIENCES	5%	A212294	001	Apr 10, 2023	Mar NEWA
----	--------------------	----	---------	-----	--------------	----------

TAZAROTENEGEL;TOPICALTAZAROTENE

>A> AB	PADAGIS ISRAEL	0.05%	A213079	001	Apr 25, 2023	Apr NEWA
>A> AB		0.1%	A213079	002	Apr 25, 2023	Apr NEWA
AB	SOLARIS PHARMA CORP	0.05%	A213644	001	Mar 20, 2023	Mar NEWA
AB		0.1%	A213644	002	Mar 20, 2023	Mar NEWA

TECHNETIUM TC-99M MERTIATIDE KITPOWDER;INTRAVENOUSTECHNETIUM TC 99M MERTIATIDE KIT

+! JUBILANT DRAXIMAGE N/A

N216820 001 Jan 30, 2023 Jan NEWA

TENOFOVIR ALAFENAMIDE FUMARATETABLET;ORALTENOFOVIR ALAFENAMIDE

AB	LUPIN LTD	EQ 25MG BASE	A214226	001	Mar 30, 2023	Mar NFTG
AB	+! GILEAD SCIENCES INC	EQ 25MG BASE	N208464	001	Nov 10, 2016	Mar CFTG

TENOFOVIR DISOPROXIL FUMARATETABLET;ORALTENOFOVIR DISOPROXIL FUMARATE

AB	REYOUNG PHARM	300MG	A211337	001	Mar 02, 2023	Feb NEWA
----	---------------	-------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDECAPSULE;ORALTERAZOSIN HYDROCHLORIDE

>D>	@ BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Apr CAHN
>D>	@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Apr CAHN
>D>	@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Apr CAHN
>D>	@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Apr CAHN
>A>	@ BIONPHARMA INC	EQ 1MG BASE	A075667	001	Jul 28, 2000	Apr CAHN
>A>	@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Apr CAHN
>A>	@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Apr CAHN
>A>	@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Apr CAHN

TERIFLUNOMIDETABLET;ORALTERIFLUNOMIDE

AB	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb CMFD
AB		14MG	A209613	002	Sep 28, 2018	Feb CMFD
AB	APOTEX	7MG	A209601	001	Nov 02, 2018	Jan CMFD
AB		14MG	A209601	002	Nov 02, 2018	Jan CMFD
AB	AUROBINDO PHARMA	7MG	A209638	001	Oct 26, 2018	Jan CMFD
AB		14MG	A209638	002	Oct 26, 2018	Jan CMFD

TABLET;ORAL

TERIFLUNOMIDE

AB	BIOCON PHARMA	7MG	A209639	001	Mar 13, 2023	Mar NEWA
AB		14MG	A209639	002	Mar 13, 2023	Mar NEWA
AB	HETERO LABS LTD V	7MG	A209598	001	Mar 13, 2023	Mar NEWA
AB		14MG	A209598	002	Mar 13, 2023	Mar NEWA
AB	MSN	7MG	A209623	001	Apr 24, 2019	Feb CMFD
AB		14MG	A209623	002	Apr 24, 2019	Feb CMFD
AB	MYLAN	7MG	A209702	001	Feb 28, 2020	Feb CMFD
AB		14MG	A209702	002	Feb 28, 2020	Feb CMFD
AB	SOLA PHARMS	14MG	A209677	001	Jun 17, 2020	Feb CMFD
AB	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Feb CMFD
AB		14MG	A209700	002	Sep 04, 2018	Feb CMFD
AB	ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	Jan CMFD
AB		14MG	A209668	002	Nov 30, 2018	Jan CMFD

TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

+ @ BESINS HLTHCARE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Feb CAHN
+ @	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Feb CAHN
+ @	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Feb CAHN
+ @	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Feb CAHN

GEL, METERED;NASAL
NATESTO

+! ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan CHRS
+	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan CRLD

GEL, METERED;TRANSDERMAL
ANDROGEL

AB	+! BESINS HLTHCARE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Feb CAHN
	+ @	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Feb CAHN
	TESTOSTERONE					

AB	ENCUBE	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Jan CAHN
----	--------	----------------------------------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATEINJECTABLE;INJECTION
TESTOSTERONE CYPIONATE

AO	XIROMED	100MG/ML	A215351	001	Apr 13, 2023	Mar NEWA
AO		200MG/ML	A215351	002	Apr 13, 2023	Mar NEWA

TETRABENAZINETABLET;ORAL
TETRABENAZINE

@ SUN PHARM	12.5MG	A206129	001	Aug 17, 2015	Jan DISC
@	25MG	A206129	002	Aug 17, 2015	Jan DISC

TETRACYCLINE HYDROCHLORIDECAPSULE;ORAL
TETRACYCLINE HYDROCHLORIDE

>A>	@ AUROBINDO PHARMA USA	250MG	A060783	001		Apr CAHN
>A>	@	500MG	A060783	002		Apr CAHN
>D>	@ MYLAN	250MG	A060783	001		Apr CAHN
>D>	@	500MG	A060783	002		Apr CAHN

THALIDOMIDECAPSULE;ORAL
THALIDOMIDE

>A> AB	NATCO	150MG	A213267	001	Apr 27, 2023	Apr NFTG
	THALOMID					
>D> AB	+ CELGENE	150MG	N020785	004	Jan 10, 2007	Apr CFTG
>A> AB	+ LEADING	150MG	N020785	004	Jan 10, 2007	Apr CFTG

THEOPHYLLINETABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB	AMNEAL	300MG	A216276	001	Mar 20, 2023	Mar NEWA
		450MG	A216276	002	Mar 20, 2023	Mar NEWA
>A> AB	BIONPHARMA INC	300MG	A216300	001	Apr 26, 2023	Apr NEWA
>A> AB		450MG	A216300	002	Apr 26, 2023	Apr NEWA
AB	LEADING	300MG	A214950	001	Jan 30, 2023	Jan NEWA
AB		450MG	A214950	002	Jan 30, 2023	Jan NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A215692	001	Mar 06, 2023	Feb NEWA
AP	DR REDDYS	100MG/ML	A080571	001		Mar CMFD
!		200MG/ML	A080571	002		Mar CMFD

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

@	CHARTWELL RX	10MG	A088131	001	Aug 30, 1983	Jan CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan CAHN

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

AB	RISING	1MG	A071093	002	Jun 23, 1987	Feb CAHN
AB		2MG	A071093	003	Jun 23, 1987	Feb CAHN
AB		5MG	A071093	004	Jun 23, 1987	Feb CAHN
AB		10MG	A071093	001	Jun 23, 1987	Feb CAHN

TICAGRELOR

TABLET; ORAL

TICAGRELOR

>A> AB	ALKEM LABS LTD	90MG	A208567	001	Apr 21, 2023	Apr NEWA
--------	----------------	------	---------	-----	--------------	----------

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

+!	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Jan CTEC
+!		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Jan CTEC
	TIMOLOL					
@	AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Jan DISC
@		EQ 0.5% BASE	A205309	002	Sep 30, 2016	Jan DISC

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AB	EUGIA PHARMA	EQ 0.5% BASE	A213540	001	Mar 23, 2023	Mar NEWA
AB	GLAND PHARMA LTD	EQ 0.5% BASE	A214645	002	Feb 14, 2023	Feb NEWA
	TIMOLOL MALEATE					
@	AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Jan DISC
>A> AT3	SENTISSION PHARMA	EQ 0.5% BASE	A217195	001	May 08, 2023	Apr NEWA

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

>A> AB	CHARTWELL RX	250MG	A202044	001	Apr 30, 2012	Apr CAHN
>A> AB		500MG	A202044	002	Apr 30, 2012	Apr CAHN
>D> AB	NOVEL LABS INC	250MG	A202044	001	Apr 30, 2012	Apr CAHN
>D> AB		500MG	A202044	002	Apr 30, 2012	Apr CAHN

TIOPRONIN

TABLET, DELAYED RELEASE; ORAL

THIOLA EC

>D> AB	+	MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019	Apr CTEC
>A>	+		100MG	N211843	001	Jun 28, 2019	Apr CTEC
	AB	+	100MG	N211843	001	Jun 28, 2019	Feb CFTG
>D> AB	+	!	300MG	N211843	002	Jun 28, 2019	Apr CTEC
>A>	+	!	300MG	N211843	002	Jun 28, 2019	Apr CTEC
	AB	+	300MG	N211843	002	Jun 28, 2019	Feb CFTG
>D>		TIOPRONIN					
>D> AB		PAR PHARM	100MG	A217219	001	Feb 24, 2023	Apr DISC
>A>	@		100MG	A217219	001	Feb 24, 2023	Apr DISC
	AB		100MG	A217219	001	Feb 24, 2023	Feb NFTG

>D>	TABLET, DELAYED RELEASE;ORAL TIOPRONIN						
>D> AB		300MG	A217219	002	Feb 24, 2023	Apr	DISC
>A> AB	@	300MG	A217219	002	Feb 24, 2023	Apr	DISC
		300MG	A217219	002	Feb 24, 2023	Feb	NFTG
TIROFIBAN HYDROCHLORIDE							
	SOLUTION; INTRAVENOUS AGGRASTAT						
AP	+ MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Jan	CFTG
TIROFIBAN HYDROCHLORIDE							
>A> AP	EUGIA PHARMA	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	A216379	001	May 01, 2023	Apr	NEWA
>A> AP		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A216379	002	May 01, 2023	Apr	NEWA
AP	NEXUS PHARMS	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	A213947	001	Feb 07, 2023	Jan	NFTG
TIZANIDINE HYDROCHLORIDE							
	TABLET;ORAL TIZANIDINE HYDROCHLORIDE						
>A>	@ AUROBINDO PHARMA USA	EQ 2MG BASE	A076282	001	Dec 16, 2003	Apr	CAHN
>A>	@	EQ 4MG BASE	A076282	002	Dec 16, 2003	Apr	CAHN
>D>	@ MYLAN PHARMS INC	EQ 2MG BASE	A076282	001	Dec 16, 2003	Apr	CAHN
>D>	@	EQ 4MG BASE	A076282	002	Dec 16, 2003	Apr	CAHN
TOBRAMYCIN							
	SOLUTION/DROPS;OPHTHALMIC AKTOB						
	@ AKORN	0.3%	A064096	001	Jan 31, 1996	Feb	DISC
TOBRAMYCIN SULFATE							
	INJECTABLE;INJECTION TOBRAMYCIN SULFATE						
AP	HAINAN POLY	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Jan	NEWA
TOFACITINIB CITRATE							
	TABLET;ORAL TOFACITINIB CITRATE						
AB	@ MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar	DISC
AB	ZYDUS PHARMS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar	NFTG
	XELJANZ	EQ 5MG BASE	A209829	001	Mar 13, 2023	Mar	NEWA
AB	+ PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Mar	CFTG
>A>	TOFERSEN						
>A>	SOLUTION;INTRATHECAL						
>A>	QALSDODY						
>A>	+! BIOGEN MA	100MG/15ML (6.7MG/ML)	N215887	001	Apr 25, 2023	Apr	NEWA
TOPIRAMATE							
	CAPSULE, EXTENDED RELEASE;ORAL TOPIRAMATE						
AB1	ACTAVIS LABS FL	25MG	A206210	001	Mar 10, 2023	Mar	NEWA
AB1		50MG	A206210	002	Mar 10, 2023	Mar	NEWA
AB1		100MG	A206210	003	Mar 10, 2023	Mar	NEWA
AB1		200MG	A206210	004	Mar 10, 2023	Mar	NEWA
>A> AB1	PAR PHARM	25MG	A205976	002	May 04, 2023	Apr	NEWA
>A> AB1		50MG	A205976	003	May 04, 2023	Apr	NEWA
>A> AB1		100MG	A205976	004	May 04, 2023	Apr	NEWA
AB1		200MG	A205976	001	Mar 01, 2023	Feb	NEWA
AB1	ZYDUS	25MG	A207382	001	Nov 24, 2017	Jan	CAHN
AB2		25MG	A208949	001	Nov 29, 2022	Jan	CAHN
AB1		50MG	A207382	002	Nov 24, 2017	Jan	CAHN
AB2		50MG	A208949	002	Nov 29, 2022	Jan	CAHN
AB1		100MG	A207382	003	Nov 24, 2017	Jan	CAHN
AB2		100MG	A208949	003	Nov 29, 2022	Jan	CAHN
AB2		150MG	A208949	004	Nov 29, 2022	Jan	CAHN
AB2		200MG	A208949	005	Nov 29, 2022	Jan	CAHN
AB1	ZYDUS PHARMS	200MG	A216167	001	Feb 09, 2023	Jan	NFTG
	TROKENDI XR						
AB1	+! SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Jan	CFTG

TOPOTECAN HYDROCHLORIDE

SOLUTION; INTRAVENOUS
 TOPOTECAN HYDROCHLORIDE
 @ DASH PHARMS EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A206074 001 Nov 24, 2017 Mar CAHN

TRAMETINIB DIMETHYL SULFOXIDE

SOLUTION; ORAL
 MEKINIST
 +! NOVARTIS EQ 0.05MG BASE/ML N217513 001 Mar 16, 2023 Mar NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
 TRAZODONE HYDROCHLORIDE
 AB AUROBINDO PHARMA 50MG A204852 001 Feb 05, 2020 Jan CAHN
 AB 100MG A204852 002 Feb 05, 2020 Jan CAHN
 AB 150MG A204852 003 Feb 05, 2020 Jan CAHN
 AB 300MG A204852 004 Feb 05, 2020 Jan CAHN

TREPROSTINIL

INJECTABLE; IV (INFUSION), SUBCUTANEOUS
 TREPROSTINIL
 AP DR REDDYS 1MG/ML A210214 001 May 22, 2020 Feb CMFD
 AP 2.5MG/ML A210214 002 May 22, 2020 Feb CMFD
 AP 5MG/ML A210214 003 May 22, 2020 Feb CMFD
 AP 10MG/ML A210214 004 May 22, 2020 Feb CMFD

TRETINOIN

CREAM; TOPICAL
 RETIN-A
 AB +! BAUSCH 0.025% N019049 001 Sep 16, 1988 Jan CAHN

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
 TRIAMCINOLONE ACETONIDE
 >A> AT CHARTWELL RX 0.1% A207365 001 Oct 12, 2018 Apr CAHN
 AT GLASSHOUSE PHARMS 0.05% A214532 001 Jan 27, 2023 Jan NEWA
 >D> AT NOVEL LABS INC 0.1% A207365 001 Oct 12, 2018 Apr CAHN

TRIAMTERENE

CAPSULE; ORAL
 TRIAMTERENE
 @ EYWA 50MG A214768 001 Jul 06, 2022 Jan DISC
 @ 100MG A214768 002 Jul 06, 2022 Jan DISC

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL
 TRIENTINE HYDROCHLORIDE
 AB MSN 250MG A211134 001 May 22, 2019 Mar CTEC

TROFINETIDE

SOLUTION; ORAL
 DAYBUE
 +! ACADIA PHARMS INC 200MG/ML N217026 001 Mar 10, 2023 Mar NEWA

UBROGEPEANT

TABLET; ORAL
 UBRELVY
 + ABBVIE 50MG N211765 001 Dec 23, 2019 Jan CAHN
 +! 100MG N211765 002 Dec 23, 2019 Jan CAHN

URSODIOL

CAPSULE; ORAL
 URSODIOL
 @ MYLAN 300MG A090530 001 Feb 17, 2010 Jan DISC
 >D> @ VGYAAN 300MG A214329 001 Jul 28, 2021 Apr CMFD
 >A> AB 300MG A214329 001 Jul 28, 2021 Apr CMFD

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	CHARTWELL RX	EQ 500MG BASE	A090216	001	May 24, 2010	Jan CAHN
AB		EQ 1GM BASE	A090216	002	May 24, 2010	Jan CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	+! CHEPLAPHARM	50MG/ML	N022257	001	Aug 28, 2009	Mar CAHN
AB	APPCO	50MG/ML	A216317	001	Apr 11, 2023	Mar NEWA
	TABLET;ORAL					
	VALCYTE					

AB	+! CHEPLAPHARM	EQ 450MG BASE	N021304	001	Mar 29, 2001	Mar CAHN
----	----------------	---------------	---------	-----	--------------	----------

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

>D> AA	ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010	Apr CAHN
>A> AA	QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Apr CAHN
	@ XTRRIUM LABS INC	250MG/5ML	A070868	001	Jul 01, 1986	Mar CAHN

VALSARTAN

SOLUTION;ORAL

VALSARTAN

! NOVITIUM PHARMA

20MG/5ML

A214102 001 Nov 02, 2021 Jan CHRS

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	HIKMA	EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Jan CMFD
	POWDER;INTRAVENOUS, ORAL					
	VANCOMYCIN HYDROCHLORIDE					
+!	ZHEJIANG NOVUS PHARM	EQ 500MG BASE/VIAL	N210274	001	Jan 20, 2023	Jan NEWA
+!		EQ 1GM BASE/VIAL	N210274	002	Jan 20, 2023	Jan NEWA
+!		EQ 5GM BASE/VIAL	N210274	003	Jan 20, 2023	Jan NEWA
+!		EQ 10GM BASE/VIAL	N210274	004	Jan 20, 2023	Jan NEWA

VARENICLINE TARTRATE

TABLET;ORAL

VARENICLINE TARTRATE

AB	APOTEX	EQ 0.5MG BASE	A201962	001	Jan 25, 2023	Jan NEWA
AB		EQ 1MG BASE	A201962	002	Jan 25, 2023	Jan NEWA
AB	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jan CTEC
AB	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Jan CTEC

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOSTRICT

>A>	+! PAR STERILE PRODUCTS	50UNITS/50ML (1UNITS/ML)	N204485	006	Apr 12, 2023	Apr NEWA
-----	-------------------------	--------------------------	---------	-----	--------------	----------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	Mar NEWA
AB		EQ 75MG BASE	A200430	002	Apr 04, 2023	Mar NEWA
AB		EQ 150MG BASE	A200430	003	Apr 04, 2023	Mar NEWA

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

!	CHARTWELL RX	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan CAHN
!		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan CAHN
!		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan CAHN
!		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan CAHN
!		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 37.5MG BASE	A214691	001	Apr 12, 2023	Mar NEWA
AB		EQ 75MG BASE	A214691	002	Apr 12, 2023	Mar NEWA
AB		EQ 150MG BASE	A214691	003	Apr 12, 2023	Mar NEWA
AB		EQ 225MG BASE	A214691	004	Apr 12, 2023	Mar NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

+ @ PFIZER

120MG

N019152 003 Mar 06, 1991 Mar DISC

+ @

240MG

N019152 001 Dec 16, 1986 Mar DISC

VERAPAMIL HYDROCHLORIDE

AB CADILA PHARMS LTD 120MG

A206173 003 Nov 14, 2022 Mar NEWA

AB ! GLENMARK GENERICS 120MG

A090700 001 Aug 03, 2011 Mar CHRS

AB ! 240MG

A078906 001 Sep 17, 2009 Mar CHRS

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

@ ACCORD HLTHCARE

500MG/PACKET

A214425 001 Nov 13, 2020 Mar DISC

AA ZYDUS

500MG/PACKET

A214671 001 Mar 02, 2023 Feb NEWA

TABLET;ORAL

VIGABATRIN

>A> AB PROPEL PHARMA 500MG

A215519 001 Apr 28, 2023 Apr NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

AB +! ABBVIE 10MG

N022567 001 Jan 21, 2011 Jan CAHN

AB + 20MG

N022567 002 Jan 21, 2011 Jan CAHN

AB + 40MG

N022567 003 Jan 21, 2011 Jan CAHN

VORICONAZOLE

INJECTABLE;INTRAVENOUS

VORICONAZOLE

AP EUGIA PHARMA 200MG/VIAL

A212162 001 Feb 02, 2023 Jan NEWA

AP UBI 200MG/VIAL

A211264 001 Mar 09, 2023 Mar NEWA

AP XELLIA PHARMS APS 200MG/VIAL

N208562 001 Mar 09, 2017 Mar CDFR

TABLET;ORAL

VORICONAZOLE

>A> AB CHARTWELL RX 50MG

A207371 001 May 24, 2016 Apr CAHN

>A> AB 200MG

A207371 002 May 24, 2016 Apr CAHN

>D> AB NOVEL LABS INC 50MG

A207371 001 May 24, 2016 Apr CAHN

>D> AB 200MG

A207371 002 May 24, 2016 Apr CAHN

VUTRISIRAN SODIUM

SOLUTION;SUBCUTANEOUS

AMVUTTRA

+! ALNYLAM PHARMS INC

EQ 25MG BASE/0.5ML (EQ 25MG
BASE/0.5ML)

N215515 001 Jun 13, 2022 Feb CPOT

+!

25MG/0.5ML (25MG/0.5ML)

N215515 001 Jun 13, 2022 Feb CAIN

XENON XE-129 HYPERPOLARIZED

GAS;INHALATION

XENOVIEW

+! POLAREAN

N/A

N214375 001 Dec 23, 2022 Jan NEWA

ZAVEGEPANT HYDROCHLORIDE

SPRAY, METERED;NASAL

ZAVZPRET

+! PFIZER

EQ 10MG BASE/SPRAY

N216386 001 Mar 09, 2023 Mar NEWA

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB ! RISING 600MG

A204929 001 Mar 17, 2017 Jan CHRS

ZYFLO CR

N022052 001 May 30, 2007 Jan DISC

+ @ CHIESI

600MG

ZOLMITRIPTAN

SPRAY;NASAL

ZOMIG

AB + AMNEAL 2.5MG/SPRAY

N021450 003 Sep 16, 2013 Jan CAHN

AB +! 5MG/SPRAY

N021450 004 Sep 30, 2003 Jan CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL
>A> EXCEDRIN (MIGRAINE RELIEF)
>A> +! GLAXOSMITHKLINE CONS 250MG;250MG;65MG N 020802 001 Jan 14, 1998 Apr CTNA
>D> EXCEDRIN (MIGRAINE)
>D> +! GLAXOSMITHKLINE CONS 250MG;250MG;65MG N 020802 001 Jan 14, 1998 Apr CTNA

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL
ACETAMINOPHEN AND IBUPROFEN
L PERRIGO CO 250MG;125MG A 214836 001 Feb 28, 2023 Feb NEWA

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
AUROBINDO PHARMA LTD 5MG;120MG A 212409 001 Mar 08, 2023 Feb NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL
SOLUPREP S
+! 3M HEALTH CARE 2%;70% N 208288 001 Aug 08, 2018 Mar CTNA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
COREPHARMA 25MG;220MG A 211830 001 Aug 22, 2019 Feb CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM
GUARDIAN DRUG EQ 20MG BASE A 216149 001 Mar 15, 2023 Mar NEWA

FAMOTIDINE

TABLET;ORAL
FAMOTIDINE
MARKSANS PHARMA 10MG A 217543 001 Mar 08, 2023 Feb NEWA
20MG A 217543 002 Mar 08, 2023 Feb NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
>A> AUROBINDO PHARMA USA 30MG A 202039 001 Nov 19, 2014 Apr CAHN
>D> AUROLIFE PHARMA LLC 30MG A 202039 001 Nov 19, 2014 Apr CAHN
FEXOFENADINE HYDROCHLORIDE ALLERGY
>A> AUROBINDO PHARMA USA 60MG A 202039 002 Nov 19, 2014 Apr CAHN
>A> 180MG A 202039 003 Nov 19, 2014 Apr CAHN
>D> AUROLIFE PHARMA LLC 60MG A 202039 002 Nov 19, 2014 Apr CAHN
>D> 180MG A 202039 003 Nov 19, 2014 Apr CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE
@ GRANULES 600MG;60MG A 216082 001 Aug 22, 2022 Feb DISC
@ 1.2GM;120MG A 216082 002 Aug 22, 2022 Feb DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
AUROBINDO PHARMA LTD 200MG;30MG A 213565 001 Mar 10, 2023 Mar NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
@ GRANULES 2MG;125MG A 215981 001 Aug 29, 2022 Feb DISC

LORATADINE

CAPSULE;ORAL
LORATADINE
AUROBINDO PHARMA 10MG A211900 001 Mar 24, 2023 Mar NEWA

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL
NARCAN
+! EMERGENT 4MG/SPRAY N208411 001 Nov 18, 2015 Mar CMKT

NAPROXEN SODIUM

CAPSULE;ORAL
NAPROXEN SODIUM
@ STRIDES PHARMA EQ 200MG BASE A215472 001 Aug 17, 2022 Feb DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE
@ AKORN EQ 0.1% BASE A204532 001 Jan 10, 2017 Jan DISC
@ EQ 0.2% BASE A204723 001 Dec 05, 2017 Jan DISC

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM
>A> AUROBINDO PHARMA LTD EQ 20MG BASE A213201 001 Apr 28, 2023 Apr NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL 2023

NO APRIL 2023 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2023 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	8748382	Oct 03, 2027	U-2009		>A> I-907	Dec 19, 2025
	8748382	Oct 03, 2027	U-3543			
	RE49444	Apr 28, 2031	U-2009			
	RE49444	Apr 28, 2031	U-3543			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABROCITINIB - CIBINOO</u>						
N 213871 001					NPP	Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 002					NPP	Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 003					NPP	Feb 09, 2026
<u>ACETAMINOPHEN; IBUPROFEN - COMBOGESIC</u>						
N 209471 001	10532036	Sep 22, 2025	U-3553			
	11197830	Feb 27, 2039	DP U-3553			
	11534407	Feb 27, 2039	DP U-3553			
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001					NCE	Dec 12, 2027
					ODE-352	Dec 12, 2029
<u>ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA</u>						
N 214070 001	9415009	May 28, 2030	U-3509		NP	Jan 10, 2026
<u>ALPELISIB - VIJOICE</u>						
N 215039 001					ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039 002					ODE-396	Apr 05, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPELISIB - VIJOICE</u>						
N 215039 003					ODE-396	Apr 05, 2029
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	11540981	Feb 07, 2028	DP			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR</u>						
N 208147 001	11590228	Sep 07, 2036	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5</u>						
N 210526 001	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10</u>						
N 210526 002	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15</u>						
N 210526 003	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20</u>						
N 210526 004	11590081	Sep 24, 2038	DP U-3538			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	11559559	Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	11559559	Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	11559559	Dec 18, 2034	U-3514			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	10052314	Sep 23, 2033	U-2381	Y		
	10052314	Sep 23, 2033	U-2382	Y		
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	RE49353	Sep 23, 2033	U-2381			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
	RE49353	Sep 23, 2033	U-2381			
<u>ASPIRIN - VAZALORE</u>						
N 203697 001	>A> 10646431	Sep 29, 2032	DP			
	>A> 10786444	Sep 29, 2032	U-3559			
<u>ASPIRIN - VAZALORE</u>						
N 203697 002	>A> 10646431	Sep 29, 2032	DP			
	>A> 10786444	Sep 29, 2032	U-3559			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11369567	Jun 07, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001 >A> 11603356		May 29, 2041	DS DP U-3558			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001					NPP	Dec 20, 2025
<u>AZACITIDINE - VIDAZA</u>						
N 050794 001					ODE-399	May 20, 2029
<u>AZACITIDINE - ONUREG</u>						
N 214120 001 11571436		May 14, 2029	DP			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002 11571436		May 14, 2029	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001 9737469		Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002 9737469		Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003 9737469		Nov 02, 2031	U-3500			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001 11559637		Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002 11559637		Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001 >A> 11613511		Jun 19, 2040	DS			
<u>BEMPEDOIC ACID: EZETIMIBE - NEXLIZET</u>						
N 211617 001 >A> 11613511		Jun 19, 2040	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001 9533955		Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002 9533955		Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001 11541026		Feb 19, 2040	U-3356			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001 >A> 11618733		Nov 01, 2039	U-3300			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002 >A> 11618733		Nov 01, 2039	U-3300			
<u>BEXAGLIFLOZIN - BRENZAVVY</u>						
N 214373 001 10533032		Jul 03, 2031	U-2214			
	10981942	Jun 13, 2031	DS DP			
	7838499	Jan 30, 2029	DS DP U-2214			
	8106021	Aug 22, 2028	U-2214			
	8802637	Aug 22, 2028	DS DP U-2214			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEXAGLIFLOZIN - BRENZAVVY</u>						
N 214373 001	8987323	May 14, 2032	DS DP			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	11590209	Apr 29, 2041		U-3539		
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	11596600	Jul 27, 2029		U-2222		
<u>BUDESONIDE - BUDESONIDE</u>						
A 215328 001					>A> CGT	Oct 24, 2023
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					ODE-389	Dec 15, 2028
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11534414	Nov 05, 2034	DP U-3419			
	11541021	Nov 05, 2034	U-3419			
	11541048	Nov 05, 2034	U-3419			
	11596627	Nov 05, 2034	U-3419			
>A>	11617728	Nov 05, 2034	U-3419			
>A>	11617747	Nov 05, 2034	U-3563			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11554102	Jan 11, 2033	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	11576894	Jul 06, 2030	DP			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	11529357	Jan 31, 2040	DP			
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	>A> 11439613	Mar 28, 2039		U-3557		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP S</u>						
N 208288 001					>A> M-292	Jan 20, 2026
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001					NP	Sep 27, 2025
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	8143240	Jan 12, 2024	U-2942			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 001	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 002	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 003	11541002	Jan 31, 2040	DP U-724			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	11597699	Oct 05, 2026	U-3554		ODE-416	Oct 28, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE-407	Jul 14, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE-407	Jul 14, 2029
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	>A> 11612658	Jan 27, 2026	U-3560		NP	Jun 23, 2024
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11510941	Mar 02, 2039	DP			
	11510942	Jan 15, 2039	DP U-2752			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP U-3149			
	10028912	Oct 15, 2032	DP U-3150			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034		>A>	I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296	>A>	ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034		>A>	I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296	>A>	ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	>A> 8835443	Jun 10, 2025	U-3565	>A> NP >A> ODE-428		Mar 16, 2026 Mar 16, 2030
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	May 23, 2028	U-3499			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 001	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 002	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 003	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 004	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 005	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	8975254	Mar 25, 2033	DS DP U-2605			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001				ODE-417 ODE-420 ODE-421	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028	
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002				ODE-417 ODE-420 ODE-421	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028	
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001				ODE-417 ODE-418 ODE-419	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028	
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002				ODE-417 ODE-418 ODE-419	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028	
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001				ODE-417 ODE-420 ODE-421	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001					ODE-417 ODE-420 ODE-421	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	11564917	Mar 07, 2036	U-1995			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11564917	Mar 07, 2036	U-1995			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	11564917	Mar 07, 2036	U-1995			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	10959996	Mar 07, 2036	U-3055			
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11446291	Mar 07, 2036	U-1995			
	11564917	Mar 07, 2036	U-1995			
	8524733	Apr 03, 2031	DS DP			
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	10959996	Mar 07, 2036	U-3055			
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11446291	Mar 07, 2036	U-1995			
	11564917	Mar 07, 2036	U-1995			
	8524733	Apr 03, 2031	DS DP			
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	10959996	Mar 07, 2036	U-3055			
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11446291	Mar 07, 2036	U-1995			
	11564917	Mar 07, 2036	U-1995			
	8524733	Apr 03, 2031	DS DP			
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003					NPP	Dec 16, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 005					NPP	Dec 16, 2025
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	11559501	Jan 06, 2042	DP			
<u>DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE</u>						
A 215408 001					CGT	Aug 16, 2023
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 001	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2023	DS DP U-3523			
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 002	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2023	DS DP U-3523			
<u>ELAGOLIX SODIUM - ORLISSA</u>						
N 210450 001	11542239	Jul 23, 2039	DS DP			
<u>ELAGOLIX SODIUM - ORLISSA</u>						
N 210450 002	11542239	Jul 23, 2039	DS DP			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	11542239	Jul 23, 2039	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	11564886	Mar 07, 2032	DP U-3531			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	>A> 9949997	May 17, 2034		U-3532		
	>A> 9949997	May 17, 2034		U-3533		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	>A> 9949997	May 17, 2034		U-3532		
	>A> 9949997	May 17, 2034		U-3533		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	>A> 9949997	May 17, 2034		U-3532		
	>A> 9949997	May 17, 2034		U-3533		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	>A> 9949997	May 17, 2034		U-3532		
	>A> 9949997	May 17, 2034		U-3533		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	9949997	May 17, 2034		U-3532		
	9949997	May 17, 2034		U-3533		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	9949997	May 17, 2034		U-3532		
	9949997	May 17, 2034		U-3533		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	9949997	May 17, 2034		U-3532		
	9949997	May 17, 2034		U-3533		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	9949997	May 17, 2034		U-3532		
	9949997	May 17, 2034		U-3533		
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	8501758	Aug 27, 2030	DS DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11571398	May 16, 2040		U-3183		
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 002	>A> 11464752	May 16, 2040	DP			
	>A> 11571398	May 16, 2040		U-3183		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 001	>A> 10653646	Mar 21, 2039	DP			
	>A> 11083698	Mar 21, 2039		U-3567		
	>A> 11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 002	>A> 10653646	Mar 21, 2039	DP			
	>A> 11083698	Mar 21, 2039		U-3567		
	>A> 11207280	Mar 21, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 003	>A> 10653646	Mar 21, 2039	DP			
	>A> 11083698	Mar 21, 2039		U-3567		
	>A> 11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 004	>A> 10653646	Mar 21, 2039	DP			
	>A> 11083698	Mar 21, 2039		U-3567		
	>A> 11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE</u>						
N 215875 005	>A> 10653646	Mar 21, 2039	DP			
	>A> 11083698	Mar 21, 2039		U-3567		
	>A> 11207280	Mar 21, 2039	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	11578044	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	11578044	Oct 19, 2037	DS			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001					M-289	Jan 27, 2026
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001					ODE-393	Mar 25, 2029
					PED	Sep 25, 2029
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003					>A> M-290	Mar 01, 2026
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 004	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 005	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11554229	Feb 23, 2036	U-2133			
	11602603	Oct 27, 2028	DP U-2133			
	8327844	Oct 24, 2023	U-2133			
	8522778	Apr 20, 2024	DP			
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001					M-286	Oct 27, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11529362	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11529362	Jun 02, 2037	DP			
<u>FUTIBATINIB - LYTOGOBI</u>						
N 214801 001					ODE-410	Sep 30, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	11590246	Jan 17, 2040	DP			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001					ODE-395	Jun 01, 2029
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 003	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 004	11590205	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	10456354	Oct 25, 2038	DP			
	11110054	Oct 25, 2038	DP			
<u>IBREXAFUNGERP CITRATE - BREXAFAEMME</u>						
N 214900 001	11534433	Jun 10, 2039	U-3159		I-903	Nov 30, 2025
	11534433	Jun 10, 2039	U-3508			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBREXAFUNGERP CITRATE - BREXA FEMME</u>						
N 214900 001	11534433	Jun 10, 2039	U-3159		I-903	Nov 30, 2025
	11534433	Jun 10, 2039	U-3508			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001				ODE-109 ODE-117 ODE-128 ODE-152 ODE-405 PED PED PED	Mar 04, 2023 May 06, 2023 Jan 18, 2024 Aug 02, 2024 Aug 24, 2029 Jul 18, 2024 Feb 02, 2025 Feb 24, 2030	
N 205552 002				ODE* ODE* ODE* ODE* ODE-405 PED	Mar 04, 2023 May 06, 2023 Jan 18, 2024 Aug 02, 2024 Aug 24, 2029 Feb 24, 2030	
N 210563 001				ODE* ODE* ODE* ODE* ODE-405 PED	Mar 04, 2023 May 06, 2023 Jan 18, 2024 Aug 02, 2024 Aug 24, 2029 Feb 24, 2030	
N 210563 002				ODE* ODE* ODE* ODE* ODE-405 PED	Mar 04, 2023 May 06, 2023 Jan 18, 2024 Aug 02, 2024 Aug 24, 2029 Feb 24, 2030	
N 210563 003				ODE* ODE* ODE* ODE* ODE-405 PED	Mar 04, 2023 May 06, 2023 Jan 18, 2024 Aug 02, 2024 Aug 24, 2029 Feb 24, 2030	
N 210563 004				ODE* ODE* ODE* ODE* ODE-405 PED	Mar 04, 2023 May 06, 2023 Jan 18, 2024 Aug 02, 2024 Aug 24, 2029 Feb 24, 2030	
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10106548	Jun 03, 2033	DS DP		ODE-405	Aug 24, 2029
	10106548*PED	Dec 03, 2033		PED		Feb 24, 2030
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10478439	Jun 03, 2031		U-3422		
	10478439*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	11564916	Aug 13, 2029	U-3530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	11564916	Aug 13, 2029	U-3528			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	11564916	Aug 13, 2029	U-3528			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	11564916	Aug 13, 2029	U-3528			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	11191766	Apr 04, 2037	U-2471			
	11484535	Apr 04, 2037	U-2470			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	7423050	Mar 27, 2024	DS DP U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
LASMIDITAN SUCCINATE - REYVOW						
N 211280 002	7423050	Mar 27, 2024	DS DP U-1719			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 003	7423050	Mar 27, 2024	DS DP U-1719			
LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN						
N 208259 001 >A> 11618748		Jan 27, 2030	U-1524			
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001				ODE*		Aug 28, 2026
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 002				ODE*		Apr 07, 2024
				ODE*		Aug 28, 2026
				PED		Oct 07, 2024
LENACAPAVIR SODIUM - SUNLENCA						
N 215973 001	10071985	Aug 17, 2037	DS DP		>A> NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
LENACAPAVIR SODIUM - SUNLENCA						
N 215974 001	10071985	Aug 17, 2037	DS DP		>A> NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
LENIOLISIB PHOSPHATE - JOENJA						
N 217759 001 >A> 8653092		Feb 19, 2032	DS DP		>A> NCE	Mar 24, 2028
					>A> ODE-430	Mar 24, 2030
LENVATINIB MESYLATE - LENVIMA						
N 206947 001	11090386	Feb 23, 2036	U-3519			
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	11090386	Feb 23, 2036	U-3519			
LEVOKETOCONAZOLE - RECORLEV						
N 214133 001					ODE-385	Dec 30, 2028
LEVOLEUCOVORIN - KHPZORY						
N 211226 001	11541012	Mar 25, 2039	DP			
LEVOLEUCOVORIN - KHPZORY						
N 211226 002	11541012	Mar 25, 2039	DP			
LEVONORGESTREL - LILETTA						
N 206229 001	11571328	Sep 07, 2040	DP			
LOTEPREDNOL ETABONATE - LOTEMAX SM						
N 208219 001	11534395	Jan 26, 2036	DP U-2764			
LOTEPREDNOL ETABONATE - EYSUVIS						
N 210933 001	11596599	May 03, 2033	U-2985			
LUMASIRAN SODIUM - OXLUMO						
N 214103 001				ODE-415		Oct 06, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9907794 9907794*PED	May 26, 2026 Nov 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9907794 9907794*PED	May 26, 2026 Nov 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9907794 9907794*PED	May 26, 2026 Nov 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9907794 9907794*PED	May 26, 2026 Nov 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9907794 9907794*PED	May 26, 2026 Nov 26, 2026	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001				>A> NPP >A> ODE-429	Mar 13, 2026 Mar 13, 2030	
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001				ODE-388	Nov 23, 2028	
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001				ODE-398	Apr 28, 2029	
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002				ODE-398	Apr 28, 2029	
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003				ODE-398	Apr 28, 2029	
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004				ODE-398	Apr 28, 2029	
<u>METHSUXIMIDE - MENTSUXIMIDE</u>						
A 217213 001				>A> CGT	Oct 28, 2023	
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001 >A> 11633389		Aug 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002 >A> 11633389		Aug 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003 >A> 11633389		Aug 14, 2033	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001 >A> 11628150		Dec 22, 2029	DP U-2843			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001 >A> 11612593 >A> 11612594 >A> 11622962		May 30, 2038 May 30, 2038 May 30, 2038	DS DS DS			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001				ODE-392	Feb 17, 2029	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002					ODE-392	Feb 17, 2029
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003					ODE-392	Feb 17, 2029
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11590095	Mar 18, 2036		U-1384		
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	11590286	Dec 12, 2026		DP		
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	11590286	Dec 12, 2026		DP		
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	>A> 11617713	Aug 26, 2034		DP U-3110		
	>A> 11628139	Aug 26, 2034		DP U-3110		
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854 001	11571518	Jun 14, 2041		DP U-3515		
	11571518	Jun 14, 2041		DP U-3516		
	11571518	Jun 14, 2041		DP U-3517		
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457 001	11590286	Dec 12, 2026		DP		
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	>A> 11618748	Jan 27, 2030		U-1524		
<u>NETUPITANT: PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	11559523	Nov 18, 2030		DP U-3522		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	11547758	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	11547758	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	11547758	Apr 18, 2027		U-1029		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	11517563	Apr 16, 2038		DP		Y
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	>A> 10154990	Jan 08, 2026		U-2620		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	>A> 10154990	Jan 08, 2026		U-2620		
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	11511252	Sep 21, 2029		DP		
	>A> 11554241	Aug 18, 2025		U-3037		
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	11602508	Jan 30, 2038		DP		
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	11602508	Jan 30, 2038		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	11602508	Jan 30, 2038	DP			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	11583539	Nov 12, 2041	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	11583539	Nov 12, 2041	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	11583539	Nov 12, 2041	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	11583539	Nov 12, 2041	U-3186			
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001					NCE ODE-413	Dec 01, 2027 Dec 01, 2029
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2024	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2024	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11091430	Apr 20, 2029	U-3552		NCE	Feb 28, 2028
	8124799	Dec 03, 2029	DS		>A> ODE-427	Feb 28, 2030
	8440854	Apr 20, 2029	DP			
	8993640	Apr 24, 2033	DS DP			
	9670147	Apr 20, 2029	DS			
	9701709	Apr 24, 2033	DS DP			
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001					ODE-397	Feb 28, 2029
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001					I-905 ODE-390	Dec 16, 2025 Nov 29, 2028
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001					M-288	Feb 08, 2026
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		NP	Feb 22, 2026
	10875893	Nov 15, 2033	DS U-3540			
	11292815	Nov 15, 2033	DS DP U-3540			
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	8168584	Apr 07, 2027	U-3540			
	8168584	Apr 07, 2027	U-3542			
	9056076	Oct 25, 2026	U-3540			
	9169307	Nov 18, 2027	DS U-3541			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001					ODE-404	Aug 26, 2029
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002					ODE-404	Aug 26, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003					ODE-404	Aug 26, 2029
<u>PHENOBARBITAL SODIUM - SEZABY</u>						
N 215910 001					ODE-414	Nov 17, 2029
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	7229630	Jul 31, 2023	DP			
	7575757	Jul 31, 2023	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
A 216496 001					CGT	Jul 17, 2023
<u>PHENYLEPHRINE HYDROCHLORIDE - IMMIPHENTIV</u>						
N 203826 004	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMMIPHENTIV</u>						
N 203826 005	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	>A> 10610518	Apr 24, 2039	U-3252		>A> D-187	Mar 28, 2026
	>A> 10610518	Apr 24, 2039	U-3561			
	>A> 10610518	Apr 24, 2039	U-3562			
	>A> 11285134	Apr 24, 2039	U-3252			
	>A> 11285134	Apr 24, 2039	U-3561			
	>A> 11285134	Apr 24, 2039	U-3562			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036		U-3518	ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP	U-3518		
	10918622	Dec 16, 2036		U-3518		
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036		U-3518	ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP	U-3518		
	10918622	Dec 16, 2036		U-3518		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	8771733	Jun 02, 2030	DS DP	U-257		
	8852632	Jan 28, 2028	DS DP	U-257		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	8771733	Jun 02, 2030	DS DP	U-257		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	8771733	Jun 02, 2030	DS DP	U-257		
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	11583526	Sep 29, 2037		U-3020		
<u>REZAFUNGIN ACETATE - REZZAYO</u>						
N 217417 001	>A> 10702573	Mar 14, 2033	DS DP	U-3566	>A> NCE	Mar 22, 2028
	>A> 11197909	Jul 14, 2038	DS DP	U-3566	>A> ODE-426	Mar 22, 2030
	>A> 8722619	Mar 02, 2032	DS DP	U-3566	>A> GAIN	Mar 22, 2033
	>A> 9526835	Mar 14, 2033	DS DP	U-3566	>A> GAIN	Mar 22, 2035
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	11564912	Feb 26, 2029		U-3511		
	11564912	Feb 26, 2029		U-3512		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
RIPRETNINIB - QINLOCK						
N 213973 001	11529336	Aug 12, 2040	U-3382			
	11534432	Aug 12, 2040	U-3442			
	11576903	Dec 30, 2040	DP			
	11576904	Aug 12, 2040	U-3537			
	11612591	Dec 30, 2040	DP			
RISDIPLAM - EVRYSDI						
N 213535 001	11534444	Oct 04, 2038	U-1943		ODE-400	May 27, 2029
RISPERIDONE - RYKINDO						
N 212849 001	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 002	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 003	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - UZEDY						
N 213586 001	>A> 10736965	Jan 12, 2025	DP			
	>A> 8221778	Nov 12, 2027	DP U-543			
	>A> 8741327	Nov 12, 2027	DP U-543			
	>A> 8802127	Jan 12, 2025	DP			
	>A> 9439905	Jan 12, 2025	DP U-543			
	>A> 9717799	Jan 12, 2025	DP			
	>A> 9895447	Jan 12, 2025	DP			
	>A> 9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 002	>A> 10736965	Jan 12, 2025	DP			
	>A> 8221778	Nov 12, 2027	DP U-543			
	>A> 8741327	Nov 12, 2027	DP U-543			
	>A> 8802127	Jan 12, 2025	DP			
	>A> 9439905	Jan 12, 2025	DP U-543			
	>A> 9717799	Jan 12, 2025	DP			
	>A> 9895447	Jan 12, 2025	DP			
	>A> 9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 003	>A> 10736965	Jan 12, 2025	DP			
	>A> 8221778	Nov 12, 2027	DP U-543			
	>A> 8741327	Nov 12, 2027	DP U-543			
	>A> 8802127	Jan 12, 2025	DP			
	>A> 9439905	Jan 12, 2025	DP U-543			
	>A> 9717799	Jan 12, 2025	DP			
	>A> 9895447	Jan 12, 2025	DP			
	>A> 9925268	Jan 12, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - UZEDY						
N 213586 003	>A> 9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 004	>A> 10736965 >A> 8221778 >A> 8741327 >A> 8802127 >A> 9439905 >A> 9717799 >A> 9895447 >A> 9925268	Jan 12, 2025 Nov 12, 2027 Nov 12, 2027 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025	DP DP U-543 DP U-543 DP DP U-543 DP DP DP			
N 213586 005	>A> 10736965 >A> 8221778 >A> 8741327 >A> 8802127 >A> 9439905 >A> 9717799 >A> 9895447 >A> 9925268	Jan 12, 2025 Nov 12, 2027 Nov 12, 2027 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025	DP DP U-543 DP U-543 DP DP U-543 DP DP DP			
N 213586 006	>A> 10736965 >A> 8221778 >A> 8741327 >A> 8802127 >A> 9439905 >A> 9717799 >A> 9895447 >A> 9925268	Jan 12, 2025 Nov 12, 2027 Nov 12, 2027 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025	DP DP U-543 DP U-543 DP DP U-543 DP DP DP			
N 213586 007	>A> 10736965 >A> 8221778 >A> 8741327 >A> 8802127 >A> 9439905 >A> 9717799 >A> 9895447 >A> 9925268	Jan 12, 2025 Nov 12, 2027 Nov 12, 2027 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025 Jan 12, 2025	DP DP U-543 DP U-543 DP DP U-543 DP DP DP			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001			M-285 PED		Dec 19, 2025 Jun 19, 2026	
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002			M-285 PED		Dec 19, 2025 Jun 19, 2026	
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003			M-285 PED		Dec 19, 2025 Jun 19, 2026	
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004			M-285 PED		Dec 19, 2025 Jun 19, 2026	
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 005			M-285 PED		Dec 19, 2025 Jun 19, 2026	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	11510923	Sep 04, 2040	U-3505			
	11571425	May 20, 2031	DP			
	11590136	May 20, 2031	U-3229			
	11590136	May 20, 2031	U-3404			
	11590137	Sep 04, 2040	U-3505			
	11590138	Jun 10, 2040	U-3551			
	11602536	May 05, 2041	U-3550			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	11602522	Sep 04, 2035	DP U-3169			
	11602522	Sep 04, 2035	DP U-3302			
<u>SEPERCATINIB - RETEVMO</u>						
N 213246 001				ODE-409	Sep 21, 2029	
				ODE-412	Sep 21, 2029	
<u>SEPERCATINIB - RETEVMO</u>						
N 213246 002				ODE-409	Sep 21, 2029	
				ODE-412	Sep 21, 2029	
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2024	DS			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2024	DS			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001				NPP	Dec 23, 2025	
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002				NPP	Dec 23, 2025	
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003				NPP	Dec 23, 2025	
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004				NPP	Dec 23, 2025	
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005				NPP	Dec 23, 2025	
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001				ODE-402	Jun 16, 2029	
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001				M-287	Jan 31, 2026	
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001				>A> M-287	Jan 31, 2026	
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001				>A> M-287	Jan 31, 2026	
<u>SIROLIMUS - FYARRO</u>						
N 213312 001				ODE-386	Nov 22, 2028	
<u>SIROLIMUS - HYFTOR</u>						
N 213478 001				ODE-391	Mar 22, 2029	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001				>A>	ODE-431	May 01, 2030
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002				>A>	ODE-431	May 01, 2030
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003				>A>	ODE-431	May 01, 2030
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004				>A>	ODE-431	May 01, 2030
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 001	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 002	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 003	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 005	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE - OLPRUVA</u>						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036		U-3502		
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYLBUTYRATE; TAURURSODIOL - RELYVRIQ</u>						
N 216660 001	11583542	Jul 27, 2040	DP		ODE-411	Sep 29, 2029
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	>A> 11617793	Jul 01, 2039	DP		ODE-384	Sep 20, 2029
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11160779	Mar 19, 2040		U-3521		
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP	U-3520		
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11160779	Mar 19, 2040		U-3521		
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP	U-3520		
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 18, 2038		U-2769		
	10512620	Aug 18, 2038		U-3547		
	10799138	Apr 05, 2039		U-3125		
	10799138	Apr 05, 2039		U-3549		
	11583216	Aug 21, 2039		U-3549		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 18, 2038	U-2769			
	10512620	Aug 18, 2038	U-3547			
	10799138	Apr 05, 2039	U-3125			
	10799138	Apr 05, 2039	U-3549			
	11583216	Aug 21, 2039	U-3549			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	10519146	May 21, 2038	DS DP	>A> NCE	May 28, 2026	
	11236091	May 20, 2040	DS DP U-3306	>A> ODE-352	May 28, 2028	
	11426404	Aug 11, 2040	U-3306			
<u>SPARENTEAN - FILSPARI</u>						
N 216403 001	9993461	Mar 29, 2030	U-3269	NCE ODE-389	Feb 17, 2028 Feb 17, 2030	
<u>SPARENTEAN - FILSPARI</u>						
N 216403 002	9993461	Mar 29, 2030	U-3269	NCE ODE-389	Feb 17, 2028 Feb 17, 2030	
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 001				ODE-403	Jul 14, 2029	
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 002				ODE-403	Jul 14, 2029	
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 001				ODE-403	Jul 14, 2029	
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 002				ODE-403	Jul 14, 2029	
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001				>A> M-291	Jan 22, 2024	
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002				>A> M-291	Jan 22, 2024	
<u>TAPINAROF - VTAMA</u>						
N 215272 001	11590088	Nov 13, 2039	U-2625			
	11597692	Nov 13, 2038	DS DP			
	>A> 11612573	May 19, 2036	U-2625			
	>A> 11617724	May 19, 2036	DP			
	>A> 11622945	May 19, 2036	DP			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11566011	Feb 12, 2035	DS DP			
	>A> 11633377	Jan 25, 2033	U-2149			
	>A> 11633377	Jan 25, 2033	U-3003			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11566011	Feb 12, 2035	DS DP			
	>A> 11633377	Jan 25, 2033	U-3003			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	8410088	Jan 23, 2034	DS DP			
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 001				PC	Sep 08, 2023	
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 002				PC	Sep 08, 2023	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209601 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209601 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209613 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209613 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209638 001				>A> PC		Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209638 002				>A> PC		Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209663 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209663 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209668 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209668 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209690 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209690 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209700 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209700 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209710 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u> A 209710 002					PC	Sep 08, 2023
<u>TERLIPRESSIN ACETATE - TERLIVAZ</u> N 022231 001					ODE-406	Sep 14, 2029
<u>TESTOSTERONE UNDECANOATE - JATENZO</u> N 206089 001 11564933		Apr 12, 2039		U-1103		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u> N 206089 002 11564933		Apr 12, 2039		U-1103		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u> N 206089 003 11564933		Apr 12, 2039		U-1103		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	11559530	Nov 28, 2037	U-1500			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2024	DS DP U-3100			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2024	DS DP U-3100			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001 >A> 11633374		Aug 21, 2040	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034		>A>	I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032		>A>	ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034		>A>	I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032		>A>	ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034		>A>	I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032		>A>	ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513 001	>A> 7378423	May 29, 2027	DS DP	>A>	NP	Mar 16, 2026
	>A> 8835443	Jun 10, 2025	U-3564	>A>	ODE-428	Mar 16, 2030
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001					ODE-401	Apr 28, 2029
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11529352	Jul 23, 2039	U-3504			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	>A> 11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	>A> 9212204	Jan 27, 2032	U-3556	>A>	ODE-425	Mar 10, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					ODE-422	Jan 19, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					ODE-422	Jan 19, 2030
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11524964	Oct 17, 2036	U-3371			
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
	>A> 11607411	Mar 09, 2038	U-3341			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	11535626	Oct 17, 2036	U-3298			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOQ</u>						
N 211675 003 >A> 11607411		Mar 09, 2038		U-3341		
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001 11517609		Nov 06, 2035		U-282		
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001 >A> 11638692		Mar 13, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002 >A> 11638692		Mar 13, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001 >A> 11628200		Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002 >A> 11628200		Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003 >A> 11628200		Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004 >A> 11628200		Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005 >A> 11628200		Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006 >A> 11628200		Nov 06, 2035		DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007 >A> 11628200		Nov 06, 2035		DP		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 006 >A> 10010575		Jan 30, 2035		U-1857		
>A> 9919026		Jan 30, 2035		DP		
>A> 9925233		Jan 30, 2035		U-1857		
>A> 9925234		Jan 30, 2035		U-1857		
>A> 9962422		Jan 30, 2035		U-1857		
>A> 9968649		Jan 30, 2035		U-1857		
>A> 9974827		Jan 30, 2035		U-1857		
>A> 9981006		Jan 30, 2035		U-1857		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001 11590128		Sep 06, 2033		U-3548		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002 11590128		Sep 06, 2033		U-3548		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003 11590128		Sep 06, 2033		U-3548		
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001 >A> 11622991		Dec 07, 2037		U-3056		
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002					ODE-387	Nov 19, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003					ODE-387	Nov 19, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001					ODE-394	Dec 17, 2028
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					ODE-212	Jun 13, 2029
<u>XENON XE-129 HYPERPOLARIZED - XENOVIEW</u>						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		ODE-274	Jan 19, 2030
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
<u>ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET</u>						
N 216386 001	7220862	Jan 21, 2024	DS DP		>A> NCE	Mar 09, 2028
	7314883	Dec 05, 2023		U-3555		
	8481546	Oct 07, 2031	DS DP	U-3555		
<u>ZINC SULFATE MONOHYDRATE - ZINC SULFATE</u>						
A 216145 001					CGT	Aug 14, 2023

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 43rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm